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SUMMARY 
The work described in this thesis is concerned with the 
design and evaluation of microsphere-based systems for drug 
delivery into the colon. 
In initial experiments, techniques were devised for the 
preparation of microspheres from two sustained-release 
acrylic polymers, Eudragits RL and RS, using 
emulsification-solvent evaporation techniques. For Eudragit 
RS microspheres containing the drug 5-aminosalicylic acid, 
the rate of drug release could be controlled by the type 
and concentration of surfactant used for preparation. 
Consequently, formulations could be produced which released 
encapsulated drug instantaneously or over many hours. The 
surfactants may have been altering the structure of the 
microsphere drug-polymer matrix. 
Two novel analytical techniques were employed to 
characterise Eudragit RS microspheres containing 
sulphasalazine. Fourier transform-Raman spectroscopy was 
successfully used as a non-destructive method for 
qualitative and quantitative microsphere characterisation. 
The technique provided good agreement with a UV- 
spectrophotometric method in quantifying the amount of drug 
in microsphere samples. X-ray photoelectron spectroscopy 
was used to estimate the concentration of sulphasalazine at 
the microsphere surface for samples produced with or 
without the use of surfactant. Across a wide range of 
microsphere drug loadings, the surface drug content 
remained remarkably constant, but was consistently lower in 
the samples produced using surfactant. 
In a parallel programme of work, using gamma scintigraphy, 
the transit rate of different sizes of radiolabelled 
materials through the human colon was investigated to 
determine whether there was an optimal size to maximise 
i 
colon residence. There was no clear evidence of any 
difference in the colon residence time of 0.2 mm particles, 
5 mm tablets, or 8.4 mm tablets, under normal conditions 
and during accelerated transit. In healthy subjects, 50% of 
a dose of 0.2 mm particles resided in the ascending colon 
for an average of 11 hours. 
Finally, an in vivo biopharmaceutical evaluation of 
sulphapyridine-containing Eudragit RS microspheres in the 
human colon was undertaken. For this study, a neutron 
activation technique was developed for microsphere 
radiolabelling. Microspheres could be successfully 
radiolabelled by incorporation of samarium oxide followed 
by neutron irradiation. However, it was necessary to 
minimise the period of irradiation and the amount of 
incorporated samarium oxide, since high levels of both were 
found to adversely affect microsphere performance. 
The in vivo investigation revealed that the colonic 
bioavailability of sustained-release microencapsulated 
sulphapyridine was less than 50% of unencapsulated 
sulphapyridine powder. This shortfall was possibly due to 
an interaction of the drug with colonic bacteria or in 
vitro/in vivo differences in microsphere drug release 
characteristics. 
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CHAPTER 1. 
INTRODUCTION. 
BACKGROUND 
The past two decades has seen a rapid growth in the 
development of novel dosage forms to achieve controlled 
drug delivery. This has been the result of a number of 
factors (Langer, 1990): 
1. The ability to improve the safety and efficacy of a 
drug. 
2. To allow convenient administration of "difficult" 
molecules such as peptides and proteins. 
3. Potential for providing pulsatile patterns of drug 
release. 
4. The considerable cost of developing new chemical 
entities means that increasing the lifetime of 
established drugs by formulation into new delivery 
systems is an attractive financial option. 
5. Scientific advances, especially in polymer science, 
have made the development of controlled delivery 
systems feasible. 
This introductory chapter discusses two different aspects 
of controlled drug delivery. The first part describes the 
production of drug-polymer microspheres, focusing on the 
solvent evaporation process, and their therapeutic uses. 
The second part of the introduction discusses the colon as 
a target for drug delivery. 
The experimental work described in this thesis unites these 
two themes and is concerned with the development of 
microspheres for colon drug delivery. 
2 
1.1. MICROSPHERES IN DRUG-DELIVERY 
1.1.1. Introduction 
The term "microencapsulation" is used to describe a series 
of techniques for the production of particulate carriers, 
in the nm to mm size range, in which a solid or liquid is 
entrapped within a polymer coat or matrix. Apart from 
pharmaceuticals, this technology has been used by a number 
of other industries including food (Reinaccius and Risch, 
1988), household products (Bilbrey and Versic, 1990) and 
agrochemicals (Wilkins, 1990), but perhaps most notably in 
the manufacture of carbonless carbon paper. To develop this 
product, the National Cash Register Co. in the 1950s 
developed the first microencapsulation technique 
(coacervation/phase separation), for the production of 
pressure-sensitive dye-containing microcapsules (Green and 
Schleicher, 1956). 
In the literature, "microsphere", "microcapsule" and 
"microparticle" tend to be used synonymously to describe 
the products of microencapsulation. Theoretically, 
"microcapsule" should only apply to systems that are hollow 
or in which the polymer forms an outer shell, whereas 
"microsphere" should only apply to systems that are 
spherical in shape. Sub-micron carriers are generally 
referred to as nanospheres, nanocapsules or nanoparticles. 
The production and use of micro- and nanoparticulates for 
pharmaceutical applications is a vast topic and has been 
the subject of many books and reviews (e. g. Arshady, 1989, 
1990a, b; Davis et al., 1984b; Davis and Ilium, 1989; Deasy, 
1984,1991; Douglas et al., 1987; Guiot and Couvreur, 1986; 
Juliano, 1985; Kreuter, 1988; Oppenheim, 1981; Tomlinson, 
1983). This section aims to provide a general overview of 
microspheres as drug carriers, but will concentrate in 
particular on their production using emulsification-solvent 
evaporation procedures. 
3 
1.1.2. Methods of manufacture 
There are five principal techniques for producing 
drug/polymer microspheres of pharmaceutical interest: 
- 
Coacervation/phase separation. 
- 
Suspension cross-linking. 
- 
Emulsion polymerisation. 
- 
Mechanical methods. 
- 
Emulsification-solvent evaporation. 
1.1.2.1. Coacervation/phase separation 
As mentioned in the introduction, this was the first 
microencapsulation technique to be developed, and a number 
of articles describing the method have been published 
(Arshady, 1990a; Bakan, 1980; Deasy, 1984; Madan, 1978). 
Coacervation refers to the aggregation of polymer molecules 
brought about by their partial desolvation. Partial 
desolvation is a phase separation process and leaves the 
polymer existing in a state between full solvation and 
precipitation. 
Coacervation techniques can use aqueous or non-aqueous 
systems. In an aqueous system, the coating polymers are 
water-soluble and the material to be encapsulated is water- 
insoluble or, in the case of liquids, water-immiscible. 
Aqueous systems can be further subdivided into simple and 
complex. Simple systems involve one coating polymer, 
whereas complex involve two, oppositely charged, coating 
polymers. In non-aqueous systems, the coating polymer is 
water-insoluble and this technique is suitable for the 
encapsulation of water-soluble materials. 
In practice, the material to be encapsulated, liquid or 
solid, is dispersed into a solution of the coating polymer 
by stirring. The coacervating agent is then gradually 
added. The precise mechanism by which the encapsulation 
4 
process takes place is not entirely clear, but the material 
to be coated may act as nuclei for formation of the 
coacervates. Alternatively, large coacervates may form 
which then engulf the material to be encapsulated. 
There are numerous examples of the application of phase 
separation techniques to the preparation of microcapsules 
of pharmaceutical interest. Although many apply to 
hydrophilic polymers such as gelatin (e. g. Dixon, 1981; 
Paradissis and Parrott, 1968; Raymond et al., 1990) and 
methylcellulose (Salib et al., 1976), the hydrophobic 
polymer, ethylcellulose, has also been widely used (e. g. 
Alpar and Walters, 1981; Benita and Donbrow, 1982; Jalsenak 
et al., 1976). Other polymers used have included the 
acrylic EudragitsTM (Benita et al., 1985; Chattaraj et al., 
1991; El-Sayed et al., 1982) and lactic/glycolic acid 
copolymer (PLGA) (McGee et al., 1991; Sanders et al., 
1984). 
1.1.2.2. Suspension cross-linking 
In suspension cross-linking, a solution or melt of the 
polymer of interest is suspended in an immiscible liquid. 
Hardening of the droplets is then carried out and the 
microspheres/capsules collected (Arshady, 1989; Deasy, 
1984). 
The main pharmaceutical application of this technique is 
for the preparation of albumin microspheres. Here, the drug 
to be encapsulated is dispersed into an aqueous solution of 
albumin which is then emulsified into an immiscible liquid 
e. g. vegetable oil. Cross-linking can be brought about by 
heating the emulsion or by addition of glutaraldehyde 
(Arshady, 1989; Deasy, 1984). Pharmaceutical examples 
include the encapsulation of mitomycin C (Fujimoto et al., 
1985), adriamycin (Gupta et al., 1986) and 5-fluorouracil 
(Sugibayashi et al., 1979). 
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Suspension cross-linking has also been used to produce 
microspheres from gelatin (Yoshioka et al., 1981), 
fibrinogen (Miyuzaki et al., 1986) and haemoglobin (Levy et 
al., 1982). 
1.1.2.3. Emulsion polymerisation 
The most noteworthy application of this technique is for 
the production of biodegradable poly(alkylcyanoacrylate) 
nanoparticles. Here the alkylcyanoacrylate monomer solution 
is dispersed into an aqueous phase containing surf actant as 
stabiliser and drug. The hydroxyl ions present in the 
aqueous phase act as initiators for polymerisation. To slow 
down the rate of polymerisation and to enable nanoparticle 
formation, the aqueous phase has to be made acidic. In such 
systems, drug is generally considered to be adsorbed to the 
particle surface (Couvreur et al., 1986). 
Examples of drugs incorporated include anticancer agents 
(Couvreur et al., 1986; Verdun et al., 1986), pilocarpine 
(Harmia et al., 1986), triamcinolone diacetate (El-Samaligy 
and Rohdewald, 1983), and insulin (Michel et al., 1991). 
1.1.2.4. Mechanical methods 
There are a number of techniques especially applicable to 
the economic large scale manufacture of microencapsulated 
dosage forms for potential oral administration (Bakan and 
Anderson, 1976; Deasy, 1991; Li et al., 1988). 
These techniques firstly require the production of a drug- 
containing core. There are two main methods of core 
production. The first involves spraying a solution of drug 
and adhesive onto inert sucrose pellets (non-pareils) in a 
coating pan. Alternatively, extrusion-spheronisation may be 
used to produce pellets from drug and suitable excipients. 
Polymer films are then applied to the drug cores by pan 
coating or air suspension techniques to generate the 
6 
desired properties e. g. enteric protection, sustained 
release. 
1.1.2.5. Emulsification-solvent evaporation 
The first report of the application of this technique for 
the microencapsulation of pharmaceuticals was in 1979 (Beck 
et al., 1979) in a paper describing the preparation of 
poly(lactic acid) (PLA) microspheres containing 
progesterone. 
The process is outlined in figure 1.1. In the first step, 
a solution of polymer containing the drug to be 
encapsulated (either dissolved or in suspension) is 
emulsified into a second, immiscible, liquid containing a 
surfactant. This results in the formation of a dispersion 
of drug-polymer-solvent droplets. 
In the second stage of the process, the solvent is 
evaporated from the dispersed droplets. In many instances, 
the volatility of the solvent is sufficient for it to 
rapidly evaporate at room temperature whilst stirring of 
the emulsion continues. To hasten evaporation, and for 
systems where solvent evaporation is less rapid, heat 
and/or vacuum may be applied. The evaporation of solvent 
results in precipitation of polymer around the drug and the 
formation of a suspension of microspheres. The microspheres 
can then be extracted by filtration or centrifugation and 
dried. 
One of the attractions of the solvent evaporation technique 
is that by selection of suitable solvent systems, 
hydrophilic and hydrophobic drugs can be encapsulated into 
a wide range of polymers. In addition, the technique is 
able to produce microspheres over a wide size range, from 
nanometre to millimetre. 
Although the emulsification-solvent evaporation process is 
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Figure 1.1. Microencapsulation using emulsification-solvent evaporation. 
1. 
ki 
Polymer dissolved in organic 
solvent. Drug added to form 
a solution or suspension. 
'Woooý 
2. 
Emulsifier dissolved 
in second liquid immiscible 
with drug-polymer solution. 
Polymer-drug solution mixed 
into emulsifier solution to 
form a dispersion of drug- 
polymer-solvent droplets. 
5. 
looses 
Solvent removed by: 
a) Stirring at room temperature. 
b) Application of heat. 
c) Application of vacuum. 
Completed microspheres recovered 
by filtration or centrifugation then 
washed and dried. 
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conceptually simple to understand, the final structure and 
composition of a completed microsphere will result from a 
complex interplay between the polymer, drug, solvent and 
emulsifier solution. The following sections discuss the 
importance of some of these factors in more detail. 
A. Optimisation of drug loading 
Clearly one of the prime objectives in designing a 
microencapsulation process is to maximise the efficiency of 
drug encapsulation. The loading efficiency will be 
determined by the extent to which the drug is lost from the 
forming microspheres into the surrounding emulsifier 
solution during solvent evaporation. In turn, this will be 
determined by the relative affinity of the drug for the two 
liquid phases i. e. the solvent containing drug and polymer 
(dispersed phase) and the emulsifier solution (continuous 
phase). 
Table 1.1. lists some of the important criteria to be 
considered when selecting the dispersed and continuous 
phase liquids. 
In general, poor efficiency of drug encapsulation might be 
predicted if a polymer solution containing a hydrophilic 
drug is emulsified into an aqueous surfactant solution to 
form an oil-in-water dispersion (o/w). For example, three 
hydrophilic drugs, salicylic acid, theophylline and 
caffeine, could not be encapsulated into PLA by dispersion 
of a drug-polymer solution into aqueous surfactant solution 
(Bodeneier and McGinity, 1987a). 
The problems of encapsulating highly water-soluble drugs 
can be overcome by the use of oil-in-oil (o/o) type 
emulsion systems where the polymer and drug, contained in 
a hydrophilic organic solvent are emulsified into an 
immiscible hydrophobic liquid (e. g. mineral oil). Water- 
soluble drugs encapsulated in this way have included 
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Table 1.1. Criteria for selection of continuous and dispersed 
phase solvents. 
Disneohase solvent 
1. Able to dissolve encapsulating polymer. 
2. Ideally, able to dissolve drug to be encapsulated. 
3. Immiscibility with continuous phase solvent. 
4. Lower boiling point than continuous phase solvent. 
5. Low toxicity. 
Continuous nhnse solvent 
1. Immiscibility with dispersed phase solvent. 
2. Low solubility toward encapsulating polymer. 
3. Low solubility toward drug. 
4. Higher boiling point than dispersed phase solvent. 
5. Low toxicity. 
6. Allows easy recovery and clean-up of microspheres. 
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diphenhydramine hydrochloride (Huang and Ghebre-Sellasie, 
1989), cephradine and cefadroxil (Uchida and Goto, 1988), 
mitomycin C (Tsai et al., 1986) and adriamycin (Wada et 
al., 1988). However, one of the drawbacks of this technique 
is clean-up of the completed microspheres. Removal of the 
oil phase from the microspheres may involve washing with 
solvents such as hexane, residues of which would be 
undesirable in the final product. 
The problem of microsphere clean-up when using o/o 
techniques can be avoided by the use of a (water-in-oil)- 
in-water technique (w/o/w), outlined in figure 1.2. This 
method has been used to encapsulate the highly water- 
soluble LHRH agonist, leuprolide acetate (Ogawa et al., 
1988). The encapsulating polymer, PLA or PLGA, dissolved in 
dichloromethane was emulsified into an aqueous drug 
solution to form a w/o emulsion. This emulsion was then 
emulsified into 0.5% aqueous poly vinyl alcohol) (PVA) 
solution to produce a w/o/w dispersion. Subsequent 
evaporation of the dichloromethane left an aqueous 
suspension of microspheres. This technique has also been 
used for other systems including the entrapment of proteins 
into PLGA microspheres (Cohen et al., 1991; O'Hagan et al., 
1991) and a somatostatin analogue into branched PLGA d- 
glucose polymers (Bodmer and Kissel, 1991). 
Enhancement in drug loading has also been attempted by 
including drug in the continuous phase as well as the 
polymer solution. For example, increased loading of 
quinidine sulphate in PLA microspheres was achieved by 
using an aqueous surfactant solution saturated with drug 
(Bodmeier and McGinity, 1987b). In the case of cisplatin- 
containing polyester microspheres, preloading the external 
aqueous phase with drug also changed their morphology. In 
the absence of extra cisplatin the microsphere surface was 
smooth, but when drug was present in the external phase 
crystals were seen on the surface. Their presence was 
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Figure 1.2. A (water-in-oil)-in water technique for encapsulation 
of water-soluble drugs. 
1. 
3. 
Water-immiscible 
solvent containing 
polymer and w/o 
emulsifier. 
2. 
d / 
Aqueous drug solution. 
6. 
N 
Aqueous drug droplets 
dispersed in polymer 
solution. 
4. 
Aqueous solution of 
o/w emulsifier. 
/ 
Solvent removed to leave a 
suspension of microspheres 
containing aqueous drug 
solution. 
w/o/w emulsion: droplets of 
polymer solution containing 
droplets of drug solution. 
7. 
aß 
1 
"gD In 
Microsphere suspension 
filtered or centrifuged, 
washed and dried. 
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thought to result from an inability to dissolve into the 
drug-saturated aqueous phase during microsphere formation 
(Splenhauer et al., 1988). 
For drugs with pH-sensitive solubility, it may be possible 
to reduce partitioning by adjustment of the aqueous phase 
pH. The solubilities of quinidine and quinidine sulphate 
decrease with increasing pH, and below pH 7, where aqueous 
solubility was high, very little could be encapsulated into 
PLA. However, above pH 10, loading was maximised at an 
incorporation efficiency greater than 67%, although 
detrimental changes in microsphere surface morphology 
resulting from polymer damage were also observed (Bodmeier 
and McGinity, 1987b). Diazepam showed a similar pH- 
sensitive loading; at pH 2 the microsphere drug content was 
14.5%, increasing to 21.1% at pH 7 (Bodmeier and McGinity, 
1987a). 
The choice of the dispersed phase solvent has also been 
shown to have effects on microsphere drug loading. A high 
entrapment efficiency of quinidine sulphate into PLA 
microspheres was favoured by dissolution of drug and 
polymer in water-immiscible solvents with significant water 
solubility. It was considered that such solvents caused 
rapid precipitation of polymer at the droplet interface, 
thereby creating a barrier to drug diffusion out of the 
forming microsphere. The solvent able to achieve the 
highest drug loading (23% w/w) was dichloromethane, which 
had the highest aqueous solubility (2% w/w). On the other 
hand, insignificant drug loading (0.4% w/w) was achieved 
with chloroform, which had an aqueous solubility of just 
0.8% w/w. If water-miscible solvents were used, polymer 
agglomerates were formed on mixing, although it was 
possible to produce discrete microspheres with a high drug 
loading by using a dispersed phase containing 30% of a 
water-miscible solvent (Bodmeier and McGininty, 1988). 
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B. Emulsifier 
The role of the emulsifier in solvent evaporation processes 
is the short term stabilisation of the suspended polymer 
droplets. 
Many of the published o/w emulsification techniques utilise 
polymeric stabilisers such as gelatin, PVA and 
methylcellulose and the increase in solution viscosity that 
these polymers can produce may affect microsphere 
properties. For example, the use of methylcellulose 400 as 
a stabiliser produced a high viscosity external phase that 
resulted in distorted, ovoid-shaped microparticles 
(Cavalier et al., 1986). In another system, for a given set 
of mixing conditions, microsphere size was found to 
increase with increasing PVA concentration (Benita et al., 
1984). On the other hand, other workers have produced 
smaller microspheres with 1% sodium alginate as an 
emulsifier than with a lower viscosity 1 or 2% gelatin 
solution (Wakiyama et al., 1981; Kojima et al., 1984). 
Other o/w stabilisers used have included the polysorbates 
(TweensTM) (e. g. Bodmeier and McGinity, 1984b; Smith and 
Hunneyball, 1986), sodium oleate (Fong et al., 1986) and 
sodium dodecyl sulphate (SDS) (Suzuki and Price, 1985). 
Typical emulsiers for o/o systems are the sorbitan esters 
(SpansTM) (e. g. Huang and Ghebre-Sellasie, 1989) and 
lecithin (e. g. Wada et al., 1988). 
An unfortunate effect of emulsifiers is their ability to 
enhance the solubility of drugs. When attempting to 
encapsulate lomustine and progesterone in PLA, crystals 
appeared both on the microsphere surface and in the aqueous 
phase as a result of enhanced solubilisation by the 
emulsifiers, PVA and methylcellulose. The crystals could be 
eliminated and drug loading enhanced by removal of the 
emulsifier solution halfway through solvent evaporation and 
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resuspension of the partly solidifed microspheres in water 
(Benita et al., 1984b). 
The use of PVA as an emulsifier has also been found to have 
dramatic effects on the release of insulin from PLA 
microspheres. The emulsifier was thought to promote the 
growth of insulin crystals, by solubilisation, at the 
microsphere surface, and this resulted in a marked burst 
effect with instantaneous release of up to 88% of the 
encapsulated drug on in vitro testing. However, the use of 
1% gelatin solution as an emulsifier resulted in an initial 
release of only 26% of the encapsulated drug. This 
difference in behaviour may have resulted from gelatin 
being a less efficient solubiliser than PVA of insulin 
(Kwong et al., 1986). 
In another paper, an increase from 0 to 2% in the 
concentration of Tween 20 in the aqueous phase caused a 
small reduction in microsphere quinidine content. Apart 
from enhanced drug solubilisation, another reason 
attributed to reduced drug content was stabilisation of the 
drug-polymer interface by the surfactant; It was proposed 
that this would reduce the rate of solvent loss, thereby 
reducing the polymer precipitation rate and allowing more 
drug to escape from the forming microsphere before an 
adequate polymeric diffusional barrier could be formed 
(Bodmeier and McGinity, 1987c). 
C. Control of microsphere size 
The principal parameters controlling microsphere size are 
the speed, equipment, and technique used for mixing the two 
phases, and the concentration of polymer in the dispersed 
phase. 
The microsphere size tends to decrease exponentially with 
increasing mixing speed, accompanied by a narrowing in the 
particle size distribution (Benita et al., 1984b; Babay et 
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al., 1988; Barkai et al., 1990). 
The design of the mixing vessel can affect both the size 
and yield of microspheres. Inclusion of baffles in the 
mixing vessel eliminated vortex formation, and as a result 
the microsphere yield increased from 50 to 90 %. In 
addition, break-up of the drug-polymer droplets on the 
baffles reduced the average microsphere size from greater 
than 75 µm to less than 30 µm (Bodeneier and McGinity, 
1987b). 
The microsphere size, in general, tends to increase with 
polymer concentration. For example, microspheres made from 
a 2% w/v solution of EudragitTM polymers had a mean 
diameter of 140 µm, whereas microspheres produced with a 5% 
w/v solution had a mean diameter of 295 µm (Pongpaibul et 
al., 1984). There are two contributing factors here: 1) By 
increasing the concentration of polymer in the dispersed 
phase, the solution viscosity will increase and so for a 
given set of mixing conditions the droplet size and so 
final microsphere size will tend to be larger; 2) An 
increase in the concentration of polymer inside the droplet 
increases the volume it occupies when the solvent has 
evaporated, although this will be offset to some extent by 
a reduction in microsphere porosity with increasing polymer 
concentration. An increase in the density of 
poly(anhydride) microspheres was observed when the 
concentration of polymer solution used for preparation was 
increased (Mathiowitz et al., 1990). 
1.1.3. Polymers used for microsphere fabrication 
There are two main classes of polymer used for producing 
microspheres by solvent evaporation, biodegradable and non- 
biodegradable. In general, microspheres produced from 
biodegradable polymers are for potential parenteral 
administration whereas microspheres produced from non- 
biodegradable polymers are for potential oral 
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administration. 
1.1.3.1. Biodegradable polymers 
A. Polyesters 
The most important class of biodegradable polyesters are 
those based upon lactic and glycolic acids: poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA) and lactic/glycolic 
acid copolymers (PLGA). In vivo, these polymers degrade by 
hydrolysis to their constituent acids which are non-toxic 
and easily excreted. Excellent biocompatibility has been 
demonstrated through their use as resorbable sutures and 
prostheses. The other major attraction of the polyesters is 
their ability to achieve prolonged release of drug. Drug 
permeability is low and release is measured in days, weeks 
or even months, and results from a combination of diffusion 
and polymer erosion (Juni and Nakano, 1987; Wise et al., 
1979). 
A large number of drugs have been encapsulated into 
polyester microspheres using emulsification-solvent 
evaporation including anticancer agents (e. g. Spenlehauer 
et al., 1988; Tsai et al., 1986; Wada et al., 1988), 
insulin (Kwong et al., 1986), corticosteroids (e. g. 
Cavalier et al., 1986; Fong et al., 1986; Smith and 
Hunneyball, 1986), steroid hormones (e. g. Beck et al., 
1979,1981; Benoit et al., 1986), narcotic antagonists (Cha 
and Pitt, 1988,1989), and neuroleptics (e. g. Fong et al., 
1986; Maulding et al., 1986; Suzuki and Price, 1985). 
Proteins have also been encapsulated into polyester 
microspheres. PLGA microspheres have been produced 
containing bovine serum albumin and horse radish peroxidase 
(Cohen et al., 1991), human serum albumin (Hora et al., 
1990), and ovalbumin (O'Hagan et al., 1991). 
PGA has not been widely used as an encapsulating polymer 
because of its poor solubility in common solvents. One 
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example is the encapsulation of prednisolone-21-acetate by 
codissolution of drug and polymer in hexafluoroacetone 
sesquihydrate, followed by emulsification into carbon 
tetrachloride containing sorbitan sesquioleate as 
surfactant (Redmon et al., 1989). In this system, solvent 
evaporation was carried out by two different methods. The 
solvent was partially evaporated to produce a suspension of 
part-formed microspheres. Complete removal was then carried 
out by either stirring the dispersion in 1,4-dioxane and 
allowing solvent to evaporate or by freeze-drying the part- 
formed microspheres. The microspheres completed by stirring 
released drug more rapidly than those completed by freeze- 
drying. The difference in release was thought to reflect 
differences in microsphere porosity, since the surface area 
of the microspheres completed by stirring was two to three 
times greater than the freeze-dried microspheres. 
Other biodegradable polyesters utilised in solvent 
evaporation processes have been poly(ß-hydroxybutyrate) 
(PHB) (Bissexy et al., 1984; Juni et al., 1987), and 
poly(carbonates) (Kojima et al., 1984). 
PHB microspheres less than 200 nm in diameter have been 
prepared by dispersion of a 1.6% w/v solution of polymer in 
chloroform into 0.2% w/v aqueous SDS solution. Following 
initial mixing of the two phases by homogeniser, the 
emulsion was sonicated for 30 minutes followed by 
evaporation of solvent (Koosha et al., 1989). 
B. Polv(anhvdrides) 
Poly(anhydrides) are hydrophobic polymers which undergo 
surface erosion via water-labile anhydride linkages. By 
choosing different backbone structures, a wide range of 
degradation and thus drug release rates can be achieved 
(Leong et al., 1986). Good biocompatibility has been 
demonstrated, and drug-containing poly(anhydride) implants 
for treatment of brain cancer are undergoing human clinical 
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trials (Domb et al., 1991). 
Drugs microencapsulated into poly (anhydrides) using solvent 
evaporation have included insulin (Mathiowitz et al., 1988, 
1990) and bethanechol (Howard et al., 1989). 
Insulin-containing microspheres were produced by both an 
o/w and o/o emulsification procedure. On implantation into 
rats, the rate of insulin release from the microspheres 
produced by the o/w procedure was so fast that most of the 
animals died within a day from hypoglycaemia, whereas a 
prolonged lowering of serum glucose was seen for the 
microspheres produced by the o/o procedure. The rapid 
release of insulin from the o/w microspheres was considered 
to be due to high porosity and possibly accelerated polymer 
degradation during microsphere preparation (Mathiowitz et 
al., 1990). 
1.1.3.2. Non-biodegradable polymers 
A. Acrylic polymers 
i). Eudragits 
The main group of pharmaceutically important acrylic 
polymers are the Eudragits (trade mark of Rdhm Pharma, 
Darmstadt, Germany), based upon acrylic and methacrylic 
acids. There are five different Eudragit polymers and their 
chemical structures are detailed in table 1.2. They are 
available as solids or ready-to-use solutions and latexes. 
Eudragit E is a so-called "reverse enteric" which dissolves 
at acidic pH, but is insoluble at higher pH levels. One of 
the uses of this material is for coating tablets to provide 
improved stability or taste masking whilst allowing rapid 
disintegration in the stomach (Handbook of Pharmaceutical 
Excipients, 1986; Eudragit technical data). 
Eudragits L and S are enteric polymers which dissolve above 
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pH 6.0 and 7.0 respectively to form polymeric salts. 
Eudragit L dissolves at the lower pH since it contains the 
greater proportion of soluble poly(methacrylic acid) 
functions. Below the critical pH values, the polymers are 
water-impermeable (Handbook of Pharmaceutical Excipients, 
1986; Eudragit technical data). 
Eudragits RL and RS are both insoluble in the pH range of 
the gastrointestinal tract, yet are permeable. The 
permeability is conferred by the trimethyl ammonioethyl 
chloride functions (CH2CH2N(CH3)3+C1-) which are present as 
fully dissociated salts in the pH range 2 to 8. The 
proportion of these groups is greatest in Eudragit RL and 
so this polymer has the higher permeability to water and 
drugs (see figure 1.3, adapted from Eudragit technical 
data). The materials are commonly used as coatings to 
produce sustained-release tablets and pellets (Handbook of 
Pharmaceutical Excipients, 1986; Eudragit technical data). 
There are a number of reports on the use of Eudragits for 
manufacturing microspheres by the solvent evaporation 
technique. The majority have focused on the encapsulation 
of non-steroidal antiinflammatory drugs (NSAIDs). 
The first report of Eudragit microspheres being produced by 
emulsification-solvent evaporation appeared in 1985 (Goto 
et al., 1985). An attempt was made to encapsulate 42 
different drugs in Eudragit RS by dispersion of drug, 
polymer and magnesium stearate (stabiliser) in 
dichloromethane into water. Using this technique, only 
three of the drugs could be successfully encapsulated, 
sulphamethizole, frusemide and piretanide. Following 
solvent evaporation it was claimed that the microspheres 
were highly swollen, and removal of water, under reduced 
pressure, took several days. On drying, microspheres were 
found to be very fragile. 
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Figure 1.3 
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a) Permeability of Eudragit RWRS mixtures to water vapour 
b) Permeability of RLIRS mixtures to trifluoperazine HCI, 
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Microspheres with improved physical properties were 
produced using an o/o technique. Ketoprofen (a NSAID) and 
aluminium tristearate as stabiliser were dispersed into a 
solution of Eudragit RS dissolved in acetone. This mixture 
was emulsified into liquid paraffin, the acetone evaporated 
by warming, and the completed microspheres washed with 
hexane prior to drying. A marked sustaining of drug release 
was observed (Kawata et al., 1986). 
Further work investigated ketoprof en encapsulation into the 
entire range of Eudragit polymers. Eudragit E, L, and S 
microspheres containing up to 40% w/w ketoprofen were 
produced. In an acidic medium, Eudragit E microspheres 
dissolved rapidly and released their encapsulated drug, 
whereas the L and S microspheres resisted release until pH 
6.06 and pH 6.74 respectively (Goto and Kawata, 1986a). RL 
microspheres containing 40% w/w ketoprofen released all of 
their drug within 1 hour, while equivalent RS microspheres 
had released less than 50% of encapsulated drug within 8 
hours. Microspheres produced from a 50: 50 blend of RL and 
RS provided an intermediate rate of drug release (Goto et 
al., 1986b). All of these Eudragit microspheres were 
between 0.25 and 1 mm in diameter. 
Other workers have successfully produced Eudragit RS and RL 
microspheres containing indomethacin using o/w techniques. 
In one case, microspheres were produced by dispersion of 5- 
10 ml of polymer solution in methylene chloride into 1.4 L 
of 0.25% w/v PVA solution. RL microspheres (105-180 µm in 
diameter) released about 70% of drug within 8 hours, while 
equivalent RS microspheres had released less than 10% 
(Bodeneier and Chen, 1989a). In another report, Eudragit RL 
microspheres were produced by emulsification of 20 ml of 
10% w/v polymer in dichloromethane into 250 ml of 0.8% w/v 
PVA solution. Sustained release of drug was demonstrated 
(Babay et al., 1988). 
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A comparison has been made between Eudragit RL/RS- 
indomethacin microspheres produced by o/w and o/o 
techniques. In the first instance, microspheres were 
produced by emulsification of polymer and drug dissolved in 
75 ml of dichloromethane into 300 ml of 0.5% aqueous PVA 
solution. The second set of microspheres were produced by 
emulsification of drug and polymer in ethanol into an 
external phase consisting of 270 ml liquid paraffin, 30 ml 
of silicone oil and 3g of Span 85 as emulsifier. 
Microspheres produced using the o/w system were more 
porous, had a higher drug content, and released drug more 
rapidly than microspheres produced using the o/o system 
(Malamataris and Avgerinos, 1990). 
Indomethacin microspheres have also been produced from a 
blend of Eudragits RS and L using an o/o technique. 
Dissolution testing was carried out at pH 6.5, and as the 
proportion of L increased, so did the drug release rate 
(Pongpaibul et al., 1984). 
ii). Polv(methvlmethacrvlate) 
Poly(methylmethacrylate) (PNNA) is a water-insoluble, 
water-impermeable polymer, and one of its uses is as a bone 
cement (Charnley and Pusso, 1968). 
Using an o/o solvent evaporation procedure, theophylline 
has been microencapsulated in PMMA. As a result of the low 
permeability of the polymer, polyethylene glycol (PEG) 4000 
was included in all formulations. In contact with water, 
the PEG dissolved to form pores in the microsphere matrix, 
and the higher the PEG content the more rapid the rate of 
drug release (Pongpaibul et al., 1988). 
B. Celluloses 
Ethylcellulose is a hydrophobic, highly water-insoluble 
polymer, widely' used as a pharmaceutical excipient for 
orally administered dosage forms (Handbook of 
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Pharmaceutical Excipients, 1986). It has also been used to 
produce microspheres by solvent evaporation. 
Using o/w techniques, ethylcellulose microspheres 
containing indomethacin have been produced. In one case, 
the drug release rate was increased by the addition of PEG 
to the microspheres, but it was still considered too low to 
be of practical use (Babay et al., 1988). 
In another example, indomethacin-ethylcellulose 
microspheres (105-180 µm diameter) were prepared using 
either chloroform or dichloromethane to dissolve drug and 
polymer. Microspheres prepared from both solvents had the 
same drug content, but the drug release rates differed 
dramatically. The microspheres prepared using chloroform 
released more than 75% of encapsulated drug within two 
hours, whilst the microspheres prepared with 
dichloromethane had released less than 5% of drug within 24 
hours. The differences were considered to be due to 
differences in the relative solubility of drug and polymer. 
When dichloromethane was used, polymer precipitated before 
drug, but with chloroform, drug precipitated before polymer 
and crystals were evident on the microsphere surface. The 
indomethacin release rate from the microspheres prepared 
using dichloromethane could be increased by incorporation 
of the more permeable polyester, poly(caprolactone) 
(Bodmeier and Chen, 1989a). 
Addition of water-insoluble plasticisers to ethylcellulose 
microspheres containing diphenhydramine hydrochloride 
reduced the drug release rate, possibly as a result of 
reducing the porosity of the polymer matrix (Huang and 
Ghebre-Sellassie, 1989). 
For the antibiotics cephradine and cefadroxil, 
ethylcellulose microspheres containing up to 70% w/w drug 
were produced (Uchida and Goto, 1988). 
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Microspheres containing the diuretic, piretanide, have been 
produced from a mixture of ethylcellulose and hydroxypropyl 
cellulose. As the proportion of ethylcellulose was 
increased, the drug release rate decreased (Tsuyoshi et 
al., 1989). 
Different sizes of theophylline crystals have been 
encapsulated into cellulose acetate propionate (Shukla and 
Price, 1989). For microspheres of similar size and drug 
loading, the release rate of theophylline was faster from 
microspheres containing medium and large drug crystals than 
from samples containing micronised drug crystals. The rapid 
release from the larger drug crystals was probably a result 
of incomplete coating by the polymer. When encapsulating 
large drug particles, the result will tend to be misshapen 
drug-polymer microparticles, where any imperfections in the 
polymer coat will expose a large proportion of the 
underlying drug, resulting in rapid dissolution. However, 
with small drug particles, the drug will be highly 
dispersed within the microsphere polymer matrix, leading to 
a lower rate of release. 
1.1.4. Clinical use of microsphere-based delivery systems 
Figure 1.4. outlines some of the potential clinical uses of 
microsphere-based drug delivery systems. In the next 
section, some of these concepts will be expanded. 
1.1.4.1. Parenteral drug-delivery 
It is perhaps in the area of parenteral drug-delivery that 
microsphere-based drug delivery systems hold the greatest 
promise. There are two potential major applications: 
A. Sustained-release depots 
Parenteral sustained-release delivery systems based on 
biodegradable polymers have the potential for providing 
very long periods of drug release. One of the first systems 
to be clinically evaluated was norethisterone-containing 
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PLA microspheres, a potential long-acting contraceptive 
system. In female volunteers, release of drug for a period 
of up to six months was demonstrated (Beck et al., 1981). 
However, since complete biodegradation of the microspheres 
was thought to take a further six months, a more rapidly 
dissolving PLGA system was evaluated. On clinical testing, 
this system was shown to release norethisterone over a 
three month period (Beck et al., 1983). 
More recently, testosterone-PLGA microspheres have 
undergone clinical evaluation. A biphasic release pattern 
was seen, and during week 1 and between weeks 6 and 11 
postinjection, significant increases in plasma testosterone 
levels were measured (Burris et al., 1988). 
Parenteral delivery is of particular interest for the 
delivery of therapeutic peptides and proteins (Pitt, 1990) 
since these molecules generally show very poor 
bioavailability by other routes. A monthly-administered 
depot of PLGA microspheres has been developed for the 
delivery of the peptide, leuprolide acetate (Toguchi et 
al., 1991) and is now marketed ("Prostap SR", Lederle, UK). 
Other microsphere-based sustained-release parenteral depots 
have also progressed to the marketplace (Kissel et al., 
1988). 
B. Targetable drug carriers 
There are envisaged to be two mechanisms by which targeting 
of microspheres can take place: 
i). Passive targeting 
Passive targeting applies to systems where no effort is 
made to circumvent the body's natural defence against 
injected foreign particulate material. 
The simplest example would be the administration of 
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microspheres larger than the diameter of capillaries (3-11 
µm). Material would be entrapped in the first capillary bed 
encountered, which in the case of intravenous injection 
would be the lungs (Tomlinson, 1983). This principle is 
used for diagnostic imaging of the lungs by administration 
of radiolabelled albumin microspheres (Rhodes et al., 
1969). However, it is not clear whether lung entrapment 
could have any useful application in drug delivery (Davis 
and Illum, 1989). Selective arterial catheterisation can 
deposit material in the capillary bed of organs such as the 
liver or kidneys. This is the principle of arterial 
chemoembolisation (Kerr et al., 1991) in which microspheres 
containing anticancer agents have successfully been used to 
treat tumours (Nemoto and Kato, 1984; Fujimoto et al., 
1985). 
Particles small enough to flow through the capillaries will 
be trapped by cells of the reticuloendothelial system 
(RES). The RES consists of phagocytic cells found 
principally in the liver (Kupffer cells) but also in the 
spleen, lymph nodes, bone marrow, lungs and circulating in 
the blood and lymph (Altura and Saba, 1981). On entry into 
the circulation, foreign particles are rapidly coated with 
proteins (opsonins) that allow recognition and uptake by 
RES phagocytes. Thus, radiolabelled 1-5 µm PLG microspheres 
were primarily deposited in the liver of rats whether 
administered through the hepatic portal vein or jugular 
vein (Hazrati et al., 1989). Uses of RES targeting may 
include treatment of intracellular parasites and enzyme 
storage disorders (Davis and Ilium, 1986). However, the 
treatment of liver cancer in this way may be limited; a 
study in man demonstrated minimal uptake of particulates by 
liver tumour cells (Poste, 1985). 
ii). Active targeting 
Active targeting applies to systems that are designed to 
elude capture by the body's natural defence mechanisms, 
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thereby allowing drug delivery to tissues outside the RES 
or the carrier to remain in the circulation for prolonged 
periods. 
A major obstacle in achieving active targeting is the 
avoidance of RES uptake. It appears that the surface 
characteristics of the carrier are an important factor in 
determining its in vivo distribution. For example, coating 
microspheres with the surfactant, poloxamer 407, directed 
them away from the liver and spleen and toward the bone 
marrow, whereas a coating of poloxamine 908 increased 
retention in the vascular compartment. The presence of 
surfactant may have altered the profile of adsorbed 
opsonins or sterically inhibited interaction between the 
microspheres and phagocytic cells (Ilium et al., 1987). 
1.1.4.2. Oral drucr-delivery 
Multiparticulate carriers have been used for many years for 
the oral delivery of drugs, beginning with "Spansules" in 
the 1950s. Such systems are primarily used to provide 
sustained or delayed release of drug and technologies for 
their production were described in section 1.1.2.4. 
As mentioned earlier, most of the publications concerned 
with production of microspheres for potential oral 
administration have involved encapsulation of NSAIDs. One 
of the major side-effects of NSAIDs is gastric irritation 
leading to bleeding, and in some cases ulceration (Woodbury 
and Finch, 1975). By administering the drug in a dispersed 
system, the risk of local high concentrations of drug and 
therefore gastric irritation is greatly reduced. However, 
it is unlikely that microencapsulation techniques such as 
solvent evaporation would offer any benefits over the more 
conventional mechanical methods for the manufacture of 
these systems. 
A pharmacokinetic comparison of sustained-release 
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indomethacin administered as a commercially available 
pellet preparation or in Eudragit RL/RS microspheres has 
been reported. Both formulations demonstrated similar in 
vitro dissolution performance and were administered to 12 
healthy male volunteers in a cross-over study. Relative to 
a conventional capsule formulation the microspheres 
demonstrated higher bioavailability than the pellets, 
although the difference was not statistically significant 
(94.6±28.9 % and 84.8±26.5 % respectively) (Avgerinos and 
Malamataris, 1990). 
There are two potential areas of use for much smaller 
orally administered microencapsulated dosage forms which 
techniques such as solvent evaporation are able to provide. 
The first is the production of sustained-release or taste- 
masked oral liquid preparations. The major problem in such 
formulations is to minimise the particle size of the drug 
carrier since the texture of the product in the mouth is 
important for patient acceptability. Leaching of drug from 
the microspheres when suspended in a liquid carrier is a 
major potential obstacle to the development of these 
systems. Most enteric polymers tend to be relatively 
impervious and so provided the suspending vehicle is at the 
correct pH, loss of drug should not be a problem. Indeed 
dosage forms with bitter drugs contained within Eudragit 
microspheres, produced by solvent evaporation, are under 
development (Colston and Crainich, 1990). 
Sustained-release microparticulate suspensions of the 
poorly water-soluble drugs, indomethacin (Bodmeier and 
Chen, 1989a) and ibuprofen (Iwamoto et al., 1988), have 
been proposed. Leaching is more of a problem when 
developing sustained-release formulations for hydrophilic 
drugs, but can be overcome by the prior adsorption of the 
drug onto ion-exchange resin beads, which are then 
suspended in an ion-free vehicle (Raghunathan et al., 
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1981). 
Another potential application of orally-administered 
particulate carriers is for the delivery of vaccines and 
therapeutic proteins and peptides. There is increasing 
evidence for the intact uptake of very small (probably less 
than 5 µm) particulates when administered by the oral 
route, with the uptake considered to take place through the 
Peyers patches in the intestine (Jani et al., 1989). The 
number of particles taken up in this way is probably small, 
but for therapeutic agents with very small dosage 
requirements, and in particular vaccines, this might prove 
to be a viable route of administration (O'Hagan et al., 
1991). 
1.1.4.3. Other routes 
Systemic drug delivery by the nasal route is currently 
generating considerable interest, since it appears to be a 
suitable site for the absorption of peptides and proteins 
(Chien et al., 1989). However, without the use of 
absorption enhancers, the bioavailability of these 
molecules is invariably low, but has been shown to be 
increased by administering the drug in bioadhesive 
microspheres (Illum et al, 1990). The enhanced absorption 
from the bioadhesive formulation was probably a result of 
a reduced rate of nasal clearance. 
Another route of administration in which rapid clearance 
reduces drug bioavailability is the eye. Here also, 
particulate drug carriers have been used in an attempt to 
prolong contact between drug carrier and eye (Harmia et 
al., 1986; Fitzgerald et al., 1987). 
1.1.5. Summary 
Microsphere-based formulations hold great promise for 
improving the therapeutic performance of drugs administered 
by a number of routes and such delivery-systems are now 
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beginning to reach the marketplace. 
Of the various techniques available for microsphere 
production, the one chosen will depend on a number of 
factors including: 
a) The size of drug carrier required. 
b) The encapsulating polymer to be used. 
C) Solubility characteristics of drug. 
d) Physical stability of drug and polymer in different 
solvents. 
e) Practicality and economics of large scale-production. 
The emulsification/solvent evaporation technique is 
suitably versatile that it can be adapted to meet most of 
these requirements and accounts for its widespread usage. 
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1.2. THE COLON AS A SITE FOR DRUG-DELIVERY 
1.2.1. Introduction 
There is currently intense interest in the colon as a site 
for drug absorption and targeted drug release. Until 
recently, this portion of the gastrointestinal (GI) tract 
was largely neglected when considering oral drug delivery, 
and interest was confined to rectally administered dosage 
forms i. e. enemas and suppositories. 
There are primarily three reasons for the current interest 
in the colon as a site for drug-delivery: 
1. With the advent of gamma scintigraphy for the study of 
the GI transit of dosage forms, it has become apparent that 
small intestinal transit times are significantly less than 
previously thought. As a consequence, many sustained 
release oral dosage forms may be spending a considerable 
period of their drug-releasing lifetime in the colon. Thus 
knowledge of the colon absorption characteristics of the 
drugs in question are crucial, to ascertain whether or not 
a sustained-release system is appropriate. 
2. The second reason for an interest in the colon is as a 
site for local treatment of colonic disease. The major 
stimulus for research in this the area is the demand for 
dosage forms capable of delivering 5-aminosalicylic acid 
into the colon for topical treatment of inflammatory bowel 
disease. Targeted delivery is required since this drug is 
well absorbed from the small intestine and, as a result, 
not available for topical action in the colon. 
3. A proliferation of novel molecules arising from 
biotechnology is injecting new impetus into research of the 
feasibility of oral peptide/protein delivery. The colon is 
of particular interest in this respect since the lumenal pH 
and enzyme content are considered to be more favourable to 
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peptide/protein stability than the rest of the GI tract. 
Later sections of the chapter will consider these issues in 
more detail, including strategies for targeting drugs into 
the colon. 
1.2.2. Structure and function of the colon 
The colon forms the lower part of the GI tract, extending 
from the ileo-caecal junction to the anus. Its general 
function is to consolidate the intestinal contents into 
faeces by the absorption of water and electrolytes, and to 
store the faeces until excretion. The slow movement of 
materials through the colon also allows a large bacterial 
population to thrive, which has important nutritional 
implications in some mammals (Christensen, 1987). 
The colon is divided into a number of anatomical regions, 
namely the caecum, the ascending colon, the hepatic 
flexure, the transverse colon, the splenic flexure, the 
descending colon, the sigmoid colon and the rectum/anal 
canal (figure 1.5). 
The intestinal contents (chyme) enter into the colon from 
the ileum through the ileo-caecal junction. The caecum 
forms a pouch, about 6.5 cm long, above which lies the 
ascending colon, approximately 20 cm in length extending to 
the hepatic flexure. Between the hepatic and splenic 
flexures lies the transverse colon, 40-50 cm in length. The 
descending colon extends for 30 cm and then becomes the 
sigmoid colon, between 15 and 50 cm in length. The colon 
ends with the rectum and anal canal (Haubrich, 1985). 
In common with rest of the GI tract, the colon wall 
contains three layers of muscle, two longitudinal and one 
circular which allow mixing and propulsive movements to 
take place (Ganong, 1981). In the colon however, the outer 
layer of longitudinal muscle is concentrated into three 
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Figure 1.5. Anatomy of the human colon. 
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bands, the teniae coli. Between these bands the 
longitudinal muscle is still present but it is very thin, 
which allows the inner layer of circular muscle to form 
outward bulges. At regular intervals, there are tight 
contractions of circular muscle resulting in formation of 
the haustra (Christensen, 1987)(see figure 1.5). 
Activity in the colon consists of two modes, segmental and 
propulsive. Segmenting movements, effected by circular 
muscle and causing the appearance of haustra, predominate 
and result in mixing of the lumenal contents (Steed et al., 
1989). The mixing function has been demonstrated by a study 
involving administration of different-sized radiopaque 
discs 36,24 and 12 hours before X-ray imaging of the 
colon. The images showed the discs to be out of 
chronological order with some of the most recently 
administered having travelled furthest (Halls, 1965). 
Significant propulsive activity, effected by longitudinal 
muscle, is less common and in humans occurs an average of 
three or four times daily (Steed et al., 1989). The 
predominant activity is considered to depend on the 
function of the different colon regions. Retrograde 
movements are common in the proximal portions of the colon 
and serve to increase the retention of material in the 
ascending colon and caecum. In the middle section of the 
colon, segmenting movements result in a slow progression of 
faeces towards the rectum, whereas in the distal portions 
of the colon propulsive activity, associated with 
defecation, predominates (Christensen, 1987). 
Each day, approximately 1500 ml of chyme enter the colon 
from the ileum, from which more than 90% of the fluid is 
absorbed (Phillips and Giller, 1973). Fluid and salt 
absorption is assisted by the segmenting movements which 
circulate the chyme across the colonic mucosa. In the 
healthy human colon, sodium and chloride ions are usually 
absorbed, while potassium and bicarbonate ions are usually 
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secreted (Binder and Sandle, 1987). 
The progressive absorption of water as material passes 
along the colon results in a progressively solidifying 
mass. Whereas the contents of the caecum and ascending 
colon are fluid and semi-solid, in the transverse colon 
solidification commences, while in the descending colon, 
solid faeces has formed (Steed et al., 1989). 
1.2.3. Colon environment 
1.2.3.1. Microorganisms 
All parts of the GI tract contain microorganisms, but in 
the human the greatest population by far is found in the 
colon. Over 400 species of bacteria are present and a small 
number of fungi. Anaerobic bacteria predominate and the 
most prevalent species are Bacteroides, Bifidobacterium, 
and Eubacterium (Simon and Gorbach, 1987). 
The principal source of nutrition for the colonic 
microflora are undigested polysaccharides. These include 
starch, lactose and various other di- and trisaccharides. 
Also digested by the bacteria for their energy content are 
some of the non-starch polysaccharides (dietary fibres). 
The main products of fermentation are short chain fatty 
acids, carbon dioxide, methane and hydrogen (Rubinstein, 
1990). 
1.2.3.2. pH in the colon 
Radiotelemetry has been used to measure the 
gastrointestinal pH in healthy human subjects. The highest 
pH levels (7.5±0.5) were found in the terminal ileum. On 
entry into the colon, the pH dropped sharply to 6.4±0.6. 
The pH in the mid-colon was measured at 6.610.8 and in the 
left colon, 7.0±0.7 (Evans et al., 1988). The drop in pH on 
entry into the colon is probably due to the presence of 
short chain fatty acids arising from the bacterial 
fermentation of unabsorbed polysaccharides. 
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Polysaccharide drugs and dietary content can affect the 
colonic pH. For example, the laxative, lactulose, a semi- 
synthetic disaccharide, is fermented by the colonic 
bacteria to produce considerable amounts of lactic acid. 
This results in acidification of the colon contents with 
the pH dropping to about 5 (Avery et al., 1972). The in 
vitro fermentation of two other pharmaceutical 
polysaccharides, ispaghula and guar gum, in the presence of 
faecal bacteria also resulted in a fall in pH (Tomlin and 
Read, 1988). 
A diet high in dietary fibre would result in a high colonic 
concentration of unmetabolised polysaccharides and would 
presumably also cause a reduction in colonic pH. 
1.2.3.3. Faecal content 
By weight, faeces is typically 75% water. Of the solid 
material, about 30% is bacteria, 15% inorganic materials 
(principally calcium and phosphates), 5% fat, and the 
remainder mainly undigested plant fibres (Ganong, 1981). 
1.2.4. Issues of importance to drug delivery 
1.2.4.1. Transit of materials through the colon 
Traditionally, GI transit has been measured by oral 
administration of a marker (e. g. radiopaque pellets) 
followed by monitoring of its appearance in the stools 
(Hinton et al., 1969). More valuable information on transit 
can be obtained by administration of radiopaque pellets 
followed by regular X-rays (Hossain et al., 1990), although 
the drawback of this technique is the high radiation 
exposure received by the subjects being examined. 
Gamma scintigraphy has proved to be a more valuable method 
for measuring transit times through the GI tract (Digenis 
and Sandefer, 1991; Wilding et al., 1991; Wilson and 
Washington, 1988). A major benefit is the considerably 
reduced radiation dose received by the patient compared to 
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X-ray techniques; whereas when using radiopaque markers, 
images are generally only recorded daily to minimise 
radiation exposure, this problem is not encountered with 
gamma scintigraphic investigations. This allows frequent 
images to be recorded and yields considerably more 
information on the dynamics of GI transit. 
The total transit of a dosage form through the GI tract can 
essentially be divided into three phases, gastric, small 
intestinal and large intestinal. 
Gastric emptying of dosage forms is highly variable and 
depends principally on whether the subject is fed, and the 
physical properties of the dosage form such as size and 
density (Wilson and Washington, 1988). The emptying of non- 
disintegrating single units from the fasted stomach in one 
study varied from 15 minutes to more than three hours (Kaus 
et al., 1984). The presence of food may result in prolonged 
retention of the dosage form and in some cases, with 
regular feeding, dosage forms have been seen to reside in 
the stomach for periods in excess of 11 hours (Davis et 
al., 1984a; Wilson et al., 1989). 
The small intestinal transit time is less variable. A 
summary of 201 gamma scintigraphic studies reported that 
the mean small intestinal transit time was 3-4 hours and 
appeared to be independent of the type of dosage form 
(single units, pellets, solutions) and whether the subject 
was in a fed or fasted state. The longest times recorded 
were in excess of 6 hours whereas the shortest were less 
than 1 hour (Davis et al., 1986). 
Therefore, a non-disintegrating, orally administered dosage 
form can potentially arrive at the colon within less than 
four hours after administration. 
In comparison to the other regions of the GI tract, 
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movement of materials through the colon is slow. The total 
time for transit tends to be highly variable and influenced 
by a number of factors such as diet, in particular dietary 
fibre content, mobility, stress, disease and drugs (Barrow 
et al., 1991). 
A. Transit under normal conditions 
There have been a number of detailed studies of transit 
through the colon. Using a radiopaque marker technique, 
transit times in a group of 73 healthy adults have been 
estimated. For the male subjects, mean time to the hepatic 
flexure was 8h and to the splenic flexure, 14 h, with a 
mean total colon transit time of 31 h. For the female 
subjects, movement of markers was considerably slower with 
transit taking 11 h to the hepatic flexure and 21 h to the 
splenic flexure, with a mean total transit time of 39 h 
(Metcalf et al., 1987). 
The effect of gender on transit is unclear since some 
studies have found slower transit in females (Abrahamsson 
et al., 1988; Metcalf et al., 1987) whereas others have 
shown no difference (Hinds et al., 1989; Wyman et al., 
1978). 
Five 5 mm radiolabelled non-disintegrating tablets were 
administered to six healthy subjects on three consecutive 
days. In all cases, the tablets were found to become widely 
dispersed on passage through the colon. The transit rates 
varied considerably, with the mouth to anus transit time 
for a group of five tablets varying from 18 hours to 72 
hours. The mouth to colon component of total transit was 
between 2h and >11 h (Khosla and Davis, 1989). 
The GI transit of a non-disintegrating osmotic tablet 
("Oros") has been measured in six subjects. On a fasted 
stomach, gastric emptying was rapid with a mean of 0.8 h. 
Mean small intestinal transit was 3.0 h. Movement through 
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the colon was considerably more variable with a median 
transit time of 20.9 h. In one of the subjects, colon 
transit was exceptionally fast at just 2.5 h, giving a 
whole gut transit time of just 6h (Davis et al., 1988). 
Findlay et al. (1974) suggested that under certain 
conditions the rate of transit of solid and liquid phases 
through the colon could differ. In a group of healthy 
volunteers receiving a 20 g/day bran supplementation, 
"streaming" of solid and liquid phase markers occurred with 
the liquid travelling faster than the solid. On the other 
hand, in patients with diverticular disease, the solid 
phase travelled more quickly than the liquid phase. 
A number of more recent studies have also investigated the 
rate of transit of different phases and sizes of material 
through the colon. 
The colonic transit rate of 0.5-1.8 mm indium-labelled 
beads, delivered as a bolus into the colon in an enteric- 
coated gelatin capsule, has been compared to a 
radiolabelled liquid phase. When the capsule containing the 
beads arrived at the colon, 10 ml of technetium-DTPA 
solution was infused into the colon through an oro-caecal 
tube at a rate of 1 ml/min. The two phases were seen to 
empty simultaneously from the ascending colon. The transit 
rate through the other regions of the colon was also 
identical, suggesting no discrimination between solid and 
liquid phases in normal subjects (Proano et al., 1991). 
In a related study, the transit rate of 0.5-1.8 mm 
radiolabelled beads was compared to the transit rate of 6 
mm diameter pieces of radiopaque tubing. The mean transit 
time of the radiopaque markers through the ascending colon 
was 9.9±3.8 h and for the beads, 11.9±2.0 h. This 
difference was statistically significant (p<0.05) (Proana 
et al., 1990) 
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A study of the effects of capsule size and density on colon 
transit has been reported. Although capsule transit was 
found not to depend on density, there was a tendency for 
the transit rate to increase with size. However, 
intersubject variability was considerable and there was no 
significant difference in transit between the different 
sizes (0.3,0.8 and 1.8 cm3). In general, 50% of the dosage 
forms reached the splenic flexure within 7 hours of 
entering the colon (Parker et al., 1988). 
A comparison of the simultaneous colonic transit rate of a 
radiotelemetry capsule (25 mm long x9 mm diameter) and 
radiolabelled ion-exchange resin beads (0.5-1.8 mm 
diameter) has been carried out. Although both the beads and 
the capsule entered the colon simultaneously, the transit 
of the capsule through the ascending colon appeared to be 
more rapid, reaching the hepatic flexure ahead of 86% of 
the beads, which became widely distributed. Whole colon 
transit of the capsule varied widely, ranging from 13 h to 
68 h (Hardy et al., 1985). 
From the studies described above, there is evidence to 
suggest that the rate of transit of material through the 
colon may be size-dependent. 
B. Effects of disease on colon transit 
Diseases affecting colon transit have important 
implications for drug delivery. Disorders which may cause 
diarrhoea and an increase in colon transit include the 
inflammatory bowel diseases (ulcerative colitis and Crohn's 
disease), irritable bowel syndrome, coeliac disease and 
lactose intolerance (Barrow et al., 1991). 
Consequences of accelerated transit might. be a reduction in 
the bioavailability of drugs generated by colonic bacterial 
metabolism and compromised performance from sustained- 
release formulations (Read and Sugden, 1987). 
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The effect of ulcerative colitis on gastrointestinal 
transit has been investigated using gamma scintigraphy. A 
group of six patients was used, two with active disease at 
the time of the study. The residence time of individual 
tablets in the ascending colon varied from as little as 0.8 
hours to greater than 20 hours. Combined residence times in 
the ascending and transverse colon were about seven hours 
in the two subjects with active disease, and in excess of 
17 hours in the remainder (Hardy et al., 1988). 
C. Effects of diet 
The principal component of diet which can influence colon 
transit is dietary fibre content. In general, dietary fibre 
supplementation increases faecal weight and reduces the 
colon transit rate. For example, addition of 20 g/day of 
bran to the diet of a group of healthy subjects increased 
stool weight by 127% and reduced whole gut transit from a 
mean of 73±24 h to 43±7 h (Cummings et al., 1978). In 
another study, the same level of bran supplementation 
reduced whole gut transit from 66±18 h to 50±11h, with a 50 
% increase in stool weight (Findlay et al., 1974). 
A cross-over study investigating the effects of two levels 
of fibre intake on the GI transit of a radiolabelled tablet 
and radiolabelled beads has been reported. A group of four 
vegetarian and four omnivore subjects received diets 
containing 15 or 40 g/day dietary fibre for six days prior 
to the scintigraphic investigation. The results for colon 
transit were generally inconclusive. For the omnivores, the 
tablet residence time in the colon was similar at both 
fibre levels with a mean ascending colon residence time of 
267 minutes for the high fibre and 245 minutes for the low 
fibre diet. Surprisingly, for the vegetarians, colon 
transit was in both cases slower than for the omnivores 
with mean ascending colon residence times for the tablet of 
405 and 627 minutes for the high and low fibre diets 
respectively (Price et al., 1991a). 
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The intrinsic variability of colon transit has been 
assessed by administering radiolabelled tablets to a group 
of subjects receiving a controlled diet providing 25 g/day 
of dietary fibre. Despite the same food intake, colon 
transit times were extremely variable (Price et al., 
1991b). 
D. Effects of drugs 
Many drugs are known to reduce or increase colonic motility 
(Beeley and Stewart, 1987). 
An obvious cause of drug-induced diarrhoea is from laxative 
abuse. Magnesium-based antacids in large quantities may 
also cause diarrhoea as a side-effect. 
Antibiotics, in particular those with a broad spectrum of 
activity, may cause diarrhoea, probably a result of effects 
on the colonic microflora leading to overgrowth of 
particular species. A less common, but more serious 
complication of antibiotic therapy is pseudomembraneous 
colitis. This condition is caused by overgrowth of 
Clostridium difficile which in turn produces a toxin which 
damages the colonic mucosa leading to diarrhoea. Other 
drugs which can cause colitis include vasopressin, oral 
contraceptives and non-steroidal antiinflammatory agents. 
Drugs causing constipation include the opiates and 
anticholinergics and high doses of aluminium hydroxide and 
calcium carbonate antacids. 
1.2.4.2. Colonic microflora 
The colonic bacteria appear to have the ability to 
transform many drug substances. 
Some drugs are converted into pharmacologically active 
species by the action of colonic bacteria. Examples include 
the glycoside cathartics, cascara and senna (Peppercorn and 
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Goldman, 1976), the disaccharide, lactulose (Avery et al., 
1972), and sulphasalazine (Das et al., 1974). The colonic 
metabolism of sulphasalazine has been the prime stimulus 
for a variety of colon-targeting strategies, explained in 
detail in later sections. 
The action of other drugs may be prolonged by colonic 
microflora. Many drugs are excreted into bile as inactive 
sulphate or glucuronate conjugates. Cleavage of the 
conjugating function by bacterial action will yield free 
drug which may then be reabsorbed from the colon. Drugs 
whose action may be prolonged in this way include 
stilboestrol, morphine, and indomethacin (Peppercorn and 
Goldman, 1976). 
There is also the potential for the generation of toxic 
drug species by bacterial action. Drugs for which colonic 
metabolism has been implicated in causing toxicity include 
L-dopa and chloramphenicol. In the case of chloramphenicol, 
aplastic anaemia has only been reported in patients taking 
the drug orally. It has been suggested that this type of 
toxicity is confined to patients whose microflora contain 
organisms capable of converting chloramphenicol into 
suitable toxic metabolites (Holt, 1976). 
Similarly, there are examples of drugs whose efficacy is 
reduced when exposed to colonic bacteria. A pharmacokinetic 
evaluation of an enteric-coated digoxin preparation 
revealed that in some subjects a large proportion of the 
drug was converted to its inactive dihydro- derivative. It 
was suggested that bacterial metabolism of the drug was 
responsible (Magnusson et al., 1982). 
It has been suggested that atropine may also be subject to 
colon inactivation (Peppercorn and Goldman, 1976). 
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1.2.4.3. Absorption of drugs from the colon 
On the surface, the colon would appear to have few 
desirable properties conducive to efficient drug 
absorption. In comparison with the small intestine, its 
surface area is small. Additionally the progressive 
absorption of water means that the further one travels 
around the colon, the more viscous the contents will 
become. This will theoretically reduce the dissolution rate 
of particulate drug and slow the diffusion of dissolved 
drug to the mucosa. Nevertheless, many drugs appear to be 
well absorbed from the colon. It is the slow transit rate 
that is the major compensatory factor in achieving good 
colonic drug absorption. 
However, the colon is a more selective site for drug 
absorption than the small intestine. Drugs shown to be well 
absorbed include glibenclamide (Brockeneier et al., 1985), 
diclofenac (Gleiter et al., 1985), theophylline (Staib et 
al., 1986), ibuprofen (Wilson et al., 1989), metoprolol 
(Godbillon et al., 1986) and oxprenolol (Antonin et al., 
1985). 
Drugs whose absorption from the colon is reduced by 
comparison to other parts of the GI tract include frusemide 
(Bieck, 1989), piretanide (Brockmeier et al., 1986), 
buflomedil (Wilson et al., 1991), and lithium, which is not 
absorbed at all (Erlich and Diamond, 1983). 
The absorption of digoxin was found to be reduced when the 
colon was diseased. In healthy subjects, relative 
bioavailability from the colon was found to be 85%. In a 
group of four patients suffering from ulcerative colitis, 
the bioavailability was reduced to 9% (Ochs et al., 1975). 
The poor absorption of many drugs in the colon may be due 
to the fact that epithelial cell junctions are very tight 
(Powell, 1981) and as a consequence the predominant route 
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of absorption will be transcellular, which favours 
hydrophobic molecules. Thus in the rat, the rates of 
absorption of two hydrophilic drugs, hydrochlorothiazide 
and atenolol, were found to be uniform throughout the small 
intestine, but fell dramatically on entry into the colon 
(Taylor et al., 1989). 
Less is understood about regional differences in drug 
absorption within the colon. However, absorption might be 
expected to be less efficient in the distal regions of the 
colon, where the lumenal contents are viscous and have a 
low water content. The bioavailability of diclofenac was 
the same whether distilled into the colon at the caecum or 
at the splenic flexure, but since the colon was cleansed by 
enema prior to drug administration, the study merely 
demonstrated that the permeability of the mucosa to the 
drug was the same at both locations (Gleiter et al., 1985). 
A capsule containing ciprofloxacin was remotely triggered 
to release its contents into different portions of the 
gastrointestinal tract. Colonic absorption was poor 
compared to the small intestine. However, within the colon, 
drug absorption from the descending colon was reduced by 
comparison to the ascending colon (Staib et al., 1989). 
Studies with an "Oros" system containing oxprenolol have 
demonstrated the importance of the colon in determining 
drug bioavailability from sustained release dosage forms. 
In a subject in which the device was resident in the colon 
for just 2.5 h, the absolute bioavailability of oxprenolol 
was 13.8%, with 79% of the dose remaining in the excreted 
tablet. On the other hand, in a subject where the device 
took 27.5 h to pass through the colon, the bioavailability 
was 54.3% with only 14.3% of the dose remaining in the 
excreted tablet (Davis et al., 1988). 
Absorption from the majority of the colon is into the 
superior and inferior mesenteric veins. These veins become 
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part of the portal venous system and drain directly into 
the liver. Thus drugs absorbed by this route will be 
subjected to first pass metabolism. The lower rectum and 
anal canal ultimately drain into the vena cava and thus 
drugs absorbed here may avoid the first pass effect. 
However, there are many anastomoses between rectal veins 
and so even absorption from the lower rectum/anal canal may 
result in a first pass through the liver (Steed et al., 
1989). 
Since it now apparent that many sustained-release dosage 
forms rely on a degree of colonic absorption to remain 
therapeutically effective (Davis et al., 1988; Wilson et 
al., 1989), when designing such formulations it is clearly 
essential to establish the absorption characteristics of 
the drug in question. If the drug is only poorly absorbed 
from the colon, a sustained release dosage form may be 
wholly inappropriate. Knowledge of colon absorption may 
also be of importance when developing enteric-coated dosage 
forms. Poor bioavailability from a erythromycin tablet was 
thought to be a result of its enteric coat resisting 
dissolution until pH 6.5. This probably resulted in tablet 
disintegration beyond the proximal small intestine, the 
main absorption site for erythromycin (Watanabe et al., 
1977). 
1.2.5. Reasons for targeting drugs into the colon 
1.2.5.1. Local treatment of colonic disease 
A major stimulus for the development of delivery systems 
targeted at the colon has been to improve the treatment of 
colonic disease, in particular the inflammatory bowel 
diseases (IBD): Crohn's disease and ulcerative colitis. 
A. Inflammatory bowel diseases 
i). Clinical features 
The inflammatory bowel diseases are principally diseases of 
Western societies and have a prevalence of 5- 
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7/100,000/year, with the incidence being greater in whites 
than non-whites. The cause is unknown, although infection, 
diet, immune disorders and genetic influences have all been 
suggested (Gaska and Sarafpour, 1989; Baker, 1988). 
Crohn's disease most commonly involves the terminal ileum 
and colon, although any part of the GI tract may be 
affected. The disease is characterised by inflammation 
extending through all layers of the gut wall which may 
ultimately lead to the formation of fistulae. The 
inflammation is not continuous however, and healthy tissue 
may remain around the diseased areas. The clinical features 
of Crohn's disease depend upon its site but may include 
diarrhoea, abdominal pain and weight loss (Gaska and 
Sarafpour, 1989; Baker, 1988). 
Ulcerative colitis generally remains confined to the 
rectum, although it can affect the whole colon. Unlike 
Crohn's disease, tissue inflammation and ulceration is 
confined to the mucosa. The most prominent clinical 
features are abdominal pain and the passage of bloody 
diarrhoea (Gaska and Sarafpour, 1989; Baker, 1988). 
IBD tends to be associated with periods of illness 
interspersed with periods of remission, sometimes lasting 
months or years (Gaska and Sarafpour, 1989; Baker, 1988). 
ii). Treatment 
The mainstay of IBD treatment for many years has been 
sulphasalazine (salicylazosulphapyridine; SASP). The drug 
was originally developed as a treatment for rheumatoid 
arthritis and combines the sulphonamide antibiotic, 
sulphapyridine (SP), and 5-aminosalicylic acid (5-ASA), 
with the two molecules linked by an azo bond (-N=N-) 
(figure 1-6). 
The rationale behind the design of SASP was based on two 
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factors: i) rheumatoid arthritis was thought at the time to 
be bacterial in origin and, ii) it responded to treatment 
with the salicylate, aspirin. Thus a molecule was 
synthesized containing a salicylate and an antibacterial 
(Svartz, 1942). 
Although the drug was reasonably successful in the 
treatment of rheumatoid arthritis, its effectiveness in 
patients with IBD was dramatic. However, it is only 
comparatively recently that its mechanism of action has 
been understood (Azad Khan et al., 1977). 
SASP is essentially a prodrug and at least 85% of an oral 
dose passes unabsorbed into the colon (Klotz, 1985). In the 
colon, the action of azoreductase enzymes cleaves SASP into 
its two constituent molecules, 5-ASA and SP (figure 1.6). 
The azoreductase activity predominantly arises from 
bacteria, although tissue-based enzymes also play a minor 
role (Azad Khan et al., 1983). 5-ASA is largely unabsorbed 
from the colon where it is thought to exert topical 
antiinflammatory activity, whereas SP is largely absorbed 
and gives rise to side-effects (Klotz, 1985). SP-induced 
toxicity is a major problem, and as many as 30% of patients 
are unable to tolerate treatment with SASP (Peppercorn, 
1984). 
Although it is not universally accepted that its only role 
is as a carrier for 5-ASA (Hayllar and Bjarnason, 1991), 
because of the toxicity of SP, there has been considerable 
interest in the use of 5-ASA alone as a treatment for IBD. 
Unfortunately, since 5-ASA is well absorbed from the small 
intestine (Jarnerot, 1989), it is unavailable for topical 
action in the colon if administered in a conventional oral 
dosage form. It has been the desire to deliver 5-ASA 
directly into the colon by the oral route that has led to 
the development of a number of novel colon delivery 
systems, to be discussed later in this chapter. 
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Figure 1.6. Colonic metabolism of sulphasalazine. 
HOOC 
H 
Sulphasalazine (SASP) 
N=N S02 NH-- 
N 
OQ 
5-aminosalicylic acid (5-ASA) Sulphapyridine (SP) 
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Azoreductase 
The second major class of drugs used in the treatment of 
IBD are the corticosteroids. Whereas SASP and other 5-ASA 
based drugs are used for maintenance therapy and the 
treatment of mild attacks, corticosteroids are used for the 
treatment of more severe attacks (Piper et al., 1987). The 
major drawback of the corticosteroids are their wide- 
ranging side-effects (Haynes and Larner, 1975). Side- 
effects may also result from the systemic absorption of 
rectally applied drug (Farmer and Schumacher, 1970). 
Corticosteroids with reduced systemic side-effects are 
under investigation. For example, beclomethasone 
dipropionate (Kumana et al., 1982) and tixocortal pivalate 
(Hanauer et al., 1986) are both rapidly metabolised on 
absorption into the systemic circulation and consequently 
side-effects are minimised. 
Although drugs for topical action in the colon can be 
administered rectally, by enema or suppository, there are 
problems both in patient acceptability and in accessibility 
to the proximal colon. 
The spread of rectally-administered dosage forms is 
limited. A 60 ml radiolabelled enema remained mainly 
confined to the rectum in healthy volunteers, though in 
subjects who had received a prior evacuation enema, spread 
as far as the ascending colon was seen (Jay et al., 1986). 
In another study, 50 ml enemas were mainly confined to the 
rectum and sigmoid colon, whilst with a 200 ml volume, 
spread as far as the transverse colon was observed. It was 
concluded that the optimum enema volume is probably 100 ml 
(Hardy et al., 1986). The spread of 5 ml of a radiolabelled 
foam enema was generally confined to the sigmoid colon in 
a group of IBD patients and was not significantly altered 
by increasing the volume to 50 ml (Farthing et al., 1979). 
The spread of enemas is probably greater in active colitis 
(Swarbrick et al., 1974; Campieri et al., 1986). 
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Thus for the treatment of inflammation in proximal regions 
of the colon, topically acting drugs need to be given by 
the oral route. Since many of these drugs are well absorbed 
from the small intestine (e. g. 5-ASA, corticosteroids), 
their effective use requires targeted delivery into the 
colon. 
B. Other diseases 
Other colon-targeting strategies might be for the delivery 
of anticholinergics for treatment of irritable bowel 
syndrome (IBS) or anticancer agents for treatment of colon 
cancer (Tozer, 1990). 
1.2.5.2. Systemic delivery of drugs 
The second major reason for wishing to target dosage forms 
into the colon might be to utilise the organ as a site for 
absorption of drugs for systemic therapy. 
A. Conventional drugs 
It was mentioned in section 1.2.4.3 that many sustained 
release oral dosage forms rely on colonic absorption to 
remain therapeutically effective in view of the relatively 
short period of residence in the small intestine. A number 
of drugs shown to be well absorbed from the colon were 
listed. 
It is also conceivable that colon-targeted dosage forms 
containing absorbable drugs might offer novel therapeutic 
opportunities. For example, a colon-targeted device 
containing an antiinflammatory agent taken at bedtime might 
be useful in providing therapeutic levels of drug several 
hours later to relieve morning stiffness associated with 
arthritis. 
B. Protein and Peptides 
A more elusive goal is to use the colon as a site for the 
oral delivery of therapeutic peptides and proteins. 
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Although there have been many reports of peptide and 
protein absorption following oral administration, 
bioavailability is invariably extremely low (Zhou and Li 
Wan Po, 1991; Lee and Yamamoto, 1990). 
There are considered to be four barriers limiting the oral 
bioavailability of these molecules (Zhou and Li Wan Po, 
1991): 
1. Degradation in the acidic environment of stomach. 
2. Enzymatic degradation in the GI tract. 
3. Low mucosal permeability. 
4. First pass metabolism by the absorbing membrane and the 
liver. 
One of the attractive properties of the colon is often 
considered to be its relative lack of degradative enzymes 
compared to the stomach and small intestine. Although 
peptidase enzymes are present in the mucosal cells lining 
the colon, their level is very low compared to the small 
intestine (Longer et al., 1989). However the colon lumenal 
contents contain large quantities of peptidase and protease 
enzymes produced by colonic bacteria (Woodley, 1991; 
MacFarlane et al., 1988). The stability of insulin and 
insulin B chain in the presence of lumenal contents 
isolated from guinea pig colon has been examined (Ikesue et 
al., 1991). Whereas after eight hours incubation insulin 
showed minimal degradation, about 40% of the insulin B 
chain had degraded, suggesting that protein structure might 
be an important determinant of stability. 
Even if peptide/protein stability could be ensured, by for 
example structural modification or coadministration of 
enzyme inhibitors, the molecule still needs to be absorbed. 
The use of penetration enhancers to increase mucosal 
permeability is being intensively investigated (Lee and 
Yamamoto, 1990) and colon-targeted protein/peptide delivery 
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systems employing these substances have been patented (e. g. 
Davies et al., 1986). Although penetration enhancers may 
indeed promote colonic absorption, they are unlikely to 
provide a practical solution since their action is 
generally non-specific and consequently many undesirable 
substances present in the lumenal contents, such as 
bacterial enterotoxins, may also be absorbed, with 
potentially undesirable effects. 
1.2.6. Methods for targeting drugs into the colon 
There are essentially three practical mechanisms by which 
a delivery system can be targeted into the colon following 
oral administration, two of which rely on unique properties 
of the target organ. 
The two unique properties of the colon which have been 
exploited are: 
1. pH. 
2. The presence of a large bacterial population. 
The third, non-colon-dependent, mechanism which has been 
utilised is the time taken for the dosage form to travel to 
the colon. 
A summary of the different approaches to colon targeting is 
provided in figure 1.7 and will now be expanded in the 
following sections. 
1.2.6.1. pH-tricrctered systems 
Site-specific delivery into the small intestine has been 
achieved for many years by the use of enteric coatings. pH- 
sensitive coatings are also being utilised to achieve colon 
targeting of dosage forms. 
As discussed in section 1.2.3.2, the pH in the terminal 
ileum and colon is higher than any other region of the GI 
56 
Figure 1.7. Strategies for targeting into the colon: the point of 
drug release from different delivery systems. 
Time-dependent systems: any point in GI tract 
57 
Azo-bonds Suppositories 
Glycosidic bonds and enemas 
tract and thus dosage forms which disintegrate at suitably 
high pH levels have the potential for site-specific 
delivery into the colon. 
The principal group of polymers utilised have been the 
Eudragits, and in particular Eudragits L and S, the 
properties of which were described in section 1.1.3.2. A. 
Eudragits L and S are enteric polymers which dissolve above 
pH 6 and 7 respectively. 
Dew et al. first reported the use of Eudragit S as a colon- 
targetable coating in 1982. Hard gelatin capsules 
containing barium sulphate as a radiopaque marker and SP as 
a marker for drug release were coated with a 120 µm-thick 
coat of Eudragit S using an air suspension technique. Six 
subjects each swallowed six capsules. Twelve hours after 
administration, of the 36 capsules administered, 4 had 
broken in the distal ileum, 23 in the colon, and 9 remained 
intact. After 24 hours, four capsules remained intact. 
This approach was extended to the evaluation of 5-ASA 
tablets, each containing barium sulphate and coated with an 
80 µm-thick coat of Eudragit S. Eight patients received a 
total of 64 tablets. After 6 h, 24 tablets were in the 
stomach, intact, whilst the remaining 40 tablets were in 
the terminal ileum and ascending colon, and only two of 
these were intact. At 12 h, 20 tablets were in the stomach, 
and four tablets remained intact in the terminal 
ileum/colon. At 24 h, all tablets had reached the colon and 
had disintegrated (Dew et al., 1983). 5-ASA tablets coated 
with Eudragit S are now marketed for the treatment of mild 
to moderate ulcerative colitis (AsacolTM, SmithKline 
Beecham). (5-ASA is now commonly called mesalazine). 
Since 5-ASA is well absorbed from the small intestine but 
poorly absorbed from the colon, urinary excretion of the 
drug is a good indicator of the quantity released at sites 
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proximal to the colon. Urinary excretion of about 20% of 
the dose of 5-ASA has been reported following 
administration of AsacolTM tablets, a quantity comparable 
to sulphasalazine administration (Dew et al., 1984). The 
colon-specificity of AsacolTM is also emphasized by the 
fact that stool dialysate concentrations of 5-ASA were 
twenty times higher than in subjects taking uncoated drug 
(Mardini et al., 1988). 
The principal drawback of AsacolTM is from inadequate 
performance of the polymer coat; occasional failure of the 
tablets to disintegrate has been noted, with patients 
observing intact tablets in their stools (Schroeder et al., 
1987). In addition, other drugs may affect the performance 
of AsacolTM. In particular, patients receiving AsacolTM 
tablets are warned not to take lactulose, since the 
acidification of the colon that it causes may prevent 
dissolution of the Eudragit S coat (Data Sheet Compendium, 
1989). 
Two 5-ASA tablets coated with Eudragit L are also 
available, ClaversalTM and SalofalkTM. These products are 
intended to deliver 5-ASA into the proximal small intestine 
and terminal ileum and as such are suitable for the 
treatment of Crohn's disease affecting these parts of the 
GI tract. A scintigraphic assessment indicated that in a 
group of 13 patients more than 70% of administered 
ClaversalTM tablets disintegrated in the small intestine, 
on average 3.2 h after gastric emptying (Hardy et al., 
1987). 
PentasaTM tablets consist of microgranules of 
ethylcellulose-coated 5-ASA. The tablets readily 
disintegrate in the stomach. The rate of release of 5-ASA 
from the dispersed granules is pH-dependent. In vitro, at 
pH 2 and pH 6, less than 90% of the drug was released after 
24 hours, whilst at pH 7.5, an equivalent amount of drug 
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was released within 8 hours (Rasmussen et al., 1982). As 
for the Eudragit L-based tablets, PentasaTM is particularly 
suitable for treatment of inflammation of the lower small 
intestine but not especially reliable for delivery of 5-ASA 
into the colon; with this preparation, about 50% of the 
administered dose of 5-ASA was excreted into the urine, 
indicating appreciable absorption proximal to the colon 
(Rasmussen et al., 1982). 
Capsules coated with the enteric polymer, cellulose acetate 
phthalate (CAP) have been reported to enhance the delivery 
of the corticosteroid, beclomethasone dipropionate, to the 
terminal ileum. Ileostomy patients received drug-containing 
capsules that were uncoated, coated with shellac, or coated 
with CAP. The mean recovery of drug and active metabolite 
in ileostomy effluent was significantly greater when 
administered in CAP-coated capsules (43.0±24.1%) compared 
to shellac-coated (18.8±13.5%) or uncoated (13.5±8.5%) 
(Levine et al., 1987). 
The Alza Corporation has patented osmotic pumps coated with 
pH-sensitive polymers for potential colon drug-delivery 
applications (Wong and Theeuwes, 1986,1987). 
1.2.6.2. Enzyme-triggered delivery systems 
Both prodrugs and dosage forms from which the release of 
drug is triggered by the action of colonic bacterial 
enzymes have been devised. 
A. Azo- bonds 
The reduction of azo- bonds by the action of colonic 
azoreductase enzymes has been utilised to develop colon 
targeted prodrugs and polymers. 
I. Pro= 
The first azo- bond prodrug was, serendipitously, SASP. 
However, due to its toxicity, SP is not the ideal carrier 
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molecule for 5-ASA and consequently, a number of other 5- 
ASA prodrugs have been developed (figure 1.8). 
The first of these to be introduced to the clinic is 
olsalazine (I), a dimer of 5-ASA (Campbell and Berglindh, 
1988). This drug appears to be as effective as 
sulphasalazine in maintaining remission in ulcerative 
colitis (Sandberg-Gertzen et al., 1988) and in treating 
mild forms of the disease (Willoughby et al., 1988). 
Other 5-ASA prodrugs include balsalazine (II) and 
ipsalazine (III). In these two molecules, 5-ASA is azo- 
linked to 4-aminobenzoyl-13-alanine and p-aminohippurate 
respectively (Chan et al., 1983). 
5-ASA has also been azo-linked to polymers. One approach is 
based on a poly(vinylamine) backbone to which are attached 
benzenesulphonamide groups which in turn contain azo-bonded 
5-ASA (termed as "polymer 7", IV). Release of 5-ASA from 
the polymer was demonstrated in vivo in rats and the 
compound was effective in reducing carrageenan-induced 
colon inflammation in guinea pigs (Brown et al., 1983). 
Polymeric prodrugs have also been produced by azo-bonding 
5-ASA via a spacer group to poly(methyl vinyl ether-co- 
maleic anhydride), poly(vinyl-pyrrolidone-co-malefic 
anhydride) and to activated derivatives of dextran and 
poly[(2-hydroxyethyl)aspartamine]. When incubated with 
human colon contents, the dextran conjugate liberated 5-ASA 
at the same rate as sulphasalazine (Schacht et al., 1991). 
Potentially bioadhesive polymeric 5-ASA carriers have been 
reported. To N-(2-hydroxylpropyl)methacrylamide copolymers 
have been attached bioadhesive monosaccharides and, via azo 
bonds, 5-ASA. Copolymers containing fucosylamine 
monosaccharide moieties selectively bound to isolated 
guinea pig colon, with the degree of binding increasing 
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Figure 1.8. Structure of some 5-ASA prodrugs. 
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with fucosylamine content (Kopeckova et al., 1991). 
II. Polymers 
The first work in this field was published by Saffran et 
al. in 1986 and describes the synthesis of polymers of 
polystyrene and hydroxyethyl methacrylate cross-linked with 
divinylazobenzene. Insulin and vasopressin were 
administered to rats inside gelatin capsules and pellets 
coated with these polymers and delayed absorption was 
demonstrated. 
Bronsted and Kopecek (1990) have produced hydrogels based 
on acrylic acid, N, N-dimethylacrylamide and N-ter-butyl- 
acrylamide crosslinked with 4,4'-di(methacryloylamino) 
azobenzene. At the low pH encountered in the stomach, the 
degree of swelling of the polymer is low. However, as it 
passes down the GI tract and the pH increases, the polymer 
begins to swell. By the time it has reached the colon, the 
hydrogel is sufficiently swollen to allow access to 
bacterial azoreductase enzymes. Cleavage of the azo- bonds 
should allow release of active compound included in the 
hydrogel matrix. 
B. Glycosidic bonds 
A number of delivery systems exploiting the saccharolytic 
abilities of colonic bacteria (mediated through glycosidase 
enzymes) have been reported. 
I. Prodruas 
It was mentioned in section 1.2.4.2 that some commonly used 
laxative drugs are known to rely on colonic glycosidic 
activation to be therapeutically effective. More recently 
a number of glycosidic prodrugs have been designed in an 
attempt to achieve colon-specific delivery. 
Friend and Chang (1984,1985) have developed corticosteroid 
prodrugs by attachment to glycosidic carriers. The prodrugs 
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should theoretically pass unabsorbed into the colon where 
the glycoside bonds are cleaved by the action of bacterial 
glycosidase enzymes making the corticosteroid available for 
therapeutic action. A comprehensive review of the in vivo 
performance of these agents has been published (Friend, 
1991). A degree of selective delivery of the corticosteroid 
into the caecum was achieved in the rat and guinea-pig. 
However, these animal models possess relatively high small 
intestinal glycosidase activity, and thus more selective 
delivery might be predicted in humans. Dexamethasone-ß-D- 
glucoside was evaluated as a treatment for carrageenan- 
induced ulcerative colitis in guinea pigs. Compared to 
control, the number of large intestinal ulcers was 
significantly less in animals receiving the prodrug or 
unconjugated dexamethasone. A 0.65 µmol/kg dose of prodrug 
was equieffective as 1.30 µmol/kg dexamethasone supporting 
the hypothesis that the prodrug achieved higher caecal and 
colonic levels of free drug. 
Colon targeted corticosteroids termed as "pro-antedrugs" 
have been reported. Corticosteroid derivatives which are 
readily metabolised into inactive metabolites following 
systemic absorption were synthesized ("ante-drugs"). To the 
ante-drugs were attached glycosidic functions to allow 
colon-targeting. Generation of free antedrug in the large 
intestine of guinea pigs and rats was demonstrated (Kimura 
et al., 1991). 
The colonic microflora also possesses glucuronidase 
activity, thought to be responsible for prolonging the 
activity of some drugs (section 1.2.4.2). Glucuronide 
conjugates have been synthesized for two opiate 
antagonists, nalmefene and naloxone. Physiological effects 
concurrent with large intestinal activation of the prodrugs 
were reported (Simpkins et al., 1988). 
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II. Polymers 
A number of delivery systems based on polysaccharides which 
are selectively degraded in the colon have been reported. 
One of the major problems in using these materials is that 
they are extremely hydrophilic and thus methods have to be 
devised to ensure that drug does not prematurely diffuse 
from the dosage form. 
A potential colon-specific delivery system based on a 
poorly soluble pectate salt has been devised. The salt and 
indomethacin were compressed into a matrix and the release 
of drug evaluated in vitro. Under control conditions, 
release of indomethacin into pH 7 buffer was minimal. 
However, in the presence of pectinolytic enzyme or rat 
caecal content, release of indomethacin was significantly 
greater (Rubinstein and Radai, 1991). 
Guar gum, locust bean gum, tragacanth and xylan have been 
mixed with Eudragit polymers and used to coat tablets. The 
in vitro release of drug from tablets coated with mixtures 
of Eudragit L and guar or Eudragit RL and guar was enhanced 
in the presence of glycosidic enzymes (Lehmann and Dreher, 
1991). 
Delivery systems based on the mucopolysaccharide, 
chondroitin, have also been proposed, with the solubility 
of the polymer being reduced by cross-linkage (Sintov et 
al., 1990). 
1.2.6.3. Time-dependent delivery systems 
The final major approach to colon targeting uses time as 
the release trigger. From gamma scintigraphic studies, the 
time of passage of dosage forms from mouth to colon is now 
well understood. As discussed earlier, although gastric 
emptying tends to be highly variable, small intestinal 
transit times are less so. Small intestinal transit rates 
would dictate that for successful colon delivery the device 
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should not release drug until 3-4 hours after leaving the 
stomach (section 1.2.4.1). 
A delivery device using this basic concept has been 
developed. The PulsincapTM (Scherer DDS) is similar in 
appearance to a hard gelatin capsule, but the main body is 
water-insoluble. The contents are contained within the body 
by a hydrogel plug which is covered by a water-soluble cap. 
If necessary, the whole unit can then be coated with an 
enteric polymer. In vivo, once the cap has dissolved, the 
hydrogel begins to swell. When the swelling reaches a 
critical point, the plug pops out of the capsule body and 
the contents are released. Depending on the properties of 
the plug used, the time at which this occurs can be 
controlled (Pharmaceutical Journal, 1991). 
A PulsincapTM has been used to assess the colonic 
absorption of captopril. A device with a5 hour "pulse" was 
used, and in ten subjects the actual point of drug release 
ranged from 246 to 389 minutes (Wilding et al., 1991). 
1.2.7. Summary 
It is now appreciated that the colon can be an important 
site for the absorption of drugs from sustained release 
dosage forms. Although the surface area is low compared to 
the small intestine, this is compensated for by the 
markedly slower rate of transit. However, the colon is a 
more selective absorption site than the small intestine and 
tends not to favour hydrophilic compounds. 
The colon has a number of features which allow site- 
specific drug delivery, the most important being the 
presence of a large bacterial population. This allows the 
design of enzyme-triggered delivery systems. Although pH- 
and time-dependent systems have also been designed these 
are inherently less reliable means of achieving colon- 
specific delivery. 
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Targeted dosage forms are of particular interest for the 
delivery of drugs that are well absorbed from the small 
intestine, yet are required for local topical action in the 
colon to treat IBD e. g. 5-ASA and corticosteroids. 
For the future, the colon may become a viable site for the 
absorption of peptides and proteins although there are 
major obstacles to be overcome, in particular stability 
against bacterial protease and peptidase enzymes and 
diffusion through the poorly permeable colon epithelium. 
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1.3. AIMS OF THE THESIS 
The aim of the work carried out in this thesis was to 
investigate the use of microspheres as potential colon 
drug-delivery systems. 
Preliminary work was to focus on the development of 
microspheres using the solvent evaporation technique. It 
was planned to use the Eudragit family of polymers to 
encapsulate agents active in the treatment of inflammatory 
bowel diseases. It was hoped that characterisation of the 
microspheres using a number of different techniques would 
provide a further insight into their mechanism of 
formation. 
There were primarily two reasons for the interest in 
microspheres for colon delivery. Firstly, multiparticulate 
dosage forms become widely dispersed in the small and large 
intestine. This characteristic might be useful for the 
treatment of widespread inflammatory disease. Secondly, 
there was evidence to suggest that small particles travel 
through the colon more slowly than large. There was thus a 
possibility that colon retention could be enhanced by using 
a multiparticulate-type dosage form. 
To investigate size-transit rate phenomena, fundamental 
studies on the rate of transit of different-sized 
radiolabelled particles through the human colon were to be 
undertaken using gamma-scintigraphy. This work was planned 
in both healthy subjects and in patients suffering from 
diseases which increased colon motility. 
Ultimately it was hoped that a biopharmaceutical evaluation 
of drug-polymer microspheres in the human colon could be 
undertaken. This would require the development of a 
technique for radiolabelling the microspheres. 
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CHAPTER 2. 
PREPARATION OF MODEL EUDRAGIT NANOPARTICLES AND 
MICROPARTICLES AND THE EFFECTS OF CHANGING MANUFACTURING 
PARAMETERS ON THEIR PROPERTIES. 
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2.1. INTRODUCTION 
The first experimental chapter in this thesis describes the 
development and use of two different emulsification-solvent 
evaporation procedures for the preparation of model (drug- 
free) Eudragit RL particulates. The first technique was 
used for the preparation of nanoparticles, whereas the 
second technique was used to prepare microparticles. 
Eudragit RL was chosen as the encapsulating polymer for a 
number of reasons: 
1. The polymer has sustained-release properties (see 
section 1.1.3.2). 
2. Readily available pharmaceutical excipient. 
3. Amenable to microencapsulation using solvent 
evaporation techniques (see section 1.1.3.2). 
The aim of the work presented here was to establish how the 
alteration of basic preparation parameters can influence 
nanoparticle and microparticle properties, and in 
particular, size. The results should be broadly applicable 
to any solvent evaporation process. 
2.2. EXPERIMENTAL 
2.2.1. Materials 
Eudragit RL100 (Dumas (UK), Tunbridge Wells, UK), sodium 
dodecyl sulphate (SDS) (biochemical grade)(Sigma, Poole, 
13K), Tween (polysorbate) 80 (BDH, Poole, UK), 
dichloromethane (GPR grade)(RhBne-Poulenc, Dagenham, UK). 
2.2.2. Methods 
2.2.2.1. Particle Preparation 
Both of the preparation techniques used a two stage 
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process. In the first stage, an emulsion of Eudragit RL- 
dichloromethane droplets was produced. In the second stage, 
the dichloromethane was evaporated from the polymer 
droplets at 50 °C in a water-bath, whilst the emulsion was 
gently agitated at a lower stirring speed. 
Diagrams of the two basic preparation processes are shown 
in figure 2.1. 
A. Nanoparticles 
The required quantity of Eudragit RL was weighed into a 100 
ml glass-stoppered conical flask and 10 ml of 
dichloromethane was added to dissolve the polymer pellets. 
Dissolution of the polymer was aided by gentle agitation of 
the flask. 
The flask containing the polymer solution was then partly 
immersed in a beaker containing ice in order to minimise 
heating during the emulsification process. 25 ml of aqueous 
Tween 80 solution was slowly poured into the flask and the 
two liquids were allowed to cool for about a minute. An 
homogeniser (Silverson, Chesham, UK) was lowered into the 
polymer solution ensuring that the bottom section of the 
mixing head was completely covered with liquid. It was then 
switched on at the required speed for a predetermined time 
period (see following section for individual experimental 
conditions). 
After emulsification, the dichloromethane was evaporated 
from the dispersion of Eudragit RL droplets by placing the 
flask on top of an underwater magnetic stirrer in a water 
bath at 50 °C. The solution was gently stirred by a 
magnetic flea as the solvent evaporated. Solvent 
evaporation was generally complete within 60 minutes. The 
nanoparticles were kept suspended in the emulsifier 
solution for subsequent characterisation. 
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Figure 2.1. Preparation of Eudragit RL micro- and nanoparticles 
Solution of Eudragit RL 
in dichloromethane 
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surfactant solution. 
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Homogeniser Overhead stirrer 
The following experiments were carried out: 
i). Effect of polymer concentration on particle size. 
Eudragit RL was dissolved in dichloromethane at 
concentrations of 1,4,7.5,10,13 and 23% w/v. The 
polymer solutions were emulsified at half-maximum 
homogenisation speed (about 4000 rpm) into 1% w/v Tween 80 
solution for a period of 5 minutes. 
ii). Effect of mixing time on particle size. 
A solution of 23% w/v Eudragit RL in dichloromethane was 
emulsified into 1% w/v Tween 80 solution for 5,7.5,10 or 
20 minutes at maximum homogenisation speed (about 8000 
rpm). 
iii). Effect of surfactant concentration on particle size. 
A solution of 23% w/v Eudragit RL was emulsified into 
0.0025,0.01,0.25,1 or 5% w/v Tween 80 solution for a 
period of 20 minutes at maximum homogenisation speed. 
B. Microparticles 
The required quantity of Eudragit RL was weighed into a 
glass bottle and dissolved in 20 ml of dichloromethane. The 
surfactant, SDS, was dissolved in 50 ml of distilled water 
in a 200 ml glass beaker. To prepare the microparticles, 
the beaker containing surfactant solution was partly 
immersed into ice to minimise solvent evaporation during 
emulsification. An overhead paddle stirrer (Stuart 
Scientific, Manchester, UK) was lowered into the polymer 
solution, the surfactant solution poured in, and the mixer 
switched on. After mixing at the required speed for the 
required period of time (see below), the beaker was 
transferred to a water bath (50 °C) and stirring continued 
at 200 rpm until evaporation of solvent was complete, which 
typically took about 60 minutes. All microparticle samples 
were kept in solution for subsequent characterisation. 
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The following experiments were carried out: 
i). Effects of polymer concentration on particle size. 
A solution containing 2.5,5,7.5 or 10% w/v Eudragit RL 
was emulsified into 1% w/v SDS solution for a period of 10 
minutes at 350 rpm, followed by solvent evaporation at 200 
rpm. 
ii). Effects of mixing speed on particle size. 
Two concentrations of polymer solution were used, 2.5% and 
10% w/v Eudragit RL. Solutions were emulsified into 1% w/v 
SDS for a period of 10 minutes at 350,500 or 700 rpm, 
followed by solvent evaporation. Two microparticle batches 
were produced for each polymer concentration/speed 
combination. 
iii). Effects of stirring time on particle size. 
Again, 2.5 and 10% w/v Eudragit RL solutions were used. The 
initial emulsification stage was carried out for 1,2.5,5, 
10,20,30 or 40 minutes into 50 ml of 1% w/v SDS solution, 
at a mixing speed of 350 rpm. Two batches of microparticles 
were produced for each combination of polymer and 
surfactant solution. 
iv). Effects of SDS concentration on particle size. 
20 ml of 5% w/v Eudragit RL solution was emulsified into 50 
ml of distilled water containing 0.5,1.0,1.5,2.0,3.0, 
4.0,4.5,5.0,6.0,7.5 or 9.0 % w/v SDS, at 350 rpm. Two 
batches of microparticles were produced for each 
concentration of surfactant. 
2.2.2.2. Particle size determination 
The size of the nano- and microparticles was determined 
using laser light scattering techniques. Measurements were 
carried out by using either a Malvern photon correlation 
spectrometer or a Malvern Mastersizer (Malvern Instruments, 
Malvern, UK). 
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Photon correlation spectroscopy (PCS) is based upon the 
scattering of laser light by suspended particles undergoing 
Brownian motion. Laser illumination of the particle 
suspension generates a diffraction pattern which 
continuously changes as the particles diffuse. The rate of 
diffusion is dependent upon particle size. Therefore, 
measurement of the rate of change of the diffraction 
pattern (by a photomultiplier) enables an estimation of the 
particle size. Since PCS relies on Brownian motion of the 
particles being analysed, it is generally limited to 
measurements in the nanometre size range (Cummins and Pike, 
1977; Ho, 1989). 
The Malvern Mastersizer is also based upon laser light 
diffraction. Here however, particle size calculations are 
based upon the principle that the angle of diffraction is 
inversely proportional to particle size (Weiss and Frock, 
1976; Ho, 1989). The diffraction pattern produced by 
illumination of the sample is focused by a lens onto a 
series of detector rings. The instrument measures the 
intensity of the diffraction pattern at the different rings 
and calculates a sample size distribution. Using different 
optical arrangements, the Mastersizer is capable of 
measuring particles from 100 nm to 600 in in diameter 
(Malvern Mastersizer User Manual, 1988). The optical 
arrangement used for this work enabled measurement of 
particles over a 0.2-80 µm size range, although PCS is the 
preferred technique for sub-micron samples. 
2.2.2.3. Light microscopy 
Samples of microparticle suspension were viewed using a 
Nikon Optiphot light microscope (Nikon, Tokyo) at x20 or 
x40 magnification. 
2.2.2.4. Scanning electron microscopy (SEM) 
Onto an aluminium stub was mounted a piece of double sided- 
sticky tape. A drop of microparticle suspension was placed 
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onto the sticky tape and allowed to dry. The dried stub was 
sputter coated with gold in an argon atmosphere and then 
viewed with a Jeol JSM 35C scanning electron microscope 
(Jeol, Tokyo). 
2.3. RESULTS AND DISCUSSION 
2.3.1. Nanoparticle samples 
2.3.1.1. Effect of polymer concentration 
The mean particle size, measured by the PCS instrument, was 
seen to increase with polymer concentration, from a 
diameter of 196 nm at 1% w/v Eudragit RL to a diameter of 
451 nm at 13% w/v Eudragit RL (table 2.1). Size values in 
table 2.1 are the mean of five measurements for each 
sample. Using 23% w/w polymer solution, many of the 
particles were greater than 1 µm in diameter, and so an 
accurate size could not be obtained by PCS. 
The PCS instrument also provided data on sample 
polydispersity (the polydispersity index). Although in 
monodisperse systems the value of the polydispersity index 
approaches zero, a value below 0.1 is considered to 
represent a relatively narrow -size distribution. The 
majority of the samples had a polydispersity index below 
0.3, although the polydispersity of the 451 nm sample was 
markedly higher (table 2.1). 
Factors responsible for increases in particle size with 
polymer concentration when using solvent evaporation 
processes were described in section 1.1.2.5. C and apply 
here. 
2.3.1.2. Effect of mixing time 
Here, the particle size was determined using the Malvern 
Mastersizer. The Mastersizer generates a comprehensive 
breakdown of the percentage of the sample within 64 size 
increments between 0.1 and 80 µm. The particle size 
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Table 2.1. Effect of polymer concentration on the size and polydispersity 
of Eudragit RL nanoparticles. 
Eudragit RL 
conc. (% w/v) 
Mean particle 
size (nm) 
Polydispersity 
1 196 0.23 
4 227 0.11 
7.5 290 0.25 
10 354 0.27 
13 451 0.45 
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distribution was in all but one case bimodal, with the main 
body sized below 5 µm and a second, smaller group close to 
50 µm. An example is presented in figure 2.2. The most 
likely explanation for these two distinct groups is 
incomplete mixing, since a second population of particles 
was not seen for the batch mixed for 20 minutes. 
The presence of a bimodal distribution complicated data 
interpretation. Therefore, a meaningful comparison of the 
effect of mixing time on particle size was made by 
comparing the mode (or median) diameters of the samples 
(see figure 2.2). As might be expected, the particle size 
was seen to fall with mixing time (table 2.2). 
The Mastersizer also provides a measure of the particle 
polydispersity, termed the "span". The span is equal to the 
difference between the d90% and dlO% diameters divided by 
the d50% diameter. Polydispersity values are recorded in 
table 2.2 and fell with increasing mixing time. The 
dramatic drop in polydispersity between 15 and 20 minutes 
was due to the replacement of the bimodal distribution with 
a unimodal one. 
2.3.1.3. Effect of surfactant concentration 
The particle size using 0.0025 and 0.01% w/v Tween 20 as 
surfactant was similar, but with a further increase in 
concentration, the particle size declined (table 2.3). All 
of the samples were found to be unimodal in distribution, 
probably a consequence of the prolonged, high speed mixing. 
An important factor to be considered when evaluating the 
effects of surfactant on the size of Eudragit RL (and RS) 
nano- and microparticles, is that this polymer already 
possesses intrinsic surface active properties due to the 
quaternary ammonium groups in its structure. The successful 
production of Eudragit RL and RS nanoparticles by a solvent 
evaporation process without using surfactant has been 
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Figure 2.2. Bimodal distribution of Eudragit RL nanoparticles. 
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Table 2.2. Effect of mixing time on the size and polydispersity 
of Eudragit RL nanoparticles. 
Mixing time (minutes) 
Median particle 
diameter (nm) 
Polydispersity 
(span value) 
5 790 62 
7.5 750 53 
10 680 30 
20 610 2 
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Table 2.3 Effect of Tween 80 concentration on the size 
of Eudragit RL nanoparticles. 
Tween 80 conc. (% w/v) 
Mean particle 
diameter (dSO%)(nm) 
0.0025 720 
0.01 730 
0.25 620 
1 600 
5 520 
81 
reported (Bodmeier and Chen, 1989b). As a consequence, the 
effect that surfactant will have on particle size may be 
diminished. 
2.3.2. Microparticle samples 
2.3.2.1. Effect of polymer concentration 
The effect on microparticle size of changing the polymer 
concentration is recorded in table 2.4. As seen with the 
nanoparticles, size increased with polymer concentration. 
The dramatic difference in the particle size generated 
between the two preparation techniques is clearly 
demonstrated. Whereas the high-speed homogenisation 
technique resulted in particles of around 350 nm diameter 
using 10% w/v Eudragit RL, the gentler overhead stirrer 
method produced particles of 25 µm diameter using the same 
concentration of polymer solution. 
2.3.2.2. Effect of stirring speed 
The influence of mixing speed on microparticle size is 
shown in figure 2.3. Although there was a large difference 
in size between the two polymer concentrations when stirred 
at 350 rpm, the difference at the two higher mixing speeds 
was only small. The slower decline in size with the 10% w/v 
polymer solution reflected its higher viscosity. 
In view of the small size difference between the samples 
stirred at 500 and 700 rpm, it is likely that the 10% w/v 
polymer solution produced denser microparticles than the 
2.5% w/v solution. 
2.3.2.3. Effect of stirring time 
A similar pattern was seen as the mixing time increased. 
Thus the decline in microparticle size was most rapid for 
the lower polymer concentration, with the two groups 
approaching in size as the mixing time increased (figure 
2.4). With 10% polymer solution, after 1,2.5 and 5 minutes 
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Table 2.4 Effect of polymer concentration on the size of 
Eudragit RL microparticles. 
Eudragit RL conc. (% w/v) 
Mean particle 
diameter (d5O%)(µm) 
10 24.6±2.0 
7.5 19.1±1.8 
5.0 15.1±0.3 
2.5 7.3±0.3 
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Figure 2.3. Effect of mixing speed on size of Eudragit RL microparticles 
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Figure 2.4. Effect of mixing time on size of Eudragit RL microparticles 
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mixing, the majority of the microparticles were in excess 
of 80 µm (the upper size-limit of the Malvern Mastersizer). 
As for the previous section, it is likely that there were 
density differences between the two sets of microparticles. 
2.3.2.4. Effect of surfactant concentration 
The effect of surf actant concentration on microparticle 
size is shown in figure 2.5. An initial rapid decline in 
size with increasing surfactant concentration was followed 
by a sudden, marked increase in size at 4 and 5% w/v SDS. 
Light microscopy revealed that at these two concentrations, 
the microparticles had formed aggregates, appearing to have 
partly fused into larger bodies. 
Aggregation phenomena have been reported for aqueous 
emulsions of benzene and paraffins (Cockbain, 1952; Higuchi 
et al., 1962). In 10% benzene emulsions, globule 
aggregation was observed between SDS concentrations of 0.36 
and 0.8% w/v. At 0.97% SDS, globules were disaggregated, 
but further increasing the surfactant concentration 
resulted in the reappearance of aggregates. It was 
speculated that aggregation at the lower SDS concentration 
might have resulted from attractive forces between exposed 
hydrophobic surfactant groups residing at the droplet 
surface, while at the higher SDS concentration, aggregation 
may have resulted from forces of attraction between 
adsorbed micelles (Cockbain, 1952). 
2.3.3. Scanning electron microscopy 
SEM micrographs of a sample of Eudragit RL microparticles 
are shown in figures 2.6 a) and b). 
There appeared to be two distinctly different types of 
microparticle. Although both types were roughly spheroidal 
in shape, some contained surface pores and were whole 
spheres, whereas others appeared not to contain large pores 
but were markedly misshapen, and contained large surface 
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Figure 2.5. Effect of SDS concentration on size of Eudragit RL microparticles 
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Figure 2.6. Electron micrographs of Eudragit RL 
microparticles. 
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depressions. This latter group had the appearance of being 
hollow and having collapsed at some stage during 
manufacture or preparation for microscopy. This 
heterogeneity in appearance was confirmed by viewing the 
samples by light microscopy, and many of the individual 
particles also appeared to be transparent. 
2.4. CONCLUSIONS 
The experiments in this chapter have described the 
production of Eudragit RL particulates in two size ranges. 
Using high-speed homogenisation, particles in the nm-size 
range were produced. Much larger spherical microparticles, 
up to tens of microns in diameter, were produced using a 
lower-speed overhead stirrer. 
In the past, using o/w procedures, Eudragit RL/RS 
microspheres have been produced, almost without exception, 
with aqueous PVA solution as the emulsifier (Babay et al., 
1988; Barkai et al, 1990; Bodeneier and Chen, 1989a; 
Malamataris and Avgerinos, 1990). In these publications, 
the phase volume ratio of polymer solution: surfactant 
solution ranged between 1: 30 (Bodmeier and Chen, 1989a) and 
1: 4 (Malamataris and Avgerinos, 1990). It is clearly 
desirable, especially for the manufacture of large batches 
of microspheres, to minimise the size of the mixing vessel 
by using a low phase volume ratio. The use of SDS and 
Tweens as emulsifiers for the production of Eudragit RS/RL 
particulates has not been reported before, and the 
techniques described in this chapter have used a far lower 
phase volume ratio of 1: 2.5. Whether or not PVA can achieve 
an equally high emulsion concentration is not clear. 
The effects on size-characteristics of changing a number of 
production parameters was assessed. The ability to closely 
control the size of particulate carriers is in many cases 
critical to their successful clinical use. For example, 
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systems for parenteral administration need to be 
sufficiently small to pass through a hypodermic needle. In 
addition, as discussed in section 1.1.4.1. B, the size of a 
particulate is one factor determining its in vivo 
distribution following parenteral administration. More 
fundamentally, as the size of a microparticle is decreased, 
the more rapidly drug will be released (e. g. Suzuki and 
Price, 1985; Pongpaibul et al., 1984). 
From the experiments undertaken in this chapter, for a 
given set of manufacturing equipment, the most useful 
parameters for controlling particle size would appear to be 
the time and speed of mixing. Although surfactant 
concentration and polymer concentration were also able to 
influence size, these are probably of less practical use: 
- 
There was an initial sharp decrease in particle size with 
increasing surfactant concentration. However, thereafter 
further increases in surfactant had relatively minor 
effects on particle size and, in the case of SDS, 
aggregation was observed. 
- 
Using prolonged and/or high speed mixing, the effects of 
polymer concentration on particle size were not dramatic. 
It is probable that as the concentration of polymer 
decreases, so does particle density. Since decreased 
density means increased porosity, changes in polymer 
concentration will affect particle drug release 
characteristics. 
The microparticles were far from homogeneous in appearance. 
Many were markedly misshapen and must bring into question 
their ability to reliably retard the release of any drug 
encapsulated within. Whilst undertaking this work, a few 
test batches were produced using Eudragit RS. The 
appearance, under the light microscope of these 
microparticles was very different. In contrast to the 
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transparent, misshapen appearance of the Eudragit RL 
samples, microparticles produced from Eudragit RS were more 
uniformly round and appeared to be considerably denser. It 
was partly for this reason that subsequent work 
investigating drug incorporation concentrated on Eudragit 
RS as the encapsulating polymer. Differences in appearance 
between Eudragit RL and RS microparticles presumably 
reflect differences in polymer structure i. e. the 
proportion of trimethyl ammonioethyl methacrylate functions 
is greater in RL and results in the polymer having a higher 
permeability. 
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CHAPTER 3. 
THE ENCAPSULATION OF 5-AMINOSALICYLIC ACID INTO 
EUDRAGIT RS MICROSPHERES. 
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3.1. INTRODUCTION 
The work carried out in chapter 2 had established basic 
techniques for the production of microspheres from Eudragit 
RL. The next stage of the project was to adapt these 
methodologies and attempt to encapsulate 5-aminosalicylic 
acid (5-ASA) into Eudragit RS microspheres to produce a 
potential sustained-release system for drug delivery into 
the colon. 
The use of 5-ASA as a therapeutic agent for the treatment 
of inflammatory bowel diseases was discussed in detail in 
sections 1.2.5 and 1.2.6. A number of the strategies used 
to optimise its delivery into the colon were outlined. 
Since Eudragit RS does not possess intrinsic colon-specific 
release characteristics, 5-ASA containing microspheres 
would require delivery within a colon-targeted device to be 
of maximum therapeutic use. 
On the face of it, the rationale for developing a colon- 
targeted sustained-release form of 5-ASA might be 
questionable. Since the colonic absorption of 5-ASA is very 
poor, any dose released into the colon will theoretically 
remain available for therapeutic action until excreted in 
the faeces. However, degradation or metabolic conversion to 
inactive derivatives by colonic bacteria cannot be 
discounted. 5-ASA encapsulated within microspheres should 
be protected from potential inactivation until released. 
Another major benefit of delivering 5-ASA within a 
sustained-release dosage form is the avoidance of dose 
dumping prior to entry into the colon. It is recognised 
that significant systemic absorption of 5-ASA may result in 
renal toxicity (Hayllar and Bjarnason, 1991). This may 
arise when a dosage form designed to release its contents 
into the colon disrupts prematurely and releases drug into 
the proximal small intestine. Unwanted absorption of 5-ASA 
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will also reduce the amount available for local action in 
the colon. With a sustained-release preparation, the 
potential for dose dumping is avoided. 
An additional benefit of sustained release 5-ASA may be in 
the treatment of GI tract inflammation proximal to the 
colon e. g. Crohn's disease of the small bowel. Here, the 
dosage form would ideally release 5-ASA for topical action 
but at the same time minimise the amount of drug available 
for systemic absorption and, indeed, such a product is in 
clinical use (PentasaTM see section 1.2.6.1). 
It was apparent, at an early stage in the development of 
the 5-ASA microspheres, that the concentration of 
surfactant used in the production procedure might be able 
to influence the microsphere physical properties, most 
clearly evident in the drug release rate. This work was 
extended to investigate a range of concentrations of two 
surfactants and their effects on microsphere properties. 
These experiments are described in this chapter. 
3.2. EXPERIMENTAL 
3.2.1. Materials 
Eudragit RS100 (Dumas (UK)), 5-ASA (95-98 % purity) (Sigma), 
sodium dodecyl sulphate (GPR grade)(Sigma), polysorbate 
(Tween) 20 (Sigma), dichloromethane (GPR grade)(RhBne- 
Poulenc). 
3.2.2. Methods 
3.2.2.1. Microsphere production 
Preliminary experiments investigating the encapsulation of 
5-ASA employed minor modifications of the technique 
described in section 2.2.2.1. B. 5-ASA powder was suspended 
in 20 ml of a 10% w/v solution of Eudragit RS in 
dichloromethane (5-ASA is insoluble in dichloromethane). 
The drug: polymer mixture was then dispersed into 100 ml of 
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1% w/v aqueous SDS solution at 500 rpm for 5 minutes using 
an overhead stirrer (Stuart Scientific, Manchester, UK). 
The dichloromethane was evaporated at 40 °C in a water- 
bath, whilst stirring at 350 rpm. During solvent 
evaporation, the drug: polymer droplets coalesced to form 
large agglomerates. The agglomeration was probably heat- 
induced, and so in all subsequent encapsulation experiments 
solvent evaporation was carried out at room temperature. 
Using room temperature evaporation, the encapsulation 
process was successful. However, the drug and polymer 
formed into misshapen, elongated microparticles. This was 
a result of the polymer precipitating around the long, 
needle-shaped crystals of 5-ASA. Examination by light 
microscope indicated that the 5-ASA was in the form of 
needle-shaped crystals up to 100 pm in length. 
By finely grinding the drug powder using a pestle and 
mortar, to produce particles less than 20 µm in diameter 
(measured by light microscopy), microspheres could be 
produced. 
As a result of these preliminary experiments, the following 
production procedure was used for the microencapsulation of 
5-ASA: 
To 20 ml of a 10% w/v solution of Eudragit RS in 
dichloromethane was added 1g of finely-ground 5-ASA 
powder. The dispersibility of the ground 5-ASA was poor and 
was aided by placing the bottle containing polymer solution 
and drug into an ultrasonic bath (Decon FS100, Decon, Hove, 
UK) for a period of 20-30 minutes. 
With the dispersion complete, the drug-polymer mixture was 
poured into a 250 ml glass beaker containing 100 ml of an 
aqueous solution of one of two surfactants, SDS or Tween 
20. A range of surfactant concentrations were employed: 0, 
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0.05,0.075,0.10,0.175 and 0.25% w/v SDS and 0.025,0.05, 
0.25,0.5, and 1% w/v Tween 20. The drug-polymer mixture 
was emulsified into the surfactant solution with the 
overhead paddle stirrer set at 200 rpm. Stirring was 
continued, at room temperature, until evaporation of the 
dichloromethane was complete, which typically took 4-5 
hours. 
In all cases of 5-ASA encapsulation, two distinct groups of 
particles were observed. Some of the material formed into 
microspheres which sunk to the bottom of the beaker when 
the stirrer was stopped. The remainder of the drug and 
polymer floated on the liquid surface as misshapen 
agglomerates. These agglomerates were separated from the 
microspheres by decantation at the end of solvent 
evaporation. The remaining microspheres were collected by 
passing through a Buchner funnel containing a 20 pm paper 
filter (Whatman, Maidenhead, UK). After washing with 200 ml 
of distilled water, the microspheres were transferred to a 
small glass beaker which was then covered with pierced 
ParafilmTM (American Can, CT, USA). 
The microspheres were then frozen by plunging the beaker 
into liquid nitrogen and freeze-dried overnight (Edwards 
Modulyo, Crawley, UK). After freeze-drying, the weight of 
microspheres was recorded. Finally, a 250-500 pm sieve- 
fraction was collected for further experiments. Each 
microsphere batch was produced at least in duplicate. 
3.2.2.2. Assay for druct content 
The microspheres were finely ground using a pestle and 
mortar and an accurately weighed quantity, estimated to 
contain up to 5 mg of 5-ASA, was placed into a 100 ml 
volumetric flask. 100 ml of pH 7 phosphate buffer (appendix 
1) was added to the flask and the powdered microspheres 
dispersed by sonication in an ultrasonic bath (Decon FS100) 
for 10 minutes. The flask was then left to stand, with 
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occasional shaking, for up to 6 hours to allow the 5-ASA to 
fully dissolve from the ground microspheres. A sample of 
the flask contents was then drawn into a syringe, passed 
through a1 µm membrane filter (Whatman) to remove 
particulate material and the UV absorbance at 330 nm 
measured (Uvikon 860, Kontron Instruments, Switzerland). 
The concentration of drug present was calculated by 
reference to a calibration curve of 5-ASA dissolved in pH 
7 phosphate buffer. 
3.2.2.3. Drug release studies 
Profiles of drug release from the microspheres were 
obtained using a USP (apparatus 2) dissolution tester 
(Erweka model DT-D6, Heusenstamm, Germany). Samples were 
released into 500 ml of pH 7 phosphate buffer at 37 °C, 
containing 0.02% w/v Tween 20 to aid microsphere wetting, 
and agitated at 100 rpm with paddles. Approximately 120-140 
mg of microspheres containing about 40-45 mg of 5-ASA were 
placed into each vessel. The solubility of 5-ASA was 
estimated to be in excess of 1 g/ 500 ml at 37 °C/pH 7, and 
so the amount of drug present in each dissolution vessel 
was always well below saturation level. At 30,60,120, 
180,240,300, and 360 minute intervals a 10 ml sample of 
dissolution fluid was drawn into a syringe, filtered to 
remove any microspheres (1 in membrane filter) and the UV 
absorbance at 330 nm measured. Any microspheres retained on 
the filter were returned to the dissolution vessel with 10 
ml of fresh buffer. Concentrations of 5-ASA were calculated 
from the calibration curve of drug in pH 7 phosphate 
buffer. The dissolution rate of unencapsulated 5-ASA powder 
was assessed in the same way. 
3.2.2.4. Low temperature scanning electron microscopy 
Electron micrographs were obtained of two microsphere 
samples, those produced with no surfactant and those 
produced using 0.25% w/v SDS. 
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The electron microscope stage was maintained at 
-180 °C 
using liquid nitrogen in order to minimise damage to the 
samples from electron beam irradiation. Using this 
technique (low temperature/ cryogenic SEM) it is possible to 
obtain electron micrographs of heat sensitive materials 
such as margarine and chocolate (Sargent, 1988a, b). 
The samples were mounted on a holder using carbon cement 
and then immediately frozen by plunging into nitrogen 
"slush" at 
-210 °C. Samples were initially placed in a 
preparation chamber (Hexland CT1000A cryotransfer system, 
Oxford, UK) and then moved through onto the electron 
microscope stage (Philips SEM 505). They were examined at 
a low kV while the temperature was raised to -80 °C to 
allow sublimation of any surface water. The sample was then 
moved back into the preparation chamber, sputter coated 
with gold in an atmosphere of argon, and finally returned 
to the stage for imaging. To obtain an internal surface for 
imaging, the sample was moved back into the preparation 
chamber, fractured with a knife and recoated with gold. 
3.3. RESULTS AND DISCUSSION 
3.3.1. Microsphere production 
Eudragit RS microspheres containing 5-ASA could be produced 
successfully over the entire concentration range of Tween 
20 and SDS investigated, with the sole exception of 0.175% 
SDS. 
With 0.175% SDS, microspheres could not be produced, and 
the dispersed drug-polymer-solvent droplets rapidly 
coalesced into a single mass. This concentration of 
surfactant may represent a critical value for this system 
at which the emulsified droplets aggregate, in a phenomenon 
similar to the one reported in section 2.3.2.4. 
The microsphere formulation details are recorded in table 
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3.1. Even in the complete absence of surfactant, 
microspheres were produced, although the yield was low, and 
only 20 to 30% of the added mass of drug and polymer had 
formed into microspheres at the end of solvent evaporation, 
with the remaining material forming misshapen agglomerates. 
The ability to produce Eudragit RL/RS microspheres without 
surfactant has been noted earlier in this thesis (section 
2.3.1.3), although the presence of drug probably restricts 
this process. With SDS, yields were little different 
(varying between 20 and 40%) and were not related to 
surfactant concentration. Similarly, the yield of 
microspheres varied little over the range of concentrations 
used for Tween 20, although the efficiency of the process 
was considerably higher with 70-80% of the drug and polymer 
formed into microspheres. 
The difference in microsphere yield between the two 
surfactants may be related to their critical micellar 
concentrations (cmc). The cmc for SDS is around 0.23% w/v 
at 25 °C, whereas for Tween 20 it is 0.006% w/v (Florence 
and Attwood, 1981). Consequently, while just one of the SDS 
formulations was made with a surfactant concentration close 
to or greater than the cmc, all Tween 20 concentrations 
exceeded the cmc. 
To test this hypothesis, one batch of 5-ASA: Eudragit RS 
microspheres was produced using 1% w/v SDS solution as 
surfactant, a concentration which considerably exceeds the 
cmc. Although the emulsification efficiency was very high 
with very few agglomerates, the resulting product was not 
microspheres. Instead, a voluminous mass of extremely 
brittle drug-polymer particles had formed following solvent 
evaporation. Thus, it appeared that the low yield observed 
with SDS as surfactant was probably due to the fact that 
the concentrations were, with possibly one exception (0.25% 
w/v), below the cmc. 
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Table 3.1. Eudragit RS: 5-ASA microsphere 
formulation details. 
Surfactant concentration used 
to produce microspheres (% w/v) 
Mean microsphere 
5-ASA content (% w/v)(n=3) 
yield (by 
weight) 
No surfactant 29.3±1.3 20-30% 
so 
0.05 
0.075 
0.10 
29.2±1.5 
30.1±1.5 
30.7±1.0 20-40% 
0.25 30.7±1.4 
Tween 20 
0.025 29.5±1.3 
0.05 30.1±1.4 
0.25 28. x. 4 70-80% 
0,5 29.2±0.4 
1.0 29.6±2.0 
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The stirring speed used for microsphere production was 
chosen in order to maximise the proportion of microspheres 
between 250 and 500 µm in diameter. Typically 30-50 % (by 
weight) fell within the desired size range. 
For both surfactants, the efficiency of drug encapsulation 
was high at around 30% w/w (table 3.1), reflecting the 
relatively low aqueous solubility of 5-ASA. (The 
theoretical maximum microsphere loading was 33% w/w). The 
final drug content of the microspheres did not appear to be 
related to the concentration of surfactant used. 
3.3.2. Microsphere drug release characteristics 
The drug release profiles from microspheres produced using 
SDS and Tween 20 as surfactants are shown in figures 3.1 
and 3.2 respectively. The times for 50% of the encapsulated 
drug to be released (t50%) are presented in table 3.2. 
For both SDS and Tween 20, the rates of drug release from 
the microspheres were found to be dependent upon the 
concentration of surfactant used in the production 
procedure. An increase in the concentration of surfactant 
was accompanied by an increase in the rate of drug release. 
The microspheres made without surfactant demonstrated the 
greatest retardation in drug release, with a t50% in excess 
of 360 minutes. In contrast, microspheres made with the 
highest surfactant concentrations, 1% Tween 20 and 0.25% 
SDS, showed little or no retardation in availability over 
unencapsulated 5-ASA. 
For SDS, the fact that microspheres could not be produced 
at a concentration of 0.175% w/v combined with the rapid 
jump in drug release rate between 0.1 and 0.25% w/v 
suggested that a structural change associated with the cmc 
may have occurred. 
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Table 3.2. Time for 50% of 5-ASA to be released from 
microsphere formulations. 
Surfactant type 
and concentration (% w/v) 
t50% for drug 
release (mins) 
Sm 
0 >360 0.05 300 
0.075 160 
0.10 140 
0.25 <30 
Tween 20 
0 >360 
0.025 300 
0.05 120 
0.25 100 
0.5 30 
1.0 <30 
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3.3.3. Low temperature SEM 
Low temperature SEM was used to investigate the surface and 
internal structure of two microsphere formulations that 
represented the two extremes in drug release rate, i. e. the 
rapidly-releasing system produced using 0.25% w/v SDS and 
the sustained-release system produced without surfactant. 
The surfactant-free system produced microspheres that were 
smooth and spheroid-shaped (figure 3.3a). At higher 
magnification, the smoothness and integrity of the surface 
was emphasized and only a few small surface pores were 
visible (figure 3.3b). In comparison, the microspheres 
produced with surf actant were less spheroidal in shape with 
an uneven outer surface (figure 3.4a) 
. 
The surface was seen 
to contain areas of high porosity (figure 3.4b). Using the 
scale on the micrograph, the surface pores are estimated to 
be up to 2 µm in diameter. 
When freeze-fractured, more dramatic structural differences 
were revealed between the two systems. Figure 3.3c shows a 
sectioned view of a representative microsphere from the 
surfactant-free system. The drug-polymer matrix appeared 
generally dense with a number of large holes present. 
Figure 3.3d shows a magnified view of this section in which 
crystals of 5-ASA are visible. 
In the microspheres produced with 0.25% SDS, the internal 
structure reflected the surface topography. The drug- 
polymer matrix was extremely open and porous, resulting in 
a sponge-like or honeycomb appearance (figure 3.4c). Figure 
3.4d shows a crystal of 5-ASA suspended in this open 
framework of polymer. There are fewer crystals visible in 
the micrographs of the 0.25% w/v SDS system because, 
although the w/w drug loading is equivalent to the 
surfactant-free system, the bulk density is considerably 
lower due to their highly porous nature. 
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Figure 3.3. Electron micrographs of Eudragit RS: 5-ASA 
microspheres prepared without surfactant. 
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a) View of microsphere population (magnification x50). 
b) Detail of microsphere surface (x46f). 
c) Freeze-fractured section of microsphere (x260). 
d) Freeze-fractured section of microsphere (x2600). 
0 
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Figure 3.4. Electron micrographs of Eudragit RS: 5-ASA 
microspheres prepared with 0.25% w/v SDS as surfactant. 
a) View of mirrn phere population (magnification x50). 
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c) Freeze-fractured section of microsphere (x340). 
The SEM work demonstrated that the dramatically contrasting 
drug release characteristics of the two systems 
investigated was a result of changes in the structure of 
the drug-polymer matrix. Thus, for the microspheres 
produced using 0.25% SDS, the highly porous structure 
allowed rapid entry of dissolution fluid and rapid exit of 
dissolved drug. Conversely, in the surfactant-free system, 
the 5-ASA was embedded in a more dense, lower porosity 
matrix, and as a result diffusion of dissolution fluid into 
and dissolved drug out of the matrix would be slower, and 
to a greater extent through the hydrated polymer itself, 
rather than primarily through pores as was the case for the 
rapidly releasing system. 
3.4. CONCLUSIONS 
This chapter has demonstrated that 5-ASA can be 
successfully encapsulated with high efficiency into 
Eudragit RS microspheres. By using different concentrations 
of surfactant, the rate of drug release can be modulated to 
provide sustained-release systems or systems which release 
their encapsulated drug very rapidly. 
The mechanism responsible for an increase in drug release 
rate with increasing surfactant concentration is unclear, 
although for SDS at least, it could be due to the formation 
of pores in the microsphere matrix. This could result from 
aqueous droplets of surfactant solution entering into the 
drug-polymer-solvent droplets during the early stages of 
microsphere formation, to effectively form a multiple 
(w/o/w) emulsion system. As solvent evaporation proceeds, 
drug and polymer would be precipitated around the aqueous 
droplets. Removal of water from the microspheres by freeze- 
drying would leave a matrix containing pores. Looking at 
the micrographs showing the internal structure of the 
microspheres produced with 0.25% SDS (figures 3.4c and d) 
it is easy to imagine that the cavities seen could arise 
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from the deposition of polymer around aqueous droplets. 
It is also possible that the mechanism responsible for the 
surfactant-induced enhancement in drug release is not the 
same for Tween 20 and SDS. With Tween 20, the enhancement 
in drug release rate was progressive over the concentration 
range investigated. With SDS, the enhancement was gradual 
to a point, but the difference in drug release rate between 
0.1% and 0.25% SDS was marked. In addition, all of the 
concentrations of Tween 20 used exceeded the cmc, yet 
sustained-release microspheres could be produced. With SDS 
however, the one concentration that may have exceeded the 
cmc (0.25% w/v) produced microspheres that released drug 
instantaneously. When an even higher concentration was 
used, it was not possible to produce discrete microspheres. 
An important point to be considered when evaluating the 
effects of these two surfactants is that Tween 20 is non- 
ionic, whereas SDS is anionic. Consequently with SDS, there 
is the potential for an interaction between the negatively 
charged dodecyl sulphate ions and the positively charged 
trimethyl ammonioethyl groups in Eudragit RS. Inactivation 
of the positively charged polymer functions would certainly 
alter the microsphere formation process, since they are 
responsible for its weak surface active properties. But, 
how such an interaction would influence the final 
microsphere structure is unclear. 
As discussed in section 1.1, in solvent evaporation 
processes a number of parameters can be used to control the 
drug release rate. Examples include the drug-loading, the 
encapsulating polymer, the inclusion of additives such as 
plasticisers, and the microsphere size. This work has 
demonstrated, in addition, that the concentration of 
surfactant may be used as a controlling factor for the rate 
of drug release from Eudragit RS microspheres. For the 
system investigated here, it appeared that Tween 20 was a 
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suitable surfactant for this task. 
It is not clear if surfactant-enhanced drug release applies 
to other encapsulating polymers, although for toxicological 
reasons the presence of high concentrations of surfactant 
in microspheres for parenteral administration would 
probably be undesirable. 
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CHAPTER 4. 
BULK CHARACTERISATION OF EUDRAGIT RS-SULPHASALAZINE 
MICROSPHERES USING FOURIER TRANSFORM-RAMAN SPECTROSCOPY. 
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4.1. INTRODUCTION 
Raman spectroscopy was discovered in 1928 by C. W. Raman. 
Although widely used through the 1930s, it was rapidly 
overtaken by developments in infrared (IR) spectroscopy 
after this time and largely passed out of use as a routine 
analytical technique (Ellis et al., 1989). 
Raman and infrared spectroscopy are complementary 
techniques and provide information on both molecular 
vibrational and rotational changes. Raman spectra arise 
from the inelastic scattering of light, and are associated 
with changes in molecular polarisability. Polarisability is 
defined as the ease with which a molecule can be polarised 
by an external force. In contrast, infrared spectra are 
generated by changes in the molecular dipole moment 
(Willard et al., 1988). 
When a material is irradiated with a monochromatic light 
source the molecules present will be excited into a higher 
energy state, determined by the energy of the incident 
photons (see figure 4.1). The majority of the incident 
radiation will undergo elastic scattering and the molecules 
will fall back to ground state, with the energy and 
frequency of the emitted radiation unchanged. This process 
is called Rayleigh scattering. A very small proportion of 
the photon collisions, about one in a million, will be 
inelastic and result in net energy exchange between photon 
and scattering molecule. If the excited molecule falls back 
to an excited vibrational level (i. e. a different degree of 
polarisability), the energy and frequency of the emitted 
radiation will decrease. Such transitions result in Stokes 
lines, at frequencies lower than the incident radiation. On 
the other hand, if the molecule is already at an excited 
vibrational level when a photon interacts, energy of a 
higher frequency will be emitted if the molecule falls back 
to the ground state. This results in energy bands at 
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Figure 4.1. Energy changes involved in Rayleigh and Raman scattering (adapted from Willard et al., 1988). 
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frequencies higher than the incident radiation, so-called 
anti-Stokes lines. This type of interaction is less common 
and consequently anti-Stokes lines are less intense than 
Stokes lines (Willard et al., 1988; Ewing, 1975; Hendra and 
Mould, 1988). These interactions make up the Raman spectrum 
(see figure 4.1). 
Although Raman spectroscopy can yield useful molecular 
structural information, complementary to IR spectroscopy, 
it does have a major limitation. Raman scattering is very 
weak in intensity, since the vast majority of the incident 
radiation undergoes elastic scattering. As a result, if the 
material under investigation absorbs at the exciting or 
Raman wavelength (e. g. coloured compounds) or if it 
fluoresces even at low levels, the Raman scattering is 
overwhelmed and analysis is impossible (Hendra and Mould, 
1988). In addition, molecules may undergo photo- 
decomposition (Chase, 1987). Consequently, most materials 
are unable to yield useful Raman spectra (Hendra and Mould, 
1988). In addition, alignment of the irradiating laser and 
sample need to be very precise and as a result spectral 
acquisition may take many hours (Ellis et al., 1989). 
However, there is currently a renaissance in Raman 
spectroscopy following the introduction of near-infrared 
laser sources for sample irradiation combined with analysis 
of the Raman scatter using an FT-IR spectrometer modified 
to operate in the near-infrared region (Chase, 1987; Hendra 
and Mould, 1988). Fluoresence, absorption and photo- 
decomposition are all markedly reduced using near-infrared 
irradiation, and consequently most materials are able to 
yield useful FT-Raman spectra (Ellis et al., 1989). A 
number of Fourier transform Raman spectrometers are now 
commercially available and as a result, Fourier transform 
Raman spectroscopy (FTRS) is becoming established as an 
important and versatile technique in analytical chemistry. 
The instruments eliminate the need for tedious sample 
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alignment, and operation is straightforward and rapid with 
minimal sample preparation requirements. A major attraction 
of FTRS is the fact that it is non-destructive and so 
samples can be recovered after analysis (Ellis et al., 
1989). 
There have been a number of reports on qualitative and 
quantitative applications of FTRS to materials of 
pharmaceutical interest. It has been used to identify 
illicit drug substances (Hodges et al., 1990), and to 
distinguish between structurally related compounds (Tudor 
et al., 1990). FTRS also appears to be able to distinguish 
between different drug polymorphic forms, for example 
cimetidine (Tudor et al., 1991a) and chlorpropamide (Tudor 
et al., 1991b). 
It has also been used to investigate the structure and 
biodegradation of poly(anhydrides) (Tudor et al, 1991c), 
materials suitable for implantation as drug-delivery 
systems (see section 1.1.3.1. B). 
There is currently considerably less data on the 
application of FTRS to pharmaceutical dosage forms. One 
paper has reported the characterisation of drug-containing 
polymer matrices (Davies et al., 1990a). For a series of 
tablets containing 5-60% w/w diclofenac sodium in sodium 
alginate, a linear relationship was seen between the 
integrated area of two drug bands from the Raman spectra 
and the concentration of drug. The spectra also suggested 
a degree of drug-polymer interaction. 
The general aims of the FTRS work described in this chapter 
were to assess: 
a) If drug and polymer could be distinguished in spectra 
of drug-polymer microspheres. If this were the case, 
information would be provided on the microsphere bulk 
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structure which might enable any interactions between 
drug and polymer to be identified. 
b) The possibility of using the technique to quantify 
levels of drug present in microsphere samples. 
Although the initial work involving drug encapsulation, 
described in Chapter 3, concentrated on 5-ASA, this drug 
would be unsuitable for planned in vivo biopharmaceutical 
investigations because of low colonic absorption. For 
assessment of the in vivo colonic release characteristics 
of the Eudragit microspheres, a different drug candidate 
was chosen, sulphasalazine (SASP). The use of SASP for the 
treatment of inflammatory bowel diseases is well 
established, and was discussed in detail in section 1.2.5. 
SASP was chosen since its sulphapyridine portion, generated 
by colonic metabolism, is well absorbed and would act as a 
potential marker for drug released from the microspheres 
into the colon. 
4.2. EXPERIMENTAL 
4.2.1. Materials 
As for chapter 3, but in addition: SASP (in place of 5-ASA) 
(Sigma), acetone (Analar grade)(Rhone-Poulenc). 
4.2.2. Methods 
4.2.2.1. Microsphere production 
SASP-Eudragit RS microspheres were produced by the same 
basic technique described in chapter 3. The Eudragit RS and 
SASP were weighed into a glass bottle. 20 ml of 
dichloromethane was then pipetted into the bottle to 
dissolve the polymer. The SASP remained in suspension, 
being largely insoluble in dichloromethane. When 
dissolution of the polymer was complete, the drug-polymer 
mixture was poured into a 200 ml glass beaker containing 
100 ml of 0.1% w/v aqueous Tween 20 solution and stirred 
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with an overhead stirrer at 200 rpm. In all cases, the 
total quantity of drug and polymer in the dichloromethane 
at the start of microsphere manufacture was 2 g. Stirring 
was continued until all of the solvent had evaporated. The 
completed microspheres were then filtered, washed, and 
freeze-dried as described in chapter 3. After drying, the 
microspheres which passed through a 500 µm sieve were 
collected. 
11 batches of microspheres were prepared containing a range 
of concentrations of SASP in order to produce a calibration 
graph of drug concentration versus Raman peak intensity. 
The following drug: polymer ratios (by weight) were 
employed: 6: 94,10: 90,15: 85,20: 80,25: 75,30: 70,35: 65, 
45: 55,50: 50,55: 45, and 60: 40. In addition, a drug-free 
sample of microspheres was prepared and a sample produced 
for a dissolution study composed of a 33: 67 drug: polymer 
mixture. 
4.2.2.2. Microsphere assay 
An accurately weighed quantity of microspheres, estimated 
to contain approximately 2 mg of SASP, were placed into a 
100 ml volumetric flask. 5 ml of acetone was added to the 
flask to dissolve the microsphere polymer matrix. The flask 
was then made to volume with 0.05 N aqueous sodium 
hydroxide solution, resulting in dissolution of the SASP 
and precipitation of the Eudragit RS. The liquid was 
filtered through a1 µm membrane filter and the UV 
absorbance at 458 nm measured. The concentration of drug 
present was calculated by reference to a calibration curve 
of SASP in 0.05 N aqueous sodium hydroxide containing 5% 
v/v acetone. Assays were carried out at least in duplicate. 
4.2.2.3. Microsphere drug release study 
The microspheres made using the 33: 67 drug: polymer mixture 
were dissoluted to provide a comparison of microsphere drug 
content obtained from drug release measurements and FTRS 
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analysis. 40 mg of the microspheres (250-500 gm) were 
placed into each of the six flasks in a dissolution 
apparatus (see chapter 3) containing 500 ml of pH 7 
phosphate buffer (appendix 1). The buffer was maintained at 
a temperature of 37 °C and agitated by paddle stirrers at 
100 rpm. At 1,3,6,9,12, and 24 hours, one of the six 
flasks was removed and the microspheres collected by 
passing the contents through a Buchner funnel containing a 
20 µm filter. The filtrate was assayed 
spectrophotometrically for SASP content (359 nm). The 
microspheres were recovered from the filter and air dried 
at room temperature in preparation for FTRS analysis. 
4.2.2.4. FTRS analysis 
Samples were analysed using a Bruker IFS-88 FT-IR 
spectrometer coupled to an FRA-106 FT-Raman accessory 
(Bruker Spectrospin, Coventry, UK). A general layout of the 
instrument sample area is shown in figure 4.2. 
The samples (microspheres and pure drug) were lightly 
packed into an aluminium sample cup of 10 mm overall 
diameter containing a2 mm diameter bore to hold the 
sample. The samples were irradiated by a diode pump Nd: YAG 
laser, wavelength 1.064 pm (Adlas, Lubeck, Germany), 
focused to a spot size of 100 pm diameter onto the sample. 
The backscattered radiation was detected and the resultant 
Raman spectrum was collected after 50 scans of the sample. 
The signal/noise ratio of each FT-Raman spectrum was 
optimised by altering the parameters governing spectral 
acquisition, namely the resolution and laser power. Pure 
sulphasalazine and all of the calibration samples, apart 
from the four highest drug concentrations were analysed at 
a laser power of 180 MW and an instrumental resolution of 
4 cm-1. The remaining four samples were analysed at 140 mW 
and 4 cm-1 resolution. To achieve a comparable signal/noise 
ratio, the dissolution samples were analysed at 300 mW and 
4 cm-1 resolution. 
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Spectral reproducibility was also examined, using a 
microsphere sample containing 17.4% w/w SASP. To test 
within-sample variability, ten individual spectra were 
obtained for a single microsphere sample (140 mW/4 cm-1/50 
scans). To test between-sample variability, single spectra 
were obtained of ten individual microsphere samples 
weighing between 1.2 and 71.1 mg, using the same spectral 
acquisition parameters. 
4.3. RESULTS AND DISCUSSION 
4.3.1. Microsphere characterisation 
Microspheres were successfully produced for all of the 
drug/polymer mixtures. Table 4.1 lists the results of the 
microsphere spectrophotometric assay. With one exception, 
the efficiency of drug encapsulation was in excess of 85%, 
increasing with drug concentration and reaching a plateau 
above 24% w/w SASP. 
4.3.2. Drug release study 
The results of the microsphere dissolution study are 
presented in table 4.2. The percentage of the encapsulated 
drug released into the dissolution buffer at the seven time 
intervals is recorded. From the microsphere assayed drug 
content (32.0%, table 4.1) and the percentage of drug 
released into the buffer, the residual drug content of the 
microspheres has been calculated. The sustained-release 
properties of the microspheres are clearly demonstrated 
with only 62.3% of the encapsulated SASP released after 12 
hours. For comparison, an equivalent amount of 
unencapsulated SASP powder completely dissolved within 90 
minutes under the same conditions. 
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Table 4.1. Details of Eudragit RS: sulphasalazine microsphere 
formulations. 
Drug: polymer ratio (by weight) 
Assayed drug 
content (%w/w) 
Encapsulation 
efficiency ( %) 
6: 94 5.1 85 
10: 90 8.9 89 
15: 85 11.7 78 
20: 80 17.3 86 
25: 75 24.0 96 
30: 70 28.5 95 
35: 65 33.8 97 
45: 55 42.9 95 
50: 50 47.3 95 
55: 45 51.2 93 
60: 40 54.6 91 
33: 67 32.0 96 
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Table 4.2. In vitro release of sulphasalazine from Eudragit RS 
microspheres over a 24 hour period. 
Time after 
dissolution (h) 
% w/w of encapsulated 
drug released 
Microsphere drug 
content (% w/w) 
0 0.0 32.0 
1 12.4 28.0 
3 29.6 22.5 
6 39.8 19.3 
9 54.7 14.5 
12 62.3 12.1 
24 73.2 8.6 
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4.3.3. FT-Raman spectra 
4.3.3.1. Qualitative interpretation 
The chemical structures of SASP and Eudragit RS are shown 
in chapter 1 (figure 1.6 and table 1.2 respectively). 
Pure SASP produced an intense and complex Raman spectrum 
(figure 4.3). The intensity of the spectrum is a result of 
the three aromatic ring structures in the SASP molecule, 
since these functions are strong Raman scatterers (Willard 
et al., 1988). 
In Raman spectroscopy, each form of ring substitution 
produces a specific pattern of bands. The scattering peaks 
at 1395,1148,1077 and 708 cm-1 may originate from the 
1,2,4-trisubstituted benzene ring, whereas the peaks at 
1246,803 and 645 cm-1 may arise from the 1,4-disubstituted 
ring. The strong peak at 1584 cm-1 could originate from any 
of the three rings. Other prominent peaks in the spectrum 
arise from specific functions within the SASP molecule, 
such as the sulphonamide group (-S02NH-) at 1155 cm-1 and 
the 2-substituted pyridine which probably results in the 
peak at 1453 cm -1 and the broad shoulder at 1437 cm-1. The 
relatively weak band at 3067 cm -1 arises from the aromatic 
C-H stretching vibrations. (For information on peak 
assignments, see Colthup et al., 1975). 
Figure 4.4 is the FT-Raman spectrum of drug-free Eudragit 
RS microspheres. In comparison to SASP, the spectrum of the 
polymer was weaker in intensity and considerably less 
complex. Three major bands dominated the spectrum, at 1728, 
1449 and 2949 cm-1. The band at 1728 cm -1 arises from the 
carbonyl bond of the polymer ester functions. Stretching of 
the methyl and methylene groups results in the band at 2949 
cm 
1, 
while deformation of these groups results in the band 
at 1449 cm-1. 
In Raman spectroscopy, aromatic, heterocyclic and 
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crystalline materials usually give intense Raman spectra. 
In contrast, randomised molecular systems, particularly if 
aliphatic tend to result in a complex vibrational pattern 
(Hendra, P. J., personal communication). As a consequence, 
the numerous bands overlap producing a broad, diffuse, weak 
spectrum. SASP and Eudragit RS are good examples of a good 
and poor scatterer respectively and illustrate this 
principle well. 
Figures 4.5a-d show the spectra of four of the drug: polymer 
microsphere formulations containing 5.1,11.7,28.5 and 
54.6% w/w SASP respectively. In figure 4.5a (5.1% w/w SASP) 
the Eudragit RS bands at 2949 and 1728 cm-1 can clearly be 
seen, although the 1449 cm -1 band has been masked by SASP 
bands. The characteristic SASP bands are clearly evident 
(e. g. 1584,1453,1395,1148 and 1077 cm-1) and are of 
equivalent intensity to those from the polymer which 
reflects the high scattering intensity of the drug despite 
its low bulk concentration. As the concentration of SASP 
increases, the relative intensity of the polymer bands at 
2949 and 1728 cm-1 diminishes. In fact at 54.6% w/w SASP, 
the 1728 cm -1 band is no longer visible. Figures 4.5a-d 
clearly demonstrate the ability to distinguish Eudragit RS 
from SASP in this mixed system. 
An interesting observation in these spectra is the 
appearance of the 1437 cm-1 SASP band. In the pure drug 
this band appears as a shoulder on the larger 1453 cm-1 
band (figure 4.3). However, in the spectrum of microspheres 
containing 5.1% w/w drug (figure 4.5a), the 1437 cm -1 band 
appears resolved. As the microsphere SASP content 
increases, the resolution of this band decreases and it 
becomes a shoulder (figures 4.5b-d). This behaviour may be 
indicative of a degree of drug-polymer interaction. It is 
perhaps the case that the drug dissolves to a small extent 
in the dichloromethane phase during microsphere production 
and as a result is able to interact with the polymer as 
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Figure 4.5. FT-Raman spectra of Eudragit RS- 
suiphasalazine microspheres. 
3500 
a) 5.1 % w/w sulphasalazine. 
b) 11.7 % w/w sulphasalazine. 
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solvent evaporates. Since the quantity of drug dissolving 
and interacting in this way will be constant, depending 
only on its solubility in dichloromethane, the relative 
intensity of the affected peak will decrease as the 
microsphere SASP content increases. It should be noted that 
there appear to be no changes in the other major peaks in 
the SASP spectrum and so the degree of interaction is 
probably small. 
4.3.3.2. Quantitative interpretation 
A quantification of drug content based on SASP peak 
intensities was undertaken. Although the intensity of Raman 
scattering from the drug and polymer in each sample will be 
dependent on the quantity present within the area 
irradiated by the laser, due to variations in density and 
packing within the sample holder, the absolute intensity of 
the drug peaks within the Raman spectrum cannot be directly 
related to the concentration present. In order to eliminate 
problems arising from variations in sample packing and 
density, a peak area ratio was calculated between SASP 
(1584 cm-1 band) and Eudragit RS (2949 cm -1 band) for each 
spectrum. For SASP, the peak area was determined between 
1600 and 1557 cm-1 and for Eudragit RS, between 3047 and 
2857 cm 1, thereby avoiding the small SASP band at 3067 cm- 
1 Peak areas were directly obtained by manipulation of 
stored spectral data by the FT-Raman spectrometer. 
For each spectrum, the peak area ratio (SASP: Eudragit RS) 
was calculated and plotted against the SASP content assayed 
spectrophotometrically (from table 4.1). This relationship, 
shown in figure 4.6, is not a simple one, since as the 
concentration of drug increases, so the concentration of 
polymer decreases. Thus, even if the intensity of 
scattering from polymer and drug were linear with 
concentration, the relationship in figure 4.6 would not be 
so. 
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To simplify data interpretation, a plot of log[peak area 
ratio] vs. log[ %SASP/(100-%SASP)I has been produced (figure 
4.7). The derivation of this relationship is described in 
figure 4.8. A linear relationship was shown between the two 
parameters (r=0.995), with the y axis intercept 
corresponding to the relative difference in scattering 
intensity between the chosen drug and polymer peaks (figure 
4.7). If the area of the drug and polymer peaks increased 
in a linear fashion with concentration, the gradient of the 
line would be 1.0 (figure 4.8), and so the actual gradient 
of 1.26 in figure 4.7 might indicate some deviation in 
linearity between peak intensity and drug or polymer 
concentration. 
For each of the spectra from the dissolution samples, the 
SASP: Eudragit RS peak area ratio was also calculated. The 
ratio values were substituted into the figure 4.7 
calibration equation and the concentration of SASP 
calculated. In figure 4.9, the microsphere drug content 
values calculated in this way and from the 
spectrophotometric data (table 4.2) are plotted versus time 
for comparison. For the 1,3, and 6 hour samples, the Raman 
and UV-calculated values were in excellent agreement. 
However, for the 9,12 and 24 hour samples, the Raman- 
calculated drug content values were all higher than the 
spectrophotometrically-based data, perhaps indicating 
deviations from linearity in the calibration curve at low 
SASP levels. 
The same drug: polymer peak area ratio was employed to 
assess spectral reproducibility. For the within-sample test 
(ten spectra of the same sample), the standard deviation of 
the calculated peak area ratio was ±3.0% (n=10). For the 
between-sample test (one spectra from each of ten different 
samples) the standard deviation was ±4.4% of the mean peak 
area ratio. In fact, one of the samples began to burn 
during spectral acquisition as a result of laser damage, 
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Figure 4.7. Linear relationship between peak area ratio 
and microsphere drug content 
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Figure 4.8. Derivation of a linear relationship between drug 
concentration and peak area ratio. 
For a system containing two components, A and B, 
Drug: polymer peak area ratio, R= fA xa 
fB xb 
Where, f= fraction of component, and a and b= peak area of 100% A 
and B respectively. 
Since fB = 100 - fA 
R= fA xa 
(100-fA)xb 
If the relative difference in peak intensity between a and b is y, 
i. e. a=bxy, then, 
R=fAxaxv 
=yx A 
(100-fA)xa 100-fA 
Therefore, log R= log y+ log [JA/(100 
- 
fA)]. 
A graph of log R vs. log VA/(100 
- 
fA)] will therefore produce a 
straight line where the y axis intercept represents the relative difference 
in intensity between components A and B. 
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but the peak area ratio was not affected. The shape of 
figure 4.6' suggests that errors in peak area ratio will 
have the greatest effect at low concentrations of SASP. 
Thus, by substitution into the figure 4.7 calibration 
equation, a 3.0% variation in peak area ratio would produce 
a ±0.6% w/w error in concentration at 50% w/w SASP, whereas 
the error in concentration at 5% w/w SASP would be ±0.1% 
w/w. The between-sample variation of ±4.4% would result in 
a ±0.9% w/w error in concentration at 50% w/w SASP and a 
±0.15% w/w error at 5% w/w SASP. 
4.4. CONCLUSIONS 
The work presented in this chapter has demonstrated that 
FTRS can yield both useful qualitative and quantitative 
information on Eudragit RS-SASP microspheres. 
Analysis by FTRS was rapid, and for each sample the 
acquisition of the spectrum and determination of its peak 
area ratio took no more than 5 minutes. In fact, compared 
to UV-spectrophotometry, the assay of samples by FTRS was 
technically simpler and faster, with the only sample 
preparation being loading of the material into the sample 
holder. 
In spectra of drug-polymer microspheres, peaks attributable 
to Eudragit RS and SASP could be identified. There was 
evidence to suggest a degree of drug: polymer interaction 
although this would need to be substantiated by further 
work. 
The ability to distinguish drug from polymer in spectra of 
the Eudragit RS-SASP microspheres allowed FTRS to be used 
quantitatively. This appears to be one of the first 
examples of the successful quantitative application of FTRS 
to a two component system where the peak areas of both 
components need to be taken into consideration. Although 
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FTRS has been used to quantify levels of drug in a tablet, 
the tablets were of uniform size and density and thus the 
drug peak area could be directly correlated to drug content 
(Davies et al., 1990a). For the microspheres described in 
this chapter, this could not be done due to variations in 
sample density and packing. With a straightforward 
mathematical treatment, a linear relationship between 
drug: polymer peak area ratio and drug content was derived. 
Reproducibility of the peak area ratio both within- and 
between-samples was high. Drug content results showed good 
agreement with a conventional spectrophotometric assay. 
Although FTRS cannot yet be considered as a routine 
analytical technique, this study demonstrates that it has 
considerable future potential as a non-destructive 
technique for the qualitative and quantitative 
characterisation of drug-delivery systems. 
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CHAPTER 5. 
SURFACE CHARACTERISATION OF EUDRAGIT RS-SULPHASALAZINE 
MICROSPHERES USING X-RAY PHOTOELECTRON SPECTROSCOPY 
(XPS). 
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5.1. INTRODUCTION 
This chapter describes the use of a surface-specific 
analytical technique, X-ray photoelectron spectroscopy 
(XPS), for the characterisation of Eudragit RS-SASP 
microspheres. XPS is also known as Electron Spectroscopy 
for Chemical Analysis (ESCA). 
Much of the pioneering development work in XPS was carried 
out at the University of Uppsala in the 1940s and 1950s, 
but it was only during the 1970s that XPS equipment became 
commercially available (Christie, 1989). Since then, XPS 
has become a well established technique for the surface 
characterisation of a wide variety of materials, including 
those of biomedical interest. Some biomaterials which have 
been analysed by XPS include polyurethanes (Hearn et al., 
1988), polyesters (Davies et al., 1990b), polyorthoesters 
(Davies et al., 1990c), polyanhydrides (Davies et al., 
1990d), and the Eudragits (Davies et al., 1989). The 
technique has been the subject of a number of books and 
reviews (e. g. Briggs and Seah, 1983; Christie, 1989; Clark, 
1977; Miller and Peppas, 1986; Paynter, 1988; Ratner; 
1983). 
The XPS process is based upon the photoelectric effect. The 
material under investigation is irradiated with a 
monochromatic source of X-rays. As a result, the atoms in 
the sample undergo photoionisation. If the photoelectrons 
generated in this process have sufficient energy, they will 
be able to escape from the sample surface in a process 
called photoemission. 
The photoemission process can be described by the Einstein 
equation: 
KE = by 
- 
BE 
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Where, KE is the kinetic energy of the emitted 
photoelectrons, by is the energy of the incident X-ray 
photons and BE is the binding energy of the orbital from 
which the photoelectron is emitted (Paynter, 1988). 
Figure 5.1 presents a diagrammatic representation of an XPS 
spectrometer. Sample irradiation is most commonly provided 
by Alk, or Mgka X-rays (1486.6 and 1253.6 eV respectively). 
The sample depth from which the detected photoelectrons are 
emitted varies with the properties of the sample and the 
angle at which the X-rays strike, but in general they arise 
from no greater than 10 nm below the surface. The emitted 
photoelectrons are separated by an analyser according to 
their kinetic energy, and the number falling into each 
energy band is amplified and counted. The photoemission 
process takes place under high vacuum to minimise 
contamination, and also because many of the components of 
the spectrometer will only function under these conditions. 
To generate an XPS spectrum, the emitted photoelectrons are 
scanned by the analyser, generally over a binding energy 
range of 0-1000 eV. The binding energy of the peaks in the 
spectrum are characteristic of specific orbitals within the 
atoms of specific elements. For example the Cls binding 
energy is 285 ev, Nis is 399 eV and Ols is 532 eV (Paynter, 
1988; Christie, 1989). 
The binding energy values may be shifted according to the 
environment that the atom is situated in. For example, 
whereas the peak of C bonded to C (single bond) or H occurs 
at 285 eV, the peak of C bonded to N occurs at 286.6 eV, 
and the peak of C in a carbonyl function occurs at 289.2 
eV. If the peaks characteristic of the different bonding 
environments present in a molecule are incorporated in a 
deconvolution of the Cls peak, their relative proportions 
may be estimated. This may be employed to provide 
information on whether any of the functionalities in a 
polymer show preferential surface orientation (Clark, 1977; 
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Figure 5.1. Simplified layout of XPS spectrometer (adapted from Paynter, 1988). 
X-ray gun 
Retarding grid 
photo- 
electrons 
Sample 
Detector 
142 
Recorder Ratemeter Amplifier 
Davies et al., 1990c, d). 
XPS may also be used to quantify the elemental composition 
of a surface. Since the areas of the photoelectron peaks in 
the XPS spectrum are directly proportional to the elemental 
surface composition, by calculating peak area ratios, the 
relative proportions of the atoms present at the surface 
can be estimated. The data provided gives a breakdown of 
surface composition in terms of the percentage, by number, 
of the different atoms present, excluding hydrogen 
(Paynter, 1988). 
The application of XPS to drug delivery systems has been 
limited. Binns et al. (1989) used the technique to 
characterise tablets compressed from blends of the drug, 
diclofenac sodium with either sodium alginate or calcium 
phosphate. Surface concentrations of two elemental markers 
for diclofenac sodium, chlorine and nitrogen, were higher 
than predicted, indicating surface drug enrichment. 
In this chapter, XPS has been used to investigate the 
surface atomic composition of Eudragit RS-SASP microspheres 
to determine: 
a) How the surface drug concentration changes with 
different microsphere drug loadings. 
b) The changes in microsphere surface chemistry when 
microspheres are produced with and without surfactant. 
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5.2. EXPERIMENTAL 
5.2.1. Materials 
See chapter 4. 
5.2.2. Methods 
5.2.2.1. Microsphere production 
Eudragit RS-SASP microspheres were produced using the 
technique described in Chapter 4. This time however, the 
drug-polymer solution was emulsified into either 100 ml of 
0.1% w/v aqueous Tween 20 solution or 100 ml of distilled 
water. The total quantity of drug and polymer dissolved in 
dichloromethane was in all cases 3 g. The following 
drug: polymer combinations (by weight) were used: 0: 100, 
10: 90,20: 80,33: 67 and 50: 50. 
5.2.2.2. Microsphere assay 
As described in chapter 4. 
5.2.2.3. XPS analysis 
XPS spectra were obtained for all of the microsphere 
samples and for pure SASP. The samples were mounted onto 
aluminium stubs using double-sided sticky tape and analysed 
using a VG Scientific ESCALAB Mk II spectrometer (VG 
Scientific, Crawley, UK) employing Mgkec X-rays (1253.6 eV). 
A wide scan spectrum (0-1000 eV) and narrow scan spectra 
for Cls, Ols, Nis and S2p were recorded. The analyser was 
operated in fixed transmission mode with a pass energy of 
50 eV. Data was acquired and analysed by a VGS-5000-S data 
system, based on a DEC PDP11/73 computer. 
5.3. RESULTS AND DISCUSSION 
5.3.1. Microsphere characterisation 
Microspheres were produced for all of the drug: polymer 
combinations when emulsified into surfactant solution. 
However, in the absence of surfactant the emulsification 
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process was, not unexpectedly, considerably less efficient. 
As a result, using the 50: 50 drug: polymer mixture 
microspheres were not produced, with a single agglomerated 
mass forming as solvent evaporation progressed. 
The drug content and encapsulation efficiency of the 
different formulations is shown in table 5.1. The 
efficiency of encapsulation increased with drug content and 
was consistently higher in equivalent samples produced 
without surfactant. 
5.3.2. XPS analysis 
5.3.2.1. Qualitative analysis 
The chemical structures of SASP 
provided in chapter 1 (figure 
respectively). 
and Eudragit RS are 
1.6 and table 1.2 
Figure 5.2 shows the wide scan XPS spectrum of pure SASP. 
Peaks for Cls, Ols, Nis, and S2p environments were present 
at 286.5,533.3,401.7 and 169.9 eV respectively. The 
sample appeared to be free of contaminating elements. 
In the wide-scan spectrum of drug-free Eudragit RS 
microspheres produced without surfactant, the only 
prominent peaks are Cis and Ols (figure 5.3). Although N 
and S were both detected, their surface concentrations were 
too low to be discernible on the wide scan spectrum. 
In the spectrum of surfactant-free microspheres containing 
31.1% w/w sulphasalazine (figure 5.4), Cls and Ols again 
predominate, although Nls and S2p peaks are just evident. 
5.3.2.2. Quantitative analysis 
A quantitative assessment of the XPS data was based upon a 
comparison of the theoretical surface composition of the 
microsphere samples and the experimentally determined 
atomic composition. 
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Table 5.1. Details of Eudragit RS: sulphasalazine microsphere 
formulations. 
Drug: polymer ratio (by weight) 
Assayed drug 
content (%w/w) 
Encapsulation 
efficiency ( %) 
Produced with- 
out surfactant 
10: 90 8.9 89 
20: 80 18.4 92 
33: 67 31.1 93 
50: 50 
- - 
Produced with 
surfactant 
10: 90 8.7 87 
20: 80 18.2 91 
33: 67 30.3 92 
50: 50 47.5 95 
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To calculate the theoretical elemental surface composition 
of the samples, two assumptions had to be made: 
1) The drug and polymer are present at the microsphere 
surface as a homogeneous molecular dispersion in 
proportion to their bulk composition. 
2) There is no preferential surface orientation of either 
component. 
Thus, for each of the microsphere samples the theoretical 
number of C, 0, N and S atoms present per unit weight were 
calculated, and in turn the percentage of the total number 
of atoms present that each represented. Figure 5.5 provides 
details of the calculation of % atomic composition of SASP 
and Eudragit RS. The Eudragit RS composition is based upon 
a molar ratio of 2: 1: 0.1 of methyl methacrylate, ethyl 
acrylate and trimethylammonioethyl methacrylate chloride 
monomer units and a molecular weight of 150,000. In figure 
5.6 is a sample calculation of the theoretical surface 
composition of one of the drug: polymer microsphere samples. 
Table 5.2 records the theoretically derived and 
experimentally determined atomic compositions of the 
samples. 
For pure SASP, the experimental and predicted atomic 
compositions were in excellent agreement. This suggests 
that the surface chemistry of the SASP crystals directly 
reflects the structure of the drug molecule. 
For the surfactant-free, drug-free microspheres, the level 
of carbon was 3.7% higher than predicted. This was 
accompanied by a 3.9% fall in surface oxygen. The nitrogen 
level was close to predicted, although the accuracy of XPS 
below concentrations of 1% is not high. The very small 
quantity of sulphur detected (0.1%) may arise from a 
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Figure 5.5. Calculation of atomic % composition of microsphere components. 
1. Eudragit RS 
Eudragit RS = methyl methacrylate (MM), ethyl acrylate (EA), and trimethyl 
ammonioethyl methacrylate (TM) in a 2: 1: 0.1 ratio, respectively. 
Monomer mol. wt: MM = 100, EA =100, TM = 207 
Mol. wt. of each RS "backbone unit" = (2 x 100) + (1 x 100) + (0.1 x 207) _ 
320.7. 
Monomer atomic composition: 
MM=5C+20+8H 
EA= 5C+20+8H 
TM=9C+20+1N+18H+1C1 
Total atoms/backbone unit 
C=(2x5)+(1 x 5) + (0.1 x 9) = 15.9 
O=(2x2)+(1 x 2) + (0.1 x 2) = 6.2 
N= (0.1 x 1) = 0.1 
Cl = (0.1 x 1) = 0.1 
H=(2x8)+(1 x 8)+(0.1 x 18)=25.8 
Polymer mol. wt. = 150,000 
= 
150,000/320.7 
= 
467.7 backbone units/mole 
Therefore, total atoms/mole (excluding H) 
C= 467.7 x 15.9 = 7437 
0= 467.7 x 6.2 = 2900 
N= 467.7 x 0.1 = 47 
C1=467.7x0.1=47 
Total atoms (excluding H) = 7437 + 2900 + 47 + 47 = 22498 
Atomic %C= 7437/10431 x 100 = 71.6%. 
Atomic %0= 2900/10431 x 100 = 27.9%. 
Atomic %N= 47/10431 x 100 = 0.5%. 
2. Sui_phasalazine 
Mol. wt. = 398. 
Atomic composition = 18C, 50,4N, 1S, 14H 
Total atoms (excluding H) = 18 +5+4+ 1= 28 
Atomic %C= 18/28 x 100 = 64.3%. 
Atomic %0= 5/28 x 100 = 17.9%. 
Atomic %N= 4/28 x 100 = 14.3%. 
Atomic %S= 1/28x100=3.6%. 
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Figure 5.6. Calculation of atomic % composition of Eudragit RS microspheres 
containing 18.2% w/w sulphasalazine (SASP). 
SASP: Eudragit RS ratio (by weight) = 18.2: 81.8. 
Molar ratio = (18.2/398): (81.8/150,000) = 0.046: 0.00055. 
i) 100% SASP = 18 C atoms, 50 atoms, 4N atoms, and 1S atom. 
No. of C atoms from SASP = 18 x 0.046 = 0.828 
No. of 0 atoms ""=5x0.046 = 0.230 
No. of N atoms ""=4x0.046 = 0.184 
No. of S atoms " it =1x0.046 = 0.046 
ii) 100% Eudragit RS 
= 
7437 C atoms, 2900 0 atoms, and 47 N atoms. 
No. of C atoms from RS = 7437 x 0.00055 = 4.090 
No. of 0 atoms from RS = 2900 x 0.00055 = 1.595 
No. of N atoms from RS = 47 x 0.00055 = 0.026 
Total no. of atoms (C, 0, N, S) from SASP and Eudragit RS = 6.999 
Atomic %C= ((0.828 + 4.09)16.999] x 100 = 70.2 %. 
Atomic %0= [(023 + 1.595)16.999] x 100 = 26.1%. 
Atomic %N= ((0.184 + 0.026)16.999] x 100 = 3.0 %. 
Atomic %S= (0.046/6.999) x 100 = 0.7 %. 
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contaminant present in the raw polymer. For comparison, XPS 
analysis by Davies et al. (1989) of a film of Eudragit RS 
cast from methanol, yielded the following composition: 
C=72.8%, 0=26.9% and N=0.3%. The discrepancy between 
predicted and experimental microsphere C and 0 contents 
could be a result of surface hydrocarbon contamination. 
Alternatively, it is possible that the difference is a 
result of an unexpected polymer orientation. 
That Eudragit RS has surface active properties is clear, 
both from the work presented in this thesis, where 
microspheres have been produced without surfactant, and 
from the literature (Bodmeier and Chen, 1989b). 
Stabilisation of the polymer at an aqueous interface is 
most likely to arise from the trimethyl ammonioethyl 
functions orientating towards the interface. Although this 
might be expected to produce differences between the 
experimental and predicted surface composition, the 
magnitude of the effect is impossible to predict. For 
example, although the molar ratio of trimethyl ammonioethyl 
groups is only small in Eudragit RS (47 out of a total 1450 
monomer units in each polymer chain), conformational 
changes in the polymer chains may produce a local high 
concentration of these groups at the surface. 
For the drug-free microspheres produced with surf actant, 
the surface C content was 6.6% higher than predicted. This 
discrepancy might be expected to result in part from the 
presence of surf actant at the microsphere surface 
. 
However, 
Tween 20 (empirical formula C58H114026) has a C: 0 ratio of 
69%: 31% and thus significant amounts at the microsphere 
surface might also be expected to raise the level of 
detected oxygen. In fact the level of oxygen is 6.9% lower 
than predicted. Therefore, although Tween 20 would be 
expected to be present in this sample, it is also possible 
that the unexpected surface composition might be a result 
of preferential polymer orientation in the presence of the 
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surfactant. 
Sulphur was theoretically a unique marker for SASP in the 
drug-polymer microspheres. However, it was unsuitable for 
two reasons. Firstly, it unexpectedly appeared in the 
drug-free polymer samples, albeit at a low level, and 
secondly its predicted concentration was relatively low; 
Since 100% SASP only contains 3.8% S atoms and the accuracy 
of XPS below 1% is not high, there would be problems in 
accurately measuring the levels of S likely to be present 
in the microsphere samples. Nitrogen proved to be a better 
choice as a drug marker, since it was present in the 
polymer at only a low concentration, yet present in 100% 
SASP at 13.6%. 
For each of the two sets of drug-containing microsphere 
samples (i. e. surfactant and no surfactant) the surface 
drug concentration, as measured by surface %N, remained 
relatively constant despite marked differences in bulk drug 
content. Thus, in the samples produced with surfactant, the 
surface N concentration was 1.3% for microspheres 
containing 8.7% w/w SASP, increasing to just 1.8% at a bulk 
drug content of 47.5% w/w SASP. The theoretical increase in 
%N over this range of SASP content was from 1.8 to 7.2% 
(table 5.2 and figure 5.7). As seen for the drug-free 
sample, carbon levels were generally considerably higher 
than expected, again suggesting surfactant contamination or 
preferential polymer orientation. 
In the samples produced without surfactant, the surface N 
concentrations were again relatively constant but at a 
higher level, ranging from 2.8% to 3.2% (table 5.2 and 
figure 5.8). The relatively higher N concentrations in 
these samples are presumably a direct result of no 
surfactant being present. 
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5.4. CONCLUSIONS 
The work presented in this chapter has demonstrated that 
XPS is able to provide a valuable insight into the surface 
chemistry of microspheres manufactured by the solvent 
evaporation process under different conditions. 
An unexpected finding was that the microsphere surface SASP 
concentration, as measured by surface %N, remained little 
changed despite wide variations in the bulk drug content. 
This effect was seen for microspheres produced with and 
without surfactant. 
In microspheres produced using surfactant, considerable 
surface hydrocarbon enrichment was evident. This could have 
resulted from the presence of surfactant and/or a polymer 
surface reorientation. 
The microsphere formation process involves complex 
interactions between drug, polymer and aqueous phase at the 
microsphere surface and consequently, using XPS alone few 
definite conclusions can be made about the mechanisms 
responsible for the effects seen. However, this work has 
provided the basis for future studies investigating these 
phenomena in more detail. 
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CHAPTER 6. 
THE DEVELOPMENT OF DOSAGE FORMS FOR THE ASSESSMENT 
OF TRANSIT THROUGH THE COLON. 
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6.1. INTRODUCTION 
One of the major aims of the work carried out for this 
thesis was to further investigate the phenomenon that the 
rate of transit of materials through the colon may depend 
on their size. A summary of some of the studies 
investigating the colonic transit rate of different-sized 
units was provided in section 1.2.4.1. 
It was planned to undertake in vivo investigations in human 
subjects to compare the colonic transit rate of small 
particles with larger units. The chosen size of small 
particles was 0.2 mm, selected to represent a dispersed 
microparticulate type of dosage form. The larger units were 
non-disintegrating tablets of 5 mm or 8.4 mm diameter. By 
radiolabelling the two sizes with different radioisotopes, 
it would be possible to simultaneously measure their 
movement through the GI tract using gamma scintigraphy. 
It was intended that the two sizes of particles should be 
administered together within a hard gelatin capsule, coated 
to resist disintegration until reaching the colon. If the 
two sets of particles were administered independently, 
there was the possibility of separation higher up the GI 
tract, resulting in one size of particle arriving at the 
colon well ahead of the other, and complicating data 
interpretation. In the event of separation occurring, it 
would be at the gastric emptying stage. 
Delivery inside a coated gelatin capsule was considered to 
be most appropriate, since although direct placement of 
materials into the colon can be achieved by use of an oro- 
caecal tube (Krevsky et al., 1986; Proano et al., 1991) 
there are drawbacks. Apart from the fact that the 
intubation procedure is unpleasant for the subject, there 
is a limit on the size of material that can be passed down 
the tube. In addition, the presence of the tube may 
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stimulate colon motility, since in one study using this 
technique, transit through the ascending colon was 
abnormally rapid (Krevsky et al., 1986). 
The standard method for radiolabelling oral dosage forms 
for scintigraphic investigations is to immobilise the 
radioisotope on an ion-exchange resin. The most commonly 
used radioisotopes for human scintigraphic investigations 
are technetium-99m (99mTc, half-life=6.0 hours) and indium- 
111 (111In, half-life=67 hours) (Wilson and Washington, 
1988). The most commonly used resins for isotope binding 
are the AmberlitesTM (Rohm & Haas (UK) 
, 
Croydon), available 
in a number of different grades. AmberlitesTM IR120 and 
IRA410 resins are both cross-linked copolymers of styrene 
and divinylbenzene. IR120 is a cationic resin, and ion- 
exchange (In+) takes place at sulphate functions (SO3-). 
IRA410 is an anionic resin, and ion-exchange (TcO 4-) takes 
place at trimethylammonium functions (N(CH3)3+) (Handbook 
of Pharmaceutical Excipients, 1986). Adsorption of the ions 
of large atoms such as Tc and In to the resins is very 
strong and desorption occurs only slowly (Proano et al., 
1990). 
This chapter describes the preparation of dosage forms to 
enable in vivo transit investigations to be undertaken, and 
in particular the development of a suitable colon- 
targetable coating. A review of strategies for targeting 
dosage forms to the colon was provided in section 1.2.6, 
the principal methods being the use of pH-dependent or 
bacterially metabolised coatings. The most appropriate 
coating formulation chosen from the work in this chapter 
was then used for in vivo investigations described in 
chapters 7 and 9. 
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6.2. EXPERIMENTAL 
6.2.1. Materials 
AmberliteTM IR120 ion-exchange resin (0.3-1.8 mm) (BDH), 
AmberliteTM IRA410 ion-exchange resin (0.3-1.8 mm) (BDH), 
ethylcellulose (Sigma), size 000 hard gelatin capsules 
(Farillon, Romford, UK), Eudragit S (Dumas (UK)), "Polymer 
A", low molecular weight poly(methylmethacrylate) (BDH), 
acetone (Analar grade)(Rhöne-Poulenc), sodium hydroxide 
pellets (BDH), hydrochloric acid (36% w/v) (BDH), 111TH 
chloride (Amersham Int., Amersham, UK), sodium 
pertechnetate (99mTc) (Radiopharmacy, University Hospital, 
Nottingham). 
6.2.2. Methods 
6.2.2.1. Preparation of 0.2 mm particles 
A. Cleaning and activation 
The 0.2 mm particles were prepared from AmberliteTM IR120 
resin. Prior to use, the resin was cleaned to remove any 
contaminants, and activated, according to instructions 
provided by the manufacturer (Rohm & Haas (UK)): 
i) Resin soaked for 20 minutes in 2N hydrochloric acid. 
ii) Acid removed by filtration, resin rinsed with distilled 
water and left to soak in water for 30 minutes. 
iii) Water removed, resin soaked in 1.5 N sodium hydroxide 
solution for 20 minutes. 
iv) Wash as in step ii), and repeat steps i) to iv). 
v) Resin activated to H+ form by soaking in 2N HC1 for 20 
minutes. 
vi) Wash in water until eluent pH>4. 
B. Size fractionation 
A 0.18-0.25 mm sieve fraction of the resin was then 
prepared. Since ion-exchange resins swell when moist, the 
sieve fraction was prepared from wet resin. The wet resin 
was ground using a pestle and mortar and passed through a 
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0.25 mm sieve stacked onto a 0.18 mm sieve (Endecott, 
Crawley, UK). Resin which did not pass through the 0.25 mm 
sieve was returned to the mortar for further grinding. This 
process was continued until no resin >0.25 mm remained. The 
resin collected between the two sieves was dried at room 
temperature and stored until required. 
C. Radiolabelling 
To radiolabel the sieved resin, the required amount was 
placed into a glass beaker and moistened with water to form 
a paste. Sufficient 111In chloride solution to leave 1 
MBq/300 mg of resin at the time of dosing was then drawn by 
syringe and needle from its vial and gently mixed into the 
beaker contents. The radiolabelled resin was dried by 
heating the underside of the beaker with a hair-drier. 
6.2.1.2. Tablet preparation 
Tablets were required to remain intact for the duration of 
the in vivo study and were prepared from an insoluble 
polymer, ethylcellulose. Two different radiolabelling 
techniques were developed. The initial method (I) involved 
the incorporation of 99mTc labelled ion-exchange resin into 
the tablet blend prior to compression. Refurbishment of the 
radioisotope facilities containing the tablet press at a 
later stage in the programme necessitated the development 
of an alternative technique involving surface 
radiolabelling (II). 
Method I 
A. Cleaning and activation 
AmberliteTM IRA410 resin was required for producing the 
tablets. Prior to use, the resin was cleaned and activated, 
as follows: 
i) Resin soaked for 20 minutes in 1.5 N sodium hydroxide 
solution. 
ii) Alkali removed by filtration, resin rinsed with 
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distilled water and left to soak in water for 30 minutes. 
iii) Water removed, resin soaked in 2N hydrochloric acid 
for 20 minutes. 
iv) Wash as in step ii) and repeat steps i) to iv). 
v) Resin activated to OH- form by soaking in 2N NaOH for 20 
minutes. 
vi) Wash in water until eluent pH<9. 
Prior to use, the resin was air-dried, and then very finely 
ground using a pestle and mortar. 
B. Radiolabelling 
For radiolabelling, the required amount of sodium 
pertechnetate solution was added to a paste of water and 
ground IRA410 resin. The activity was mixed with the resin 
paste and dried using a hair-drier. 
C. Tabletting 
Tablets of 5 mm diameter and approximately 3 mm depth were 
produced by direct manual compression of a blend of 
ethylcellulose containing 1% w/w of radiolabelled Amberlite 
IRA410 resin, using a Manesty F6 tablet press. The desired 
tablet hardness was at least 6 kg and the target weight, 
55-65 mg. To ensure integrity was maintained in vivo, the 
tablets were painted with four coats of 5% w/v 
ethylcellulose in acetone. The radioactivity in each tablet 
at the time of dosing was 0.67 MBq. 
Method II 
5 mm or 8.4 mm diameter tablets were produced by the direct 
compression of ethylcellulose. Tablet hardness was adjusted 
to produce tablets with a breaking force of at least 6 kg 
(5 mm) or 12 kg (8.4 mm). Sodium pertechnetate solution was 
diluted with water such that the required amount of 
activity at the time of dosing (0.67 MBq) would be present 
in 10 µL. Using a 10 µL micropipette (Gilson), the activity 
was carefully placed onto the tablet surface and allowed to 
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dry at room temperature. When dried, the tablet was coated 
with a solution of 10% w/v poly(methylmethacrylate) in 
acetone; First, a single drop of polymer solution was 
placed onto the dried sodium pertechnetate. Then gradually 
the whole tablet was painted with four coats of polymer 
solution. 
In vitro dissolution testing (paddle stirrers at 100 rpm, 
pH 7 phosphate buffer, 37 °C (see also chapter 3)) 
indicated that the tablets produced by methods I and II 
remained intact for at least 24 hours. 
6.2.2.3. Capsule coating 
A dipping technique was employed for coating of the hard 
gelatin capsules (figure 6.1). A length of cotton was tied 
around the middle of each capsule. Of the two loose ends of 
cotton left after tying, one was cut and the other, at 
least 5 cm in length was used to suspend the capsule for 
drying. To coat, the capsules were dipped (complete 
immersion for about 5 seconds) into a bottle containing a 
solution of the coating polymer. Between dips, the capsules 
were suspended by attaching the end of the piece of cotton 
with sticky tape to a ruler fixed between two retort 
stands. When coating was complete and the coat dry, the 
suspending cotton was cut at the capsule body. 
6.2.2.4. Preliminary in vitro experiments 
In vitro coating experiments were based upon the use of two 
enteric polymers, Eudragit S which dissolves above pH 7 
(section 1.1.3.2. A) and "Polymer A". Initial experiments 
used the two polymers alone, with later work adopting a 
dual coating procedure. Coating performance was evaluated 
using a tablet/capsule disintegration apparatus (Copley). 
The coating integrity was tested by approximately half- 
filling the capsules with dry beads of Amberlite resin. 
This allowed easy detection of capsule leakage, since when 
moistened, the smooth flow of the resin beads would be 
165 
Figure 6.1. Procedure for dip-coating gelatin capsules. 
1. Cotton tied around 
hard gelatin capsule. 
3. Between immersions, 
capsule allowed to dry. 
2. Capsule completely immersed 
into a solution of coating polymer 
in acetone for about 5 secs. 
4. Suspending cotton cut 
at capsule body. 
ýý 
m 
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interrupted. Disintegration testing was carried out 
according to an adaptation of the British Pharmacopoeial 
procedure for testing enteric coated tablets/capsules 
(British Pharmacopoeia, 1988). Capsules were placed into 
0.1 N hydrochloric acid for 2 hours, followed by pH 6 
phosphate buffer (appendix 1) for 3 hours ending with a 
period at pH 7.5 to ensure disintegration of Eudragit S- 
containing samples. 
The following samples were evaluated: 
For Eudraait S 
1. Three capsules dipped ten times into 10% w/v polymer in 
acetone. 
2. Three capsules dipped six times into 15% w/v polymer in 
acetone containing 10% (by weight of polymer) dibutyl 
phthalate as plasticiser. 
For "Polymer A" 
Three capsules dipped three times into a solution of 15% 
w/v polymer in acetone. 
Dual Eudragit S/"Polymer A" coatings 
Six capsules were dipped four times into a solution of 15% 
w/v "Polymer A" in acetone. The capsules were then further 
coated by dipping twice into a 10% w/v solution of Eudragit 
S in acetone containing 20% by weight of dibutyl phthalate. 
6.2.2.5. In vivo experimentation 
The following capsule formulations were evaluated in a 
small scale scintigraphic investigation using healthy human 
volunteers. For more details on the technique of gamma 
scintigraphy, see chapter 7. 
Formulation A: Five coats of 15% w/v "Polymer A" in 
acetone. 
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Formulation B: Five coats of "Polymer A" as above with a 
top layer of two coats of 10% w/v Eudragit S in acetone 
containing 20% (by weight of polymer) dibutyl phthalate and 
5% v/v water. 
Formulation C: Four coats of 15% w/v "Polymer A" with a top 
layer of four coats of 10% w/v Eudragit S in acetone 
containing 20% (by weight of polymer) dibutyl phthalate and 
5% v/v water. 
Six healthy volunteer subjects (age 23-40) undertook the 
study. Before coating, each capsule was filled with 150 mg 
of 111In-labelled 0.2 mm Amberlite IR120 resin (1 MBq of 
activity/capsule at time of dosing). Each coating 
formulation was evaluated in two volunteers, with each 
subject receiving two capsules. 
Subjects arrived for the study at 8 am having fasted from 
10 pm the previous evening. Radioactive markers (see 
chapter 7) were attached to the subjects anterior and 
posterior over the right lobe of the liver to allow 
alignment of sequential scintigraphic images. The two 
capsules were swallowed, with a glass of water. Subjects 
received breakfast after the capsules had left the stomach. 
Anterior and posterior scintigraphic images were recorded 
immediately after dosing and thereafter at 30-60 minute 
intervals throughout the day (IGE Maxicamera II/Star 
computer system, IGE, UK). 
The point of capsule break-up, as evidenced by the 
dispersion of radioactivity, was determined from analysis 
of the stored scintigraphic images. 
6.2.2.6. Further characterisation of "Polymer A" coatings 
Ten empty 000-sized gelatin capsules were weighed and the 
mean weight determined. Each capsule was then dip-coated 
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three times into a solution of 15% w/v "Polymer A" in 
acetone. The capsules were then reweighed to determine the 
mean weight of coating applied. 
To determine the thickness of the capsule coating, thin 
slices of the coated capsules were cut using a scalpel. The 
slices were placed onto a microscope slide and examined at 
x20 magnification (Nikon Optiphot). It was possible to 
distinguish the coat from the capsule shell which enabled 
the thickness of the coating polymer to be measured using 
a graticule. 
6.3. RESULTS AND DISCUSSION 
6.3.1. In vitro capsule evaluation 
6.3.1.1. Eudragit S alone 
The studies using Eudragit S alone as a capsule coating 
proved disappointing. After the 2 hour period in 0.1 N HC11 
the capsules containing ten coats of Eudragit S had all 
allowed ingress of liquid and were beginning to spill the 
resin contained within. It was noted, before dissolution, 
that the capsule coatings had a crazed appearance. 
Eudragit S forms brittle coatings and the routine use of 
plasticisers is recommended by the manufacturer. 
Plasticiser concentrations of up to 25% by weight of 
Eudragit S are considered not to adversely affect the 
polymer performance (Eudragit technical data). 
Thus, the next set of coatings included 10% w/w dibutyl 
phthalate as a plasticiser. After 2 hours in acid, only one 
of the three capsules remained wholly intact. One of the 
capsules had spilled most of its contents and was removed. 
After three hours at pH 6, both capsules were spilling 
contents. 
Therefore, even with the inclusion of plasticiser, coating 
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integrity remained a major problem. 
6.3.1.2. "Polymer A" alone 
After 2 hours in acid, all of the capsules coated with 
"Polymer A" appeared to have resisted moisture ingress. At 
pH 6, capsules were spilling resin after 30 minutes. After 
45 minutes about half of each capsule body had dissolved 
away and after 60 minutes just small fragments of the 
thickest sections of polymer coating remained. 
6.3.1.3. Dual "Polymer A"/Eudragit S coatings 
Although the "Polymer A"-coated capsules showed excellent 
acid resistance in vitro, from their rapid dissolution at 
pH 6 it was considered that they would not remain intact as 
far as the colon in vivo. As a result, the strategy adopted 
was to coat with a base layer of "Polymer A", to provide 
improved integrity in the stomach and small intestine, and 
a top layer of S. In theory, the Eudragit S would dissolve 
in the colon exposing the coating of "Polymer A" which 
would then rapidly dissolve. 
After 2 hours in acid, there was evidence of slight 
moisture ingress in two of the six capsules. No resin had 
been lost. After 2 hours at pH 6, some of the capsules 
showed evidence of moisture ingress, but no resin had been 
lost. At 3 hours, more liquid had entered the capsules, 
although no resin had been lost. After a half hour at pH 
7.5, resin particles could be seen in the beaker containing 
the disintegration medium. Finally, after 1 hour at this 
pH, resin was spilling from all but one capsule. 
6.3.2. In vivo evaluation of capsule coatings 
Capsules arrived at the colon between 1 and 4 hours after 
administration to the human volunteers. Any delays were a 
result of retention in the stomach. Small intestinal 
transit time was only brief (less than 90 minutes). 
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Surprisingly, in the two subjects taking capsules coated 
with "Polymer A" alone (formulation A), disintegration did 
not occur until reaching the ileo-caecal/base of ascending 
colon region. 
Formulation B capsules were resident in the ascending colon 
for some time before disintegration was apparent. 
In one of the subjects taking Formulation C, disintegration 
did not begin until the hepatic flexure, whilst in the 
other subject the capsules travelled intact as far as the 
sigmoid colon. In the latter case, intestinal transit was 
very rapid. 
6.3.3. Further characterisation of "Polymer A" coating 
Before coating, the mean weight of the ten empty capsules 
was 163±4 mg. The dip coating technique proved remarkably 
reproducible with a mean capsule weight following coating 
of 229±3 mg. Since the piece of cotton remaining attached 
to each capsule weighed about 1 mg, the mean weight of 
polymer coating was approximately 65 mg. 
Light microscope analysis of the coating indicated that it 
was between about 50 and 100µm in thickness. The coat was 
thickest on the underside of each capsule and thinnest on 
the capsule ends. 
6.4. CONCLUSIONS 
Somewhat unexpectedly, "Polymer A" achieved the desired 
effect of delivering the capsules intact into the colon. 
Although capsules coated with this polymer disintegrated 
relatively rapidly in vitro, this behaviour was not evident 
in vivo. A combination of at least two factors may have 
been responsible for the unexpected in vivo behaviour. 
Firstly, the small intestinal transit time in all of the 
subjects was relatively short. Secondly, all subjects were 
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fasted and so levels of dissolution liquid in the small 
intestine to which capsules would have been exposed may 
have been low. Performance in fed subjects, where levels of 
liquid in the small intestine might be greater, or in 
subjects with a longer small intestinal transit time, could 
be very different. 
The delayed disintegration of the Eudragit S-containing 
formulations, B and C, could be a result of a number of 
factors, including the colonic pH in the subjects 
investigated and the overall thickness of the coating. In 
one subject, capsule break-up in distal portions of the 
colon was almost certainly a result of a rapid intestinal 
transit rate. 
Recently-published investigations from the Mayo Clinic into 
colon transit have also used radioisotope delivered within 
gelatin capsules (Proano et al., 1990,1991). The capsules 
were coated with a solution of 13% w/v Eudragit S by a 
dipping technique. In vitro and in vivo disintegration of 
the Eudragit S coatings was generally slow, as demonstrated 
from the work in this chapter. The time for capsule 
disintegration to begin in vitro increased with coating 
thickness. For example, with one coat the capsule began 
disintegrating after 0.22 h at pH 7.4, whereas with five 
coats disintegration did not begin until 2.3 h. In vivo, 
capsules with four and five coatings passed through the 
colon intact, with two to three coatings disintegrated in 
the caecum and ascending colon, whilst with one coating, 
capsules disintegrated in the ileo-caecal region (Proano et 
al, 1990). 
Since the "Polymer A"-based formulation developed in this 
chapter performed as required, this was selected for 
further in vivo investigations. In subsequent chapters it 
will be seen that this coating carried out its desired task 
with a high degree of reliability. 
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CHAPTER 7. 
THE TRANSIT OF MODEL DOSAGE FORMS THROUGH THE COLON, 
MEASURED USING GAMMA SCINTIGRAPHY. 
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7.1. INTRODUCTION 
The application of gamma scintigraphy for measuring the in 
vivo performance of dosage forms is now well established 
(Wilson and Washington, 1988). Although the technique has 
been applied to a wide variety of dosage forms administered 
by many routes, including buccal (Christrup et al., 1991; 
Washington and Wilson, 1988), rectal (Hardy et al., 1986; 
Jay et al., 1986), inhaled (Farr et al., 1985; Harnor et 
al., 1990), parenteral (Love et al., 1990) and ophthalmic 
(Fitzgerald et al., 1987), the majority of scintigraphic 
investigations have concerned the evaluation of oral drug- 
delivery systems (Digenis and Sandefer, 1991; Wilding et 
al., 1991; Wilson and Washington; 1988). 
In gamma scintigraphy, the dosage form under investigation 
is radiolabelled by incorporation of a gamma-emitting 
radioisotope. Following administration of the radiolabelled 
dosage form to the subject, it can be located and followed 
externally by a gamma-camera (see figure 7.1). At 
appropriate intervals, the subject is positioned in front 
of the collimator. The gamma-rays emitted from the dosage 
form pass through the body of the subject, through the lead 
collimator located on the camera face and fall onto a 
thallium-doped sodium iodide crystal lying underneath. 
Interaction of the gamma rays with the crystal causes the 
emission of light photons. The photons are detected by 
photomultiplier tubes, positioned behind the scintillator 
crystal, which convert the light signal into an electrical 
signal. The energy of the electrical signal is proportional 
to the photon energy, and so photons from different 
radioisotopes can be simultaneously detected. The pattern 
of energy across the crystal face can be stored on a 
minicomputer for later analysis (Wilson and Washington, 
1988). 
The work undertaken in chapter 6 had demonstrated the 
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Figure 7.1. The Gamma-Camera. 
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feasibility of delivering materials into the colon inside 
hard gelatin capsules coated by a simple dipping technique. 
The next stage was to use these coated capsules to deliver 
the 0.2 mm and 5 mm and 0.2 mm and 8.4 mm radiolabelled 
particles (see chapter 6) into the colon and to follow 
their movement, through the ascending colon in particular, 
using gamma scintigraphy. The ascending colon is of 
interest as a site for drug delivery for two reasons. 
Firstly, it is inaccessible to rectally administered 
treatments for IBD i. e. enemas and suppositories (see 
section 1.2.5). Secondly, it may be the most appropriate 
site in the colon for absorption of drugs for systemic 
action (see section 1.2.4.3). 
The aim of the three studies described in this chapter was 
to determine whether the transit rate of materials through 
the colon is influenced by particle size under different 
conditions. There is evidence from the literature to 
suggest that under normal conditions large particles travel 
through the colon more rapidly than small. On the other 
hand, streaming phenomena have been reported in subjects 
receiving bran supplementation, whereby the colonic transit 
of liquid was more rapid than solid (see section 1.2.4.1). 
Thus, the way in which different phases and sizes of 
material move through the colon is not entirely clear. The 
work in this chapter aimed to partly resolve this issue. 
Clearly, if selective retention of a dosage form could be 
achieved by virtue of its size there could be considerable 
benefits, especially for the treatment of diseases 
associated with rapid colon transit e. g. IBD. 
The first study assessed the transit patterns of 
radiolabelled 0.2 mm particles and 5 mm tablets in healthy 
subjects under normal conditions and with coadministration 
of the laxative, lactulose. The selective colonic 
metabolism of lactulose was described in section 1.2.3.2. 
The laxative action is due largely to the retention of 
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extra water in the colon by osmotic means, although 
acidification of the colon probably also directly 
stimulates peristalsis (Avery et al., 1972). The aim of 
lactulose administration was twofold. Firstly it would 
provide data on particle movement in a hypermotile colon 
and secondly it could be established whether it provides a 
good model for the motility patterns seen in colonic 
diseases such as irritable bowel syndrome (IBS). 
The second study investigated the differential transit of 
0.2 mm particles and 8.4 mm tablets in healthy subjects. 
The final study investigated the transit of 0.2 mm 
particles and 5 mm tablets in a group of patients suffering 
from irritable bowel syndrome. The results of this study 
would reveal any differences in particle behaviour in the 
diseased colon and whether lactulose is able to reflect 
these differences in healthy subjects. 
7.2. EXPERIMENTAL 
7.2.1. Materials 
As for chapter 6. 
7.2.2. Methods 
7.2.2.1. Dosage form production 
Dosage forms were produced using the methods described in 
chapter 6. All capsules received three coats of 15% w/v 
"Polymer A" in acetone as described previously. 
7.2.2.2. Studv desicyn 
All studies had the prior approval of the Nottingham 
University Medical School ethical committee. The 
administration of isotope was authorised by the Department 
of Health. The studies were conducted in accordance with 
the Declaration of Helsinki Guidelines for Ethics in 
Research and subjects were at all stages free to withdraw. 
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Studv 1. 
12 healthy human volunteers (7 male and 5 female, age 20- 
22) were recruited from the Nottingham University student 
population. 
Each volunteer had to meet the following criteria: 
a) Absence of gastrointestinal symptoms. 
b) Non-vegetarian diet. 
C) Free from medication likely to alter GI motility. 
d) Non- or low-smoker. 
e) Alcohol intake within accepted limits. 
f) Female volunteers not pregnant. In addition, they were 
required to take a pregnancy test on the day bef ore the 
study. 
Study 1 was carried out in two parts, A and B, separated by 
a period of two weeks. All subjects undertook both parts of 
the study. 
Part A. 
During the four days prior to the investigation, each 
volunteer was requested to follow dietary guidelines in 
order to provide approximately 20 g of dietary fibre/day. 
The guidelines excluded certain high fibre foods and 
cathartics such as spicy foods, and were used to provide a 
degree of standardisation to the group. 
on the morning of the study, volunteers arrived having 
fasted from 10 pm the previous evening. Radioactive markers 
were attached to each subject anterior and posterior over 
the right lobe of the liver to assist in alignment during 
scintigraphic imaging. Markers were produced by applying 
99mTc solution to a small piece of filter paper attached to 
a length of sticky tape. When the solution had dried, the 
tape was wrapped into a small square with the filter paper 
concealed inside. 
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Each volunteer then swallowed three "Polymer A"-coated 000- 
sized capsules with 150 ml of water. Each capsule contained 
two 5 mm ethylcellulose tablets each radiolabelled with 
0.67 MBq of 99mTc and 100 mg of 0.18-0.25 mm Amberlite 
IR120 resin labelled with 0.33 MBq of 111In. 
Immediately af ter swallowing the capsules, the subjects 
stood in front of the gamma camera for scintigraphic 
imaging. An anterior and posterior image of 30 seconds 
duration was recorded. Imaging was continued at 30-60 
minute intervals throughout the day for a period of 12-14 
hours with af inal image 24 hours post-dose. Images were 
recorded using an IGE Maxicamera II gamma camera f itted 
with a medium energy parallel collimator (300 keV maximum 
energy). Images were acquired using the 140 keV photopeak 
for 99mTc and the 245 keV photopeak for 'llIn. Data was 
stored on and processed by a Star computer system (IGE). 
Once the three capsules were seen to have lef t the stomach, 
subjects received breakfast (10-11 am) and thereafter lunch 
(1 pm), coffee/tea and biscuits (4 pm and 9 pm) and dinner 
(6 pm) as follows: 
Breakfast: Glass of orange juice. 
Two to four slices of toast with butter and 
jam or marmalade. 
Cup of decaffeinated coffee or tea. 
Lunch: Sandwiches (four slices of bread). 
Packet of crisps. 
Piece of fruit. 
Tea, decaffeinated coffee or cold drink. 
Dinner: Prawn cocktail. 
Fried steak, chips and mixed vegetables. 
Piece of sponge cake or cheesecake. 
Decaffeinated coffee. 
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Part B. 
This was identical to part A, but in addition each subject 
also ingested lactulose solution (Duphar, Southampton, UK) 
10-20 ml, three times daily for four days prior to the 
study and on the study day itself. The dose of lactulose 
was adjusted by the subjects themselves in order to 
approximately double their stool frequency. 
Studv 2. 
12 healthy student volunteers were recruited (8 male and 4 
female, age 18-24 years) 
. 
The protocol was identical to 
study 1A described above. Here however, each capsule 
contained two 8.4 mm, 99MTc-labelled, ethylcellulose 
tablets (0.67 MBq/tablet) in place of the 5 mm tablets. 
In this study, and in study 3, the scintigraphic data was 
stored on a Nuclear Diagnostics comPuter system (Nuclear 
Diagnostics, Gravesend, UK). 
Studv 3. 
7 patients suffering from IBS were recruited from a 
gastroenterology clinic (2 female and 5 male, age range 27- 
53). Two suffered predominantly from diarrhoea, two from 
constipation whereas the other three alternated between 
diarrhoea and constipation. The same basic protocol as in 
study 1A was followed. The patients were advised to follow 
their normal diet f or the period prior to the study, but to 
avoid cathartic foods and pulses. 
7.2.2.3. Data analysis 
The position of capsule break-up was determined visually 
from the images. 
From the set of stored scintigraphic images, an outline 
picture of the colon could be developed for each subject. 
Using a variable region of interest program,, the colon 
images were divided into four regions and the number of 
180 
counts in each recorded. The four regions were the ileo- 
caecal junction (ICJ), the ascending colon, the transverse 
colon and the descending colon/rectum (figure 7.2). On each 
image, background counts were also recorded. Distribution 
of the tablets could be determined visually by simply 
counting the number in each region. 
Data analysis of the counts recorded in the colon regions 
was undertaken using a spreadsheet program (Microsoft 
Excel) run on an Apple Macintosh microcomputer. The 
spreadsheet was set-up to make corrections for background 
radiation and radioactive decay, and to present results as 
the geometric mean of anterior and posterior counts. The 
geometric mean (anterior counts x posterior counts), and 
partially overcomes errors due to tissue attenuation of the 
gamma rays (Hardy and Perkins, 1985). 
The percentage of the administered dose in the whole colon 
was calculated by addition of the percentage values in the 
ascending colon, transverse colon and descending 
colon/rectum regions. By plotting the aCtivity-time course 
in the whole colon and [whole colon-ascending colon] on the 
same graph it was possible to estimate the residence time 
of the activity in the ascending colon. The difference 
between the two curves at the 50% activity level 
represented the residence time of 50% of the administered 
activity in the ascending colon and was defined as the mean 
residence time (MRT) (figure 7.3). In addition, the 
percentage of activity remaining in the whole colon and 
ascending colon after 24 hours was estimated. 
Tests for statistical significance (Wilcoxon signed rank 
sum test) were undertaken using "Statworks" program run on 
an Apple Macintosh. 
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Figure 7.2. Divisions of colon used for 
scintigraphic analysis. 
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Figure 7.3. Graph to define ascending colon mean residence time (MRT). 
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7.3. RESULTS 
7.3.1. StudV 1. 
Data is presented for 11 subjects; the data from one 
subject was excluded due to abnormally rapid colon transit. 
7.3.1.1. Part A 
The scintigraphic images showed reproducible delivery of 
the intact capsules into the ileocaecal region, from where 
they proceeded to disintegrate. Mean ICJ arrival time was 
2.2±1.3 h, with the principal source of variation in 
arrival being the time for gastric emptying. Small 
intestinal transit was invariably rapid and, although it 
was not measured precisely, in most instances it was 
probably less than 90 minutes. A period of stasis was often 
observed in the ICJ or caecum/base of ascending colon, with 
the body of activity sometimes residing there for a 
considerable length of time (2-3 hours) with very little 
spread evident. Activity generally moved from the ICJ into 
the colon as a single bolus. Material then commenced a 
gradual spread through the ascending colon and into the 
transverse and eventually descending colon. 
Table 7.1 presents the colon transit data for study 1 A. 
The mean residence time for 50% of the 5 mm tablets in the 
ascending colon (MRT) was 14.1±4.7 h and for the 0.2 mm 
resin, 12.9±3.7 h. A wide variation was seen in the 
residence time values. For example the shortest residence 
time for the tablets was 7.5 h, but the longest was 23.5 h. 
There was no significant difference between the residence 
time of the 0.2 mm particles and the 5 mm tablets (p=O. 07). 
After 24 hours, the majority of the administered dose of 
0.2 mm particles (80.7±18.6%) still resided in the colon. 
The percentage of the administered radioactivity resident 
in the ascending colon at 24 hours was 23.1±12.8%. As a 
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Table 7.1. Colon transit data for study 1A (healthy controls). 
Subject Ascending colon MRT (h) % of administered 0.2 nun 
particles remaining after 24 h 
5 nun tablets 0.2 mm particles Ascending colon Whole colon 
1 7.50 10.75 18.6 31.2 
2 23.50 23.25 56.0 94.7 
3 18.75 13M 9.6 85.4 
4 15.7S 13.50 28.0 90.2 
5 14.75 10.50 15.2 75.9 
6 11.25 10.25 14.9 85.6 
7 14.75 13.00 28.2 100 
8 16.25 14.25 26.0 89.5 
9 11.25 11.00 26.9 86.2 
10 7.50 9.75 20.2 80.8 
11 13.75 12.25 10.6 68.0 
Mean 14.11 12.99 23.1 80.7 
SD 4.67 3.75 12.8 18.6 
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result of the short-half life of the 99MTc label, it was 
not possible to accurately assess the number of tablets 
resident at 24 hours. 
7.3.1.2. Part B 
With lactulose administration, the time of capsule arrival 
at the ICJ was 2.1±1.0 h. The point of capsule break-up 
appeared to be unaffected, despite the fact that lactulose 
produces acidification of the colon. 
The rate and extent Of spread of radioactivity was 
considerably greater than for part A. In many of the 
subjects the 0.2 mm particles rapidly outlined the entire 
ascending colon. Retrograde movement of large areas of 
activity within the ascending colon was observed in some 
subjects. 
The increase in colon motility after lactulose 
administration was reflected in the transit rate data 
(table 7.2). For both particles and tablets, a marked 
reduction in residence time in the ascending colon was 
seen. The MRT value for the 5 mm tablets was 8.7t3.4 h, and 
for the 0.2 mm particles 7.0±2.5 h. These values 
represented respectively a 37% and 46% reduction in 
residence over non-lactulose treatment and were 
statistically significant (p=0.012 and 0.002 respectively). 
Figures 7.4a) and b) show the transit profiles of the 5 mm 
tablets in one subject without and with lactulose 
administration and the change in colon motility is clear. 
The MRT of the 5 mm tablets was significantly longer than 
for the 0.2 mm particles (p=0.03). However, looking at the 
individual data (table 7.2) there is no clear trend, with 
the 0.2 mm MRT being either greater than, or about the same 
as,, the 5 nm MRT in 5 of the 11 subjects. 
Lactulose administration did not significantly reduce the 
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Table 7.2. Colon transit data for study 1B (coadministration of lactulose) 
Subject Ascending colon MRT (h) % of administered 0.2 nun 
particles remaining after 24 h 
5 mrn tablets 0.2 nun particles Ascending colon Whole colon 
1 9.00 7.50 3.5 51.8 
2 8.25 9.25 4.0 100 
3 7.25 7.25 11.2 49.9 
4 9.50 9.25 22.7 97.6 
5 8.75 4.50 7.5 83.5 
6 6.75 4.25 4.5 79.8 
7 6.25 3.75 2A 51A 
8 16.00 8.50 5.6 62.7 
9 13.00 10.75 18.2 80.4 
10 3.00 3.50 6.3 94.2 
11 7.50 8.25 42.7 87.0 
Mean 8.66 6.98 11.7 76.2 
SD 3.44 2.55 12.2 19.1 
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Figure 7.4. 
a) Activity time-profile in healthy subject. 
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activity present in the whole colon after 24 hours 
(76.2±19.1%), although the amount of activity remaining in 
the ascending colon was reduced by almost 50% from 
23.1±12.8% to 11.7±12.2% (p=0.025). 
7.3.2. Studv 2 
Data from the study investigating the differential transit 
of 0.2 mm particles and 8.4 mm tablets is presented in 
table 7.3. The data is for 10 subjects, since in two 
subjects one of the capsules was resident, intact, in the 
stomach for the whole of the study day. 
The MRTs of the 0.2 mm particles and 8.4 mm tablets were 
8.9±3.2 h and 8.6±3.7 h respectively. There was no 
significant difference between these values. Activity (from 
0.2 mm particles) in the whole colon at 24 hours was 
comparable to Study 1A at 79.3±10.4%, although the 
activity residing in the ascending colon was much lower 
(12.6±8.5%). 
Surprisingly, MRT values for both sizes of particles were 
markedly reduced compared to study 1, although this may 
simply reflect the small numbers of subjects used and the 
inherently large intersubject variation in colon residence. 
Presumably, with lactulose administration the residence 
times of the subjects in study 2 would have been reduced 
still further. 
7.3-3. Irritable bowel svndrome 
Table 7.4 presents data from the investigation with the 
seven IBS patients (study 3). This was a fairly disparate 
group in terms of disease state and no overall pattern 
emerged. 
The MRT of the 5 mm tablets in the ascending colon was 
6.2i2.4 h and for the 0.2 mm particles, 8.5i3.6 h. There 
was no significant difference between these two values. 
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Table 73. Colon transit data for 0.2 mm particles vs. 
M mm tablets in bealthy subjects. 
Subject Ascending colon MRT (h) % of administered 0.2 mm 
particles remaining after 24 h 
8.4 mm tablets 0.2 mm particles Ascending colon Whole colon 
1 8.75 11.00 12.1 69.3 
2 14.00 9.75 10.3 81.3 
3 15.75 I. S. 75 29.8 87.6 
4 6.75 10.00 16.5 82.6 
5 6.00 7-50 2.5 65.3 
6 7.50 8.25 9.1 83.1 
7 9.75 5.7S 2.6 73.3 
8 6.25 9M 20.5 86.2 
9 3.50 3.7S 16.2 97.9 
10 7.75 &00 6.6 66.9 
Mean 9.60 &90 12.7 79.3 
SD 3.21 3.21 9.5 10.4 
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Table 7.4 Colon transit data for IBS patients. 
Subject Ascending colon MRT (h) % of administered 0.2 mm, 
particles remaining after 24 h 
5 nun tablets 0.2 mm particles Ascending colon Whole colon 
1 8.75 8.50 15.2 42.9 
2 3.25 16.50 52.2 92.8 
3 UO 12.50 30.9 75.3 
4 8.50 7.50 19.7 81.1 
5 2.75 5.75 73 81.0 
6 7.00 4.25 0.4 20.0 
7 6.50 6.50 1.8 4.4 
Mean 6.20 8.50 18.3 56.8 
SD 2.40 3.60 18.4 34.4 
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Both of the MRTs were considerably shorter than f or the 
normal controls in study 1 and compare favourably with the 
lactulose-treatment. However, the 0.2 mm mean MRT does not 
differ greatly from study 2. 
Again, there were individual instances where very great 
differences in MRT between the two sizes of particles were 
seen, but again there was no clear trend. The most extreme 
examples are subject 2, where the MRT values for 0.2 mm and 
5 mm particles were 16.5 h and 3.25 h respectively, and 
subject 3 (12.5 h and 7 h). On the other hand, in three of 
the subjects (1,4, and 7) there was no great difference, 
and in another (6) the 5 mm MRT was greater than the 0.2 mm 
MRT. 
There was no obvious relationship between disease state and 
ascending colon MRT. For example in subject 7, whose 
disease condition was predominantly diarrhoeal, although 
whole colon transit was rapid (4% activity remaining after 
24 hours) the ascending colon transit was not excessively 
fast (MRT = 6.5 h). 
7.4. CONCLUSIONS 
These studies have demonstrated a versatile, non-invasive 
technique for simultaneously assessing the movement of 
different sizes of particles through the colon. 
Combining the 0.2 mm data f rom studies 1A and 2, an 
ascending colon mean residence time of 11-0t4.0 h is 
obtained (n=21). This value is in good agreement with other 
studies which have reported transit times through the 
ascending colon of 10-12 h (Proano et al., 1990) and 8-11 
h (Metcalf et al., 1987). 
One of the aims of this work was to assess whether 
lactulose provided a good model f or the transit patterns 
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associated with diseases such as IBS. Since the group of 
patients studied was only small and were not all diarrhoea 
predominant, it is difficult to draw definite conclusions. 
However from study 1, the ability of lactulose to 
significantly increase the transit of materials through the 
ascending colon in healthy volunteers was clearly 
demonstrated. 
A comparison between the transit rate of the 0.2 mm 
particles and the tablets indicated that although there 
were a few individual instances where a marked difference 
in transit between the sizes was observed, overall there 
was no clear effect. Therefore, these studies suggest that 
in healthy human subjects, materials in the 0.2 mm to 8.4 
mm size range are resident for the same period of time in 
the ascending colon. Marked enhancement in transit of the 
5 mm tablets was noted in two of the IBS patients and may 
warrant further investigation. The more rapid passage of 
solid compared to liquid in a group of patients with 
diverticular disease has been reported by Findlay et al. 
(1974) (see section 1.2.4.1. A). 
Proano et al. (1990,1991) have recently reported that the 
transit through the ascending colon of 0.5-1.8 mm pellets 
was the same as a liquid phase, but slower than the transit 
of 6 mm pellets. This implied that the "cut-of f" point 
below which a separation by size does not occur lies 
between about 1 and 6 mm. The work presented in this 
chapter conflicts with this finding and indicates that the 
ascending colon transit is the same for particles between 
0.2 mm and 8.4 mm. A general problem when interpreting the 
results of colon studies is the inherent inter- and 
intrasubject variability in transit, which may be large. 
Consequently, a definitive relationship between particle 
size and colon transit may only become clear when many more 
similar studies have been undertaken. 
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However, the long period of residence of materials in the 
colon supports the premise that this part of the GI tract 
may represent a good site to achieve sustained local action 
or absorption of drug from dosage forms resident there. 
Furthermore, dispersed dosage forms such as microspheres, 
pellets, and mini-tablets are probably the most appropriate 
type of sustained-release dosage form for colon delivery 
for two reasons: 
1. Such dosage forms become widely dispersed in the colon 
and may allow maximisation of drug absorption especially in 
distal regions where close contact with absorbing surfaces 
is desirable because of probable poor diffusion through 
viscous faecal contents. 
2. The phenomenon of spread within the ascending colon 
followed by gradual emptying maximises the residence of a 
dispersed dosage form; some of the drug carriers will empty 
rapidly, some will be resident for much longer. Equally, a 
single unit dosage form under the same conditions could be 
resident for a relatively long period, yet on the other 
hand it may empty very rapidly. Depending on the intended 
use of the dosage form, rapid ascending colon emptying 
could compromise therapeutic efficacy,, but this effect 
would be minimised by administering the drug in dispersed 
form. 
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CHAPTER 8. 
RADIOLABELLING OF DRUG: POLYMER MICROSPHERES USING NEUTRON 
ACTIVATION TECHNIQUES. 
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8.1. INTRODUCTION 
The experiments described in chapter 7 established that 
under normal conditions, there was no difference in the 
colonic transit rate of model dosage forms in the size 
range 0.2 to 8.4 mm. However, it was considered that 
multiparticulate dosage forms may have benefits over single 
units for sustained drug delivery into the colon. 
The next stage of the work was to investigate the rate of 
transit and release characteristics of drug-containing 
Eudragit RS microspheres in the human colon. Since the 
transit rate was to be assessed using gamma scintigraphy, 
a method for radiolabelling the microspheres had to be 
devised and the chosen technique was neutron activation. 
Conventionally, dosage forms are radiolabelled by 
incorporation of isotopes such as 99mTc or 111In during 
manufacture as described in Chapter 6. There are however a 
number of drawbacks in using this technique for 
radiolabelling: 
1. The short-lived nature of some of these isotopes (e. g. 
half-life of 99mTc =6 hours) means that the time for 
production of the dosage form may be limited. Although this 
can be partly overcome by simply incorporating more 
radioisotope into the dosage form, this has the 
disadvantage of exposing manufacturing personnel to higher 
levels of radioactivity. 
2. The manufacture of radiolabelled dosage forms requires 
designated radioisotope facilities. One consequence is that 
radiolabelling dosage forms produced in a conventional 
pharmaceutical production environment is impractical. 
3. If specialised manufacturing equipment is needed (e. g. 
extruder/ spheroni ser for pellet manufacture or a freeze- 
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drier) it could become contaminated with radioisotope, 
putting it out of use until the isotope has decayed. 
4. If problems are encountered during manufacture of the 
dosage forms, or the final dosage forms fail to meet the 
required specifications, the investigation for which they 
were produced would have to be cancelled until a new batch 
could be made. 
Many of these problems can be overcome by the use of 
neutron activation techniques. The application of neutron 
activation for the radiolabelling of dosage forms was 
developed at the University of Kentucky and Oakridge 
National Laboratory in the early 1980s (Parr et al., 1985). 
The fundamental difference between neutron activation and 
conventional radiolabelling is that in the former process, 
the isotope incorporated is not radioactive at the time of 
dosage form manufacture. When required for the 
scintigraphic study, the dosage form containing the isotope 
is exposed to a neutron source in a nuclear reactor. The 
incorporated isotope absorbs neutrons and is converted into 
a gamma-emitting radioisotope (see figure 8.1). 
When bombarding an isotope with neutron radiation it is 
possible to estimate the amount of radioactivity generated 
(Krane, 1983). The rate of isotope production, 
R=4, o (m/M) Na 
Where, 
neutron flux (n cm-2 s-1 produced by reactor). 
neutron capture cross-section (CM2/nucleus), This 
represents the probability of the isotope conversion taking 
place. 10-24 cm2 =1 barn. 
m= mass of target nuclide. 
m= mass number/molecular weight of target nuclide. 
Na = Avogadro's number. 
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C(m/M) x Na 'ý the number of target atoms). 
When the irradiation time, t, is considerably less than the 
half-life of the isotope being generated (t h ), the activity 
generated, 
A=RA t 
Where, I= decay constant = 0.693/t h 
Thus, for a given target nuclide, the amount of 
radioactivity generated during neutron activation is 
dependent only upon: i) the neutron flux; ii) the mass of 
target nuclide; iii) the irradiation time. 
Materials for activation that are suitable for 
incorporation into dosage forms should meet certain 
requirements. The parent isotope should have low toxicity 
and be chemically inert, whereas the daughter isotope, 
generated upon neutron irradiation, should produce gamma 
rays of a suitable energy (ideally 100-300 keV), have a 
relatively short half-life, produce no alpha activity, and 
decay to a stable, non-toxic isotope. Materials which meet 
these requirements include the oxides and nitrates of 152Sm 
(samarium) and 170Er (erbium) and the carbonate, nitrate, 
chloride and sulphate of 
138Ba (barium) (Digenis and 
Sandefer, 1991)f and some of their properties are 
summarised in table 8.1. 
The effects of isotope incorporation and subsequent 
irradiation have been reported for a number of dosage 
forms. Concentrations of Ba sulphate greater than 0.33% w/w 
and Sm oxide and Er oxide greater than 10% w/w were found 
to significantly reduce the hardness of lactose tablets. 
when these tablets were irradiated at a neutron flux of 4.4 
x 1012 n cm-2 s-1 for 15 minutes, their hardness increased, 
whilst the hardness of tablets containing no isotope was 
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Figure 8.1. Neutron irradiation of Samarium-152 (Sm). 
1. Sm-152 absorbs neutrons and is converted to Sm-153: 
152 SM62 + lno 
------------- 
> 153 Sm 62 
2. Sm-153 is unstable and decays with a half-life of 46.7 hours 
to Europium-153, a stable isotope. The decay is accompanied by 
the emission of beta particles and gamma rays: 
153 Sm 62 ------------- > 153 Eu 63 oß-1 +Y 
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unaffected following the same treatment. For tablets with 
and without isotope, a direct correlation was observed 
between the irradiation time and the time for tablet 
disintegration. This emphasized the importance of 
minimising the total radiation exposure of the dosage form 
and the amount of incorporated target nuclide (Parr and 
Jay, 1987). 
The performance of enteric-coated erythromycin pellets 
containing Er oxide has been assessed before and after 
neutron irradiation. The amount of erythromycin released in 
vitro after 30 minutes was significantly reduced compared 
to non-irradiated pellets, although there was no difference 
in release after 60 minutes. Irradiation also caused a 
small decrease in the acid resistance of the pellet 
coating, which may have resulted from an increase in coat 
porosity (Parr et al., 1990). 
Sustained-release matrix tablets containing ibuprofen have 
been radiolabelled by incorporation of Er oxide followed by 
neutron irradiation. The in vitro drug release rate was 
found to increase slightly following irradiation, but the 
tablets still met the required specifications (Parr et al., 
1987). 
A number of human scintigraphic studies using neutron 
activation techniques for radiolabelling have been 
reported. Dosage f orms labelled with Er oxide have included 
ibuprofen tablets (Parr et al., 1987) and naproxen pellets 
(Hardy et al., 1991) while erythromycin pellets have been 
labelled with Sm oxide (Digenis et al., 1990Y. A study 
investigating the performance of enteric-coated 5-ASA 
pellets involved the incorporation of both Sm and Er 
oxidest one into the pellet core and one into the pellet 
coat (Digenis and Sandefer, 1991). 
Sm chelates of EDTA, DTPA and HIDA have been produced by 
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dissolution of Sm oxide in acid followed by addition to a 
solution of the chelating agent. The chelates were 
incorporated as model drugs into matrix tablets, the 
tablets irradiated, and the in vitro release of activity 
monitored. It was suggested that this technique could be 
used to scintigraphically assess the in vivo 
' 
dissolution 
performance of a formulation (Coupe et al., 1990). 
A technique f or radiolabelling microspheres produced by 
solvent evaporation has recently been reported. The target 
nuclide, 165holmium acetylacetonate, was codissolved with 
a biodegradable polyester in chloroform. Microspheres were 
produced by emulsification into aqueous PVA solution 
followed by solvent evaporation, and were then irradiated. 
Formulations could be designed which demonstrated prolonged 
retention of the nuclide. It was considered that these 
microspheres could have use in the therapy of diseases 
including cancer and rheumatoid arthritis (Mumper and Jay, 
1991). 
A technique involving the incorporation of a soluble target 
nuclide would not be suitable for the radiolabelling of 
Eudragit RS microspheres due to the relatively high 
permeability of the polymer. Therefore for the studies 
carried out for this thesis a poorly water-soluble, 
particulate material was required as the target. The 
material chosen was Sm oxide (Sm203). Although Sm203 is 
extremely water-insoluble (table 8-1), it does dissolve in 
acidic solutions, and so may not be suitable for 
radiolabelling dosage forms in which it comes into direct 
contact with gastric Juice. 
Another attraction of Sm203 is its high neutron capture 
cross-section (table 8.1) which enables non-enriched 
material to be used to generate adequate levels of 
radioactivity with reasonably short irradiation times. 
Naturally occurring Sn'203 contains seven different isotopes 
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(see table 8.2) of which the isotope of interest, 152SM, 
constitutes just 26.6%. The only factor that will preclude 
the use of this material for human investigations is the 
generation of undesirable activity from any of the other 
six isotopes. The only conversion of interest in this 
respect is the conversion of 154SM to 155SM. 155Sm is a 
high energy beta-emitter, but fortunately since its half- 
life is just 22 minutes (CRC Handbook of Chemistry and 
Physics, 1987), it will rapidly decay to insignificant 
levels. The benefit of being able to use non-enriched Sm203 
is that it is readily available. In contrast, the low 
cross-sectional area of 170Er (5.7 barns) (table 8.1) and 
its low natural abundance (15 %) mean that artificially 
enriched material (95%+ 170Er) has to be used (Digenis and 
Sandefer, 1991). 
A further factor to be considered when planning to use 
neutron activation for radiolabelling is whether the dosage 
form contains any other elements that may be activated to 
undesirable isotopes. Two examples of pharmaceutical 
interest are sodium and potassium. The products of the 
irradiation of these elementsf 24Na and 42K, are both long- 
lived (t 
-41 = 
15 h and 12 h respectively) (CRC Handbook of 
Chemistry and Physics, 1987), high energy gamma-emitting 
isotopes whose presence in the final dosage form in even 
small quantities would be undesirable. For the Eudragit RS 
microspheresr the only element present that can be 
activated, apart from samarium,, is chlorine, present as 
chloride ions in Eudragit RS (see chapter 1, table 1.2). 
37C1 absorbs neutrons and is converted to 38Cl, a beta- 
emitter.. t 
-42 = 
47 minutes (CRC Handbook of Chemistry & 
Physics). The very small neutron capture cross-section of 
37C1 (0.2 barns) and its short half-life should ensure that 
only minor amounts of 38C, will be present in irradiated 
Eudragit RS microspheres at the time of dosing (at least 18 
hours after irradiation). 
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Table 8.2. Composition of naturally occurring 
samarium oxide. 
Isotope atomic 
number 
% abundance 
144 3.1 
147 15.1 
148 11.3 
149 13.9 
150 7.4 
152 26.6 
154 22.6 
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The work described in this chapter will be divided into two 
main sections. The first part describes the incorporation 
of SM203 into SASP-containing Eudragit RS microspheres and 
the effects of irradiation on their physical properties. 
Following preliminary investigations with SASP as a colon 
absorption marker, studies were switched to its absorbed 
colonic metabolite, sulphapyridine (SP). There were two 
drawbacks to using SASP. The first was its dosage 
requirement. Since it was estimated that at least 900 mg of 
SASP would need to be administered to generate adequate 
plasma levels of SP, this would require administration of 
a considerable volume of microspheres. In addition, the 
rate of absorption of SP would be dependent not only upon 
the rate of SASP release from the microspheres, but also 
upon its rate of generation from colonic metabolism of the 
parent molecule. It was observed that the incorporation of 
Sm203 into Eudragit RS-SP microspheres had interesting 
effects on their physical properties. These phenomena are 
described further in the second section of this chapter. 
8.2. INCORPORATION OF SAMARIUM OXIDE INTO EUDRAGIT RSý 
SASP MICROSPHERES 
8.2.1. EXPERIMENTAL 
8.2.1.1. Materials 
See chapter 4, but in addition, SrR203 (Sigma), chloroform 
(HPLC grade) (Rh8ne-Poulenc) 
, 
methanol (HPLC grade) (Rh6ne- 
Poulenc), SpecpureTM samarium oxide (Johnson Matthey, 
Royston, UK), SpectrofluxTM 121A (Johnson Matthey). 
8.2.1.2. Methods 
A. Microsphere 'Production 
Microspheres were produced by the same basic method 
described in chapter 4. Brief lyr Eudragit RS (4 g) was 
dissolved in 40 ml of dichloromethane in a glass bottle. 
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SASP (2 g) and Sm203 (0,10,20,40 or 60 mg) were added to 
the polymer solution to form a suspension. The mean 
particle size of Sm203 was estimated to be about 10 pm 
using a laser diffraction technique (chapter 2) and it 
could generally not be completely dispersed by shaking 
alone. Therefore, the bottle containing drug, polymer and 
Sm203 was placed into an ultrasonic bath for 5-10 minutes 
to aid dispersion. The resulting mixture was emulsified 
into 200 ml of 0.1% w/v aqueous Tween 20 solution (overhead 
stirrer at 250 rpm) and stirring continued until all of the 
dichloromethane had evaporated. Then, any unemulsified 
drug-polymer agglomerates were decanted from the beaker, 
the microspheres filtered, washed with 150 ml of distilled 
water, and freeze-dried overnight. The weight of 
microspheres produced was recorded and a 250-500 pm sieve 
fraction collected. 
B. Microsphere druq content 
See chapter 4. 
C. Efficiency of SM293 entrapment 
The concentration of Sm203 entrapped within the 
microspheres was determined using X-ray fluorescence 
spectroscopy (XRF). With this technique, the material of 
interest is irradiated with high energy X-rays. The X-rays 
eject electrons from the inner shells of the atoms of 
interest. when the electrons fall back from the outer 
shells to the vacant inner shells, X-rays are emitted and 
the X-ray spectrum is characteristic of the element. The 
intensity of the lines in the X-ray spectrum is 
proportional to the amount of the element present and can 
be measured on a suitable detector (e. g. scintillation 
counter) (Willard et al., 1988). 
There are a number of different ways of presenting samples 
to the XRF spectrometer depending on the particular 
instrument used and on the properties and quantity of 
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sample available. The technique used in this study was to 
isolate the Sm203 f rom the microspheres by incineration, 
followed by fusing the residue with a flux. For each 
sample, 400 mg of microspheres were placed into a Pt/Au 
crucible. The crucible was ignited at 500 OC for 12 hours 
followed by further heating at 1000 OC for 15 minutes. This 
removed all of the organic matter from the microspheres, 
i. e. drug and polymer. The crucible was cooled, 2.6 g of 
SpectrofluxTM 121A added, and the sample fused at 1000 OC 
for 1 hour. The molten sample was then poured into a 32 mm 
die maintained at 225 OC, and pressed with a brass plunger. 
Standards containing 0,0.15,0.30,0.55,0.75 and 1.0 % 
w/w Sm203 were prepared by direct fusion with SpectrofluxTM 
121A. 
Concentrations of Sm203 were determined using a Philips 
PW1400 XRF spectrometer fitted with a Rh X-ray tube. The Sm 
concentration was determined using the L. 
.1 
line, a LiF200 
diffracting crystal and a scintillation counter. X-ray 
emissions for both peak and background were counted for 200 
sec. The Sm203 content of the samples was determined from 
the net intensities (peak minus background) by reference to 
the calibration performed with the six prepared standards. 
The calibration plot of corrected counts against 
concentration for the Sm203 standards was linear over the 
concentration range used (r = 0.999). 
D. Microsphere druq release rate 
For apparatus and experimental details, see chapter 3. 
Samples were taken at 30,60,120,180,240,300 and 360 
minutes. Microsphere drug-release characteristics were 
assessed before and after irradiation. The post 
- 
irradiation 
tests were carried out after radioactivity had decayed to 
background levels. 
E. Microsphere irradiation 
500 mg samples of each of the f ive microsphere batches were 
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taken to the Universities Research Reactor, Risley, 
Cheshire for irradiation. Each sample was placed into a 
polypropylene tube and irradiated at a neutron flux of 1012 
n cm-2 S-1 for a period of 90 minutes. 
The radioactivity generated (MBq) was measured 21 hours 
after irradiation using a gamma-counter (Isotope 
Calibrator, Type 238, D. A. Pitman, Surrey, UK)) set to 
detect 153Sm. The delay between irradiation and measurement 
of activity allowed time for the decay of any short-lived 
ýsotopes present in the sample, in particular 38C, (t ;I =47 
minutes) present in the polymer and 155Sm (t 
. 
11 =22 minutes). 
F. Leaching of radioactivity from the microspheres 
In gamma scintigraphy, where the position of a dosage form 
is followed by means of its incorporated radiolabel, it is 
clearly desirable that the majority of label stays with the 
dosage form for as long as possible. For the Eudragit RS 
microspheres, Sm203 is insoluble at the pH encountered in 
the large intestine and therefore any loss of radiolabel 
will be in the form of particulate material. 
To assess the extent of loss of particulate SM203 from the 
microspheres during in vitro drug release, 45 mg of 
microspheres (containing theoretical Sm203 content of 1% 
w1w) were placed into 500 ml of pH 7 phosphate buffer 
(appendix 1) in the tablet dissolution apparatus (37 *C and 
100 rpm). This study was undertaken six days after 
irradiation so that the level of radioactivity present in 
the microspheres was not too high to be measured on the 
laboratory gamma counter (Mini-Assay Type 6-20, Mini- 
Instrumentst Essex, UK) I yet high enough to allow detection 
of the loss of only small quantities of activity. 
At hourly intervals over an eight hour period, the paddle 
in the dissolution vessel was stopped. Microspheres were 
allowed to sink to the bottom of the vessel and a1 ml 
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sample of buf f er drawn into a syringe. Prior to this it was 
ascertained that the sedimentation of Sm203 was very much 
slower than the microspheres, due to its very small 
particle size. Thus this technique avoided sampling of 
microspheres, but allowed sampling of any SM203 that had 
become dissociated from the microspheres. The 1 ml sample 
was transferred to an Eppendorf tube and the counts 
recorded for a 10 second period. Each sample was counted 
five times. At each time interval, the counts from a 
reference sample of buffer solution were also recorded. 
Loss of activity was assessed by comparing dissolution 
buffer and reference buffer counts. 
G. Drug stability 
The stability of SASP to neutron irradiation was assessed 
by HPLC analysis of drug extracted f rom the microspheres 
before and after irradiation. 
To extract the drug, an accurately weighed sample of the 
microspheres was placed in a 100 ml volumetric flask and 10 
ml of methanol added to dissolve the Eudragit RS matrix. 
The polymer was precipitated and the drug dissolved by 
making to volume with 0.001 N sodium hydroxide solution. 
Prior to analysis, the samples were passed through a 0.1 pm 
membrane filter (Whatman) to remove precipitated polymer. 
20 pL samples were injected manually (valve injector, 
Rheodyne, Cotati, CA) onto the HPLC column (25 mm x 4.6 mm 
ODS, Hichrom, Reading, UK). A mobile phase of 47.5% v/v 
methanol in pH 6 phosphate buffer (appendix 1) was used at 
a flow rate of 1.3 ml/min (Kontron LC pump,, Kontron,, 
Switzerland). The UV detector (Kontron Uvikon 720 LC) was 
set at 254 nm. Peaks were detected using a Spectra-Physics 
SP4270 integrator (Spectra-Physics, San Jose, CA). The pre- 
and post-irradiated samples of all five microsphere batches 
were analysed. Drug concentrations were calculated by 
reference to a calibration curve of SASP concentration 
209 
(dissolved in 0.001 N sodium hydroxide solution containing 
10% v/v methanol) versus integrated peak area. 
H. Polymer molecular weiqht analvsis 
The effect of irradiation on polymer molecular weight was 
assessed. The molecular weight of pre- and post- irradiated 
polymer was carried out using an ultracentrifugation 
technique. To extract the polymer, the microspheres were 
placed in a test tube and dissolved in methanol. This 
dissolved the polymer whereas most of the SASP remained in 
suspension. The tubes were centrifuged (MSE Centaur) at 
2000 rpm for 10 minutes to separate SASP from polymer 
solution. The clear solution was pipetted into an 
evaporating glass and the methanol left to evaporate. The 
precipitated polymer was then redissolved in chloroform at 
an approximate concentration of 2 mg/ml in preparation for 
molecular weight analysis. 
The relative polymer molecular weight was determined at the 
School of Agriculture, Nottingham University, by a 
sedimentation equilibrium ultracentrifugation technique 
(Beckman Model E analytical ultracentrifuge), described in 
detail elsewhere (Morgan et al., 1990). 
I. Electron microscopV 
The ef f ect of irradiation on microsphere structure was 
assessed by low-temperature scanning electron microscopy, 
using the methods described in chapter 3. 
8.2.2. RESULTS AND DISCUSSION 
8.2.2.1. Before irradiation 
A. Microsphere characterisation 
Table 8.3 records the details of Sm203 incorporation into 
the SASP-Eudragit RS microspheres measured by XRF. Sm203 
was successfully encapsulated and the incorporation 
efficiency appeared to increase with concentration. Since 
210 
Table 8.3. Samarium oxide incorporation efficiency into 
Eudragit RS: sulphasalazine microspheres. 
Microsphere samarium 
oxide content (% w/w) % incorporation 
ffi 
Theoretical Assayed 
e ciency 
0 
0.17 0.08 47 
0.33 0.24 73 
0.67 0.61 91 
1.00 1 
0.80 
1 
80 
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the aqueous solubility of Sm203 is minimal, the efficiency 
of incorporation must reflect factors other than 
partitioning from the polymer solution phase to the 
emulsifier phase. One important factor could be the 
difficulty in ensuring complete dispersion of the Sm203 
into the drug-polymer mixture before emulsification; In all 
of the samples small agglomerates of Sm203 could be seen in 
the drug-polymer mixture before mixing into the surfactant 
solution, despite prior sonication. 
Incorporation of Sm203 into the microspheres did not appear 
to significantly affect their formation or composition. 
Table 8.4 records yield and drug content values. The 
proportion of drug and polymer f ormed into microspheres was 
in all cases in excess of 80 % of the total material added. 
Typically, at least 30 % by weight of any given microsphere 
batch fell between 250 and 500 pm in size. Drug levels were 
similar at all Sm203 levels at between 31 and 32 % w/w, the 
high efficiency of encapsulation reflecting the low aqueous 
solubility of SASP with only small amounts dissolving from 
the drug-polymer solution into the surrounding emulsifier 
phase during microsphere production. (The aqueous 
solubility of SASP at 37 *C was estimated to be 
approximately 0.2 g/L). 
All of the microsphere batches had a similar texture, 
colour and shape. Surface and internal SEM micrographs of 
the Sm203-free batch of SASP microspheres are shown in 
section 8.2.2.2. F. 
B., Druq release characteristics 
Figure 8.2 shows the SASP release characteristics of the 
five microsphere batches. The rate of release was similar 
for all of the samples, with approximately 60% of 
encapsulated drug released after 6 hours, and thus appeared 
to be unaffected by the incorporation of Sm 20 3' 
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Table 8.4. Drug content and yield of Eudragit RS: sulphasalazine 
microspheres. 
Samarium Microsphere Sulphasalazine Sulphasalazine 
oxide content yield (g) content (% w/w) incorporation (% W/W) efficiency 
0 5.1 31.8 95.5 
0.08 4.9 31.1 93.4 
0.24 5.4 31.8 95.5 
0.61 5.0 31.5 94.6 
0.81 5.4 31.9 95.8 
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8.2.2.2. After irradiation 
A. Microsphere characterisation 
There were obvious physical changes in the irradiated 
microspheres apparent on removal from the reactor. All of 
the samples had lightly caked into a single mass. Although 
this mass could be largely broken up by gentle shaking of 
the sample containers, all of the microspheres were passed 
through a 500 pm sieve prior to further evaluation. The 
microspheres had also appeared to have undergone some 
darkening and shrinkage which may have resulted from the 
effect of the heat of the reactor; the samples would have 
been exposed to a temperature of about 50-60 *C for the 90 
minute period of irradiation. 
In figure 8.3, the radioactivity generated in each of the 
four Sm203-containing samples is presented. The excellent 
correlation (r=0.999) between assayed Sm203 content and 
activity generated suggested that the precision of the XRF 
assay was high. 
B. Leaching of radioactivity 
The activity present in the 45 mg of microspheres to be 
dissoluted was estimated as 1.57 x 106 counts/10 secs at 
the start of the experiment. 
Throughout the 8 hour period of the dissolution experiment 
the counts in the dissolution buffer remained at the same 
level as the reference buffer (between 40 and 50 counts/10 
secs/ml). Loss of counts due to radioactive decay would 
have been minimal over this period due to the 46.7 h half- 
life of 153Sm. To demonstrate the sensitivity of this 
technique, if only 5% of the 1.57 x 106 counts had been 
lost into the surrounding buffer, the counts/10 secs/ml 
would have increased to 157 above the reference buffer. 
Although the total quantity of Sm203 present in the 45 mg 
of microspheres was only 0.36 mg (0.8% w/w),, its small 
particle size should have ensured that any that became 
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Figure 8.3. Radioactivity generated from irradiation of 
microsphere samples. 
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dissociated would have become widely dispersed into the 
dissolution medium. 
At the end of the 8 hour dissolution period, 
spectrophotometric assay of the dissolution buffer revealed 
that 75 % of the encapsulated SASP had been released. 
Therefore, it appeared that although a large proportion of 
the drug had dissolved f rom the microsphere matrix, the 
radiolabel remained in place. 
The principal route for Sm203 to be lost would presumably 
be through pores and channels in the Eudragit RS matrix. 
The degree of porosity might be expected to increase as 
SASP dissolves. However, loss of particulate SM203 would be 
prevented if the pores and channels were simply too small 
or if it was firmly "glued" to the polymer. 
C. Drucr stability 
The results of the microsphere drug stability assay are 
presented in table 8.5. The SASP elution time was extremely 
sensitive to the buffer methanol content and was between 
6.0 and 7.0 minutes using the chosen conditions. 
For the pre-irradiated samples, there was generally good 
agreement with the drug content values obtained from the 
spectrophotometric assay (table 8.4). 
Following irradiation, the assayed SASP contents were 
essentially unchanged. There were no additional peaks 
present in any of the irradiated samples and no change in 
the elution time of the SASP. For comparison, two potential 
degradative fragments of SASP, S-ASA and SP, were found to 
elute at 2.1 and 2.9 mins respectively (see figure 8-4). 
Therefore, SASP appeared to be stable to neutron 
irradiation. This is in general agreement with other 
neutron irradiation studies in which erythromycin (Digenis 
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Table 8.5. Effect of neutron irradiation on assayed microsphere 
sulphasalazine content, measured by HPLC. 
Microsphere samarium 
% / 
Microsphere sulphasalazine 
content (% w/w) 
oxide content ( w w) 
Before irradiation After irradiation 
0 31.1±0.2 31.0±0.1 
0.08 31.2±0.3 31.3±0.1 
0.24 31.8±0.3 31.3±0.6 
0.61 31.0±0.4 30.3±0.2 
0.80 30.3±0.7 29.8±0.2 
218 
Figure 8.4. Radiation stability of sulphasalazine, measured by IHPLC. 
a) Extracted from microsphere sample b) After irradiation. 
(0.8% Sm oxide) before irradiation. 
44 
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c) Elution of sulphasalazine, sulphapyridine and 5-ASA. 
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et al., 1990), ibuprofen (Parr et al., 1987b), 5-ASA 
(Digenis and Sandefer) and naproxen (Hardy et al., 1991) 
have been shown not to undergo radiolysis. 
D. Drucr release rate 
Figures 8.5a)-e) compare the drug release profiles of the 
five microsphere samples before and after irradiation. In 
all cases, the drug release rate following neutron 
irradiation was markedly enhanced. With one exception, the 
t50% time was at least halved (table 8.6). It was 
considered that the enhanced drug release rate was most 
probably a consequence of radiation 
-induced polymer damage. 
E. Polymer molecular weight analysis 
For the Eudragit RS extracted from the microspheres before 
irradiation, the relative molecular weight, determined 
using ultracentrifugation, was 10,000. Following 
irradiation this had increased to 12,000. The margin of 
error of these values was approximately ±10% (Morgan, P., 
personal communication) and so it is possible that a small 
increase in molecular weight may have occurred during 
irradiation. 
The potential effects of irradiation on polymers are 
complex and can result in backbone or side-chain scission 
and/or cross-linking (Swallow, 1973). In addition, the 
degree of damage can be inf luenced by many other factors 
such as the oxygen and moisture content of the sample 
(Swallowr 1973; Hartas et al., 1991). Consequently, further 
work would be needed to provide more definitive data on the 
ef f ects of neutron irradiation on the structure of Eudragit 
RS. 
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Figure 8.5. Effect of irradiation On sulphasalazine release rate. 
a) 0% w/w samarium oxide. 
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Table 8.6. Time for 50% of sulphasalazine to be released from 
microspheres (00%) before and after irradiation. 
t5O% (mins) 
Microsphere samarium 
oxide content (% w/w) Before irradiation After irradiation 
0 240 90 
0.08 240 120 
0.24 180 90 
0.61 210 120 
0.80 260 80 
223 
F. Electron microscopy 
Low temperature/cryogenic SEM micrographs of both the 
microsphere surf ace and internal structure were recorded 
for one of the microsphere samples before and after 
irradiation. Figures 8.6a)-d) compare the surface 
structures of the SM203-free batch at 220x and 1000x 
magnification. 
The surface of the pre-irradiated microspheres was smooth 
and contained many pores (figures 8.6a and b). Following 
irradiation the smooth surface had been replaced by a 
softened/melted appearance (figures 8.6c and d). It is 
difficult to say whether a change in pore size or density 
had occurred following irradiation. In the irradiated 
sample, details of the structure underlying the microsphere 
surface are visible, possibly a result of shrinkage of the 
microsphere matrix. 
Freeze-fracture of the microspheres revealed two distinct 
types of structure 
- 
Some were solid, whereas others were 
capsular with a large interior void, although in both cases 
the appearance of the drug-polymer matrix was similar. 
Before irradiation, the drug-polymer matrix had a porous, 
honeycombed appearance (figure 8.7a). High magnification 
views revealed a granular, possibly particulate, deposit on 
the internal matrix (figure 8.7b). 
The honeycombed internal structure still appeared to be 
intact in the irradiated microspheres (figures 8.7c and d). 
Figure 8.7d also emphasizes the bumpy microsphere surface. 
The softened appearance of the irradiated microspheres is 
probably a result of the glass transition temperature of 
Eudragit RS (42 *C)(Jones et al.,, 1991) being exceeded 
during irradiation. 
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Figure 8.6. Electron micrographs of surface of 
Eudragit RS: sulphasalazine microspheres. 
a) Non-irradiated microsphere (magnification x220). 
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c) Irradiated microsphere (x220). 
d) Irradiated microsphere (xlOOO). 
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Figure 8.7. Electron micrographs of internal structure 
of Eudragit RS: sulphasalazine microspheres. 
a) Non-irradiated microsphere (magnification x745). 
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b) Non-irradiated microsphere (x5OOO). 
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c) Irradiated microsphere (x745). 
Although electron microscopy revealed that the irradiation 
process had clear effects on the physical structure of the 
microspheres, how these might have af f ected the rate of 
drug release is unclear. 
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8.3. INCORPORATION OF SAMARIUM OXIDE INTO EUDRAGIT RSý 
SULPHAPYRIDINE MICROSPHERES 
8.3.1. EXPERIMENTAL 
8.3.1.1. Microsphere production 
To 3g of Eudragit RS dissolved in 30 ml of dichloromethane 
was added 1.5 g of SP (gif tf rom, Rh6ne-Poulenc) and 0 mg or 
67.5 mg of Sm203. Being insoluble in the dichloromethane, 
SP and Sm203 formed a suspension. As for the SASP 
microspheres, dispersion of Sm203 was aided by sonication. 
This mixture was emulsified into 150 ml of 0.05% aqueous 
Tween 20 solution (overhead stirrer, 250 rpm). The 
production process was completed as described in section 
8.2.1.2. A. Three batches were produced containing no Sm203 
and three batches were produced containing 67.5 mg of Sm203 
(1.5% W/W). 
8.3.1.2. Microsphere size and density 
Following drying, the weight of microspheres produced was 
recorded and the fraction in three size ranges determined 
by sieving: <250 pm, 250-500 pm and >500 pm. 
Microsphere tap density was measured. A known quantity of 
microspheres was poured into a 10 ml glass measuring 
cylinder. The cylinder was lightly tapped twenty times and 
the volume of microspheres measured. The tap density was 
calculated by dividing the microsphere mass by its volume. 
8.3.1.3. S10223 content 
Measured by XRF as described in section 8.2.1.2. B. 
8.3.1.4. SP content 
To assay for drug content, an accurately weighed quantity 
of microspheres estimated to contain 3-5 mg of SP was 
placed into a 100 ml volumetric flask. The polymer matrix 
was dissolved in 5 ml of methanol, followed by making to 
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volume with 0.05 N sodium hydroxide solution. 25 ml of this 
solution was further diluted to 100 ml with the 0.05 N 
NaOH, filtered (0.65 pm membrane filter, Whatman) and the 
UV absorbance measured (247 nm). SP concentrations were 
calculated with reference to a calibration curve of SP in 
0.05 N NaOH. 
8.3.1.5. Drucr release rate 
See section 8.2.1.2. D. 
8.3.1-6. Electron microscopv 
See section 8.2.1.2.1. 
8.3.1.7. Effects of irradiation 
A9g batch of Eudragit RS microspheres was produced 
containing theoretical SP and SM203 contents of 33.3% w/w 
and 1% w/w respectively. 
To establish whether a shorter period of irradiation would 
minimise damage to the microspheres, a sample was 
for 15 irradiated at a neutron flux of 1012 n cm-2 r-l 
minutes as described in section 8.2.1.2. E. 
The radiation stability of SP was assessed by extraction 
(section 8.3.1.4) followed by HPLC analysis. The HPLC 
equipment described in section 8.2.1.2-G was employed but 
with a mobile phase of pH 6 phosphate buffer containing 30% 
v/v methanol at a flow rate of 1 ml/min. 
The drug release rate was measured for irradiated and non- 
irradiated microspheres. 
In addition the loss of radioactivity from the irradiated 
microspheres was assessed by the technique described in 
section 8.2.1.2. F. 
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8.3.2. RESULTS AND DISCUSSION 
8.3.2.1. Microsphere characterisation 
Table 8.7 lists formulation details of the Eudragit RS-SP 
microspheres. There was little difference in yield between 
the two sets of samples. However, the tap density of the 
microspheres containing Sm203 was 30% higher than for the 
Sm203-free samples. Differences in density were also 
apparent from handling the samples. Whereas the Sm203-free 
samples were brittle and easily powdered between the 
fingers. for the samples containing Sm203 considerably more 
force was needed to break the microspheres. 
The presence of Sm203 also appeared to affect microsphere 
SP content; The drug content of the samples containing 
Sm203 (33.6±0.8%) was consistently higher than for those 
without (31.3±0.3%). 
There were also clear differences in the microsphere size 
distributions (figure 8.8). For microspheres containing 
Sm203, the proportion >500 pm was reduced compared to the 
Sm203-free samples, with an increase in the proportion of 
smaller microspheres. 
8.3.2.2. Drug release rate 
Figure 8.9 shows the drug release profiles of the two sets 
of microsphere samples. The incorporation of SM203 appeared 
to dramatically suppress the rate of drug release. For the 
samples containing no Sm203,54% of the encapsulated drug 
had been released after 6 hours, whereas in the same period 
of time, just 28% of encapsulated drug had been released 
from the samples containing Sm203. The suppressed drug 
release rate of the latter samples may in part have been 
related to their higher density. 
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Table 8.7. Eudragit RS: sulphapyridine microsphere 
formulation details. 
Samarium oxide Microsphere Microsphere tap Sulphapyridine 
content (%w/w) yield (g) density (gIml) content (%w/w) 
0 3.7±0.2 0.26±0.01 31.3±0.3 
1.15±0.8 3.5±0.3 0.34±0.02 33.6±0.8 
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Figure 8.8. Effects of samarium oxide incorporation on microsphere 
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8.3.2.3. Electron microscopv 
It was clear that Sn'203 was far f rom inert when 
incorporated into Eudragit RS-SP microspheres and appeared 
to be able to exert marked effects on their physical 
properties at only low concentrations. It was considered 
that these effects might have been a result of the 
accumulation of Sm203 at the organic: aqueous interface of 
the drug-polymer-solvent droplets during microsphere 
formation. 
Surface electron micrographs of the microspheres produced 
without and with Sm203 are shown in figures 8.10a)-b) and 
8.11a)-b) respectively. The SM203-free samples contained 
many large surface holes (8.10a) which were absent in the 
sample containing Sm203 (8. l1a) 
. 
Higher magnification views 
revealed that the size and number of pores was greater in 
the SM203-free samples (figure 8.10b vs. figure 8.11b). 
The internal structure of the two sets of microspheres did 
not differ greatly. Both sets consisted of a spongy drug- 
polymer matrix containing a number of large cavities. The 
size and number of cavities appeared to be greater in the 
Sm203-free microspheres (figure 8.12a) compared to the 
Sm203 
-containing microspheres (figure 8.12b),, which was 
consistent with the differences in density. 
8.3.2.4. Effects of irradiation 
The 9g batch of Eudragit RS-SP microspheres had an assayed 
drug content of 35.0% w/w. This represents an incorporation 
efficiency of 105% and again points towards Sm203 having 
effects on microsphere drug content. The assayed Sm203 
content was 0.7% (70% incorporation efficiency). 
The SP content in the irradiated samples was identical to 
the non-irradiated, and no additional peaks were evident, 
indicating that the drug was stable to neutron irradiation. 
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Figure 8.10. Electron micrographs of Eudragit 
RS: sulphapyridine microspheres containing no samarium 
oxide. 
b) Microsphere surface (xIOOO). 
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Figure 8.11. Electron micrographs of Eudragit 
RS: sulphapyridine microspheres containing 1.15% w/w 
samarium oxide. 
a) View of microsphere population (magnification x55). 
b) Microsphere surface (xlOOO). 
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Figure 8.12. Electron micrographs of interior of 
Eudragit RS: sulphapyridine microspheres. 
a) Containing no samarium oxide (magnification x170). 
b) Containing 1.15% w/w samarium oxide (x170). 
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Figure 8.13. Effect of 15 minute irradiation on sulphapyridine release rate 
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Following a 15 minute irradiation, the rate of drug release 
from the microspheres was slightly increased, suggesting 
minor radiation damage (figure 8.13). 
No leaching of radioactivity from the irradiated 
microspheres could be detected during in vitro dissolution. 
8.4. CONCLUSIONS 
The work described in this chapter has demonstrated that 
the incorporation of SM203 followed by neutron irradiation 
is a viable method for radiolabelling microspheres produced 
by the solvent evaporation process. 
Sn'203 at concentrations up to 0.8% w/w had no apparent 
effect on the physical properties of Eudragit RS-SASP 
microspheres. However, following irradiation, physical 
changes were apparent both in Sm203-containing and in 
Sm203-f ree microspheres and a marked enhancement in the 
rate of drug release was seen. The physical changes 
observed as a result of irradiation were a softened/melted 
appearance to the microsphere surf ace, and possibly a small 
increase in polymer molecular weight. The mechanism 
responsible for the enhancement in drug release is unclear, 
and would require further investigation. 
When incorporated into Eudragit RS-SP microspheres, Sm203 
had marked effects on microsphere properties at a 
concentration not too dissimilar to that used in the SASP 
microspheres. Incorporation of 1-15 ý w1w Sm203 caused an 
increase in microsphere density, a decrease in microsphere 
size, an increase in drug loading and a 50% reduction in 
the rate of drug release. It is probable that SM203 was 
exerting these effects through accumulation at the 
microsphere surface, since electron microscopy revealed 
that the surface porosity was higher in the microspheres 
containing no Sm203. 
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Irradiation of a sample of Eudragit RS-SP microspheres for 
a 15 minute period resulted in only a minor enhancement in 
drug release. 
Following the finding that Sm203 
-incorporation could affect 
microsphere properties, a single batch of Eudragit RS-SASP 
microspheres was produced containing 4% w1w Sm203. The 
microsphere yield was lower, the density was increased, and 
only 11% of the encapsulated drug was released after 360 
minutes. Thus the concentration of Sm203 at which changes 
in microsphere physical properties occur appears to be 
dependent upon the drug being encapsulated. 
In conclusion, this work has emphasized the need for 
achieving a careful balance between the irradiation time 
and the level of incorporated Sm203 when developing a 
neutron activation technique for radiolabelling 
microspheres produced by solvent evaporation. Whereas the 
rate of drug release may be increased by long periods of 
irradiation, it may be suppressed by incorporating high 
levels of Sm203. There could be clear benefits in using 
enriched material (95%+ 152Sm) for this work,, since the 
amount of radiolabel incorporated would effectively be 
reduced by almost 75%, and as a consequence, SM203-induced 
effects on microsphere physical properties would be 
minimised. 
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CHAPTER 9. 
A BIOPHARMACEUTICAL EVALUATION OF EUDRAGIT RS- 
SULPHAPYRIDINE MICROSPHERES IN THE HUMAN COLON. 
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9.1. INTRODUCTION 
Investigations in the previous chapter had established that 
the incorporation of Sm203 followed by short exposure to 
neutron radiation was a suitable method for radiolabelling 
Eudragit RS microspheres. Although Sm203 had marked effects 
on the physical properties of Eudragit RS-SP microspheres, 
this was not considered to be a problem for the study 
described in this chapter, since the chosen manufacturing 
conditions and the level of incorporated label resulted in 
microspheres with a suitable drug release rate. 
As discussed in the previous chapter, SP was the logical 
successor to SASP as a model drug for colon absorption 
studies. SP has now largely passed out of use as an 
antibiotic as a result of the introduction of newer 
treatments which are equally effective but with a lower 
incidence of side-effects. Consequently, most of the 
published pharmacokinetic data for SP has been generated 
from studies investigating the in vivo fate of SASP. 
SP appears to be well absorbed from the colon and an 
absolute bioavailability of 70% has been quoted following 
SASP administration (Bieck, 1989). 
Figure 9.1 shows the metabolic fate of SP. Elimination of 
SP is primarily by hepatic metabolism and the rate is 
dependent upon acetylator status. About 60% of caucasians 
are slow acetylators, and side-effects from SASP/SP are 2-3 
times more frequent in this group. The elimination half- 
life is about 6h in fast-acetylators and 14 h in slow 
acetylators (Klotz, 1985). In plasma samples from patients 
taking SASPI only SP and acetyl-SP (AcSP) could be detected 
in appreciable quantities by HPLC analysis (Astbury and 
Dixon, 1987; Fischer and Klotz, 1978). 
The study undertaken in this chapter aimed to address two 
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Figure 9.1. Metabolic fate of sulphapyridine (from Klotz, 1985). 
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main issues. The first was to establish the colonic transit 
rate of radiolabelled Eudragit RS-SP microspheres by 
carrying out scintigraphic experiments analogous to those 
in Chapter 7. 
The second aim was to compare the colonic absorption 
characteristics of microencapsulated and unencapsulated SP. 
This would provide information on the suitability of the 
ascending colon as a target for sustained-release 
microparticulate dosage forms and might reveal in vitro/Ln 
vivo differences in dissolution performance. 
Measurement of plasma SP levels would also ref lect the 
exposure of the colonic mucosa to drug, an important 
measure of the suitability of microsphere drug-delivery 
systems for providing drug for local topical action. 
It was considered that a microsphere formulation that 
released most of its encapsulated drug over a period of 12 
hours would be most appropriate, taking into consideration 
the ascending colon residence times established in chapter 
7. With release over longer periods, considerable amounts 
of drug would be released into areas of the colon beyond 
the hepatic flexure where the absorptive capacity may be 
more limited. 
9.2. EXPERIMENTAL 
9.2.1. Materials 
As f or chapter 8, but in addition, sulphadimidine sodium 
(Rh8ne-Poulenc), acetic anhydride (Rh6ne-Poulenc), 
Amberlite IRA410 resin, 000-sized hard gelatin capsules, 
"Polymer A", sodium pertechnetate solution. 
9.2.2. Methods 
9.2.2.1. Microsphere 1production 
Two 15 g microsphere batches were produced f or the clinical 
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investigation. For each batch, 10 g of Eudragit RS was 
dissolved in 100 ml of dichloromethane in a glass bottle. 
When the polymer had dissolved, 225 mg of Sm203 was added 
to form a suspension. Dispersion of Sm203 was aided by 
sonication of the bottle and contents for 10 minutes. 
Finally 5g of SP powder was added to the bottle and 
dispersed by shaking. This mixture was immediately poured 
into 500 ml of 0.1% w/v aqueous Tween 20 solution and 
stirred at 250 rpm. Solvent evaporation took approximately 
10 hours for each batch. Following filtration, washing and 
freeze-drying, a 120-500 pm sieve fraction was collected 
and weighed. 
The collected sieve fractions from the two microsphere 
batches were placed in a single bottle and mixed together 
by gentle rotation. 
9.2.2.2. Microsphere characterisation 
Microsphere drug content, Sm203 content, drug release 
characteristics and electron micrographs were obtained 
using the techniques described in chapter 8. 
9.2-2.3. Microsphere irradiation 
1.5 g of the Eudragit RS-SP microspheres were placed into 
each of two polypropylene tubes. The tubes containing the 
microspheres were irradiated at the Universities Research 
Reactor, Risley for 15 minutes at a neutron flux of 1012 n 
-2 -1 cm s 
Microsphere in vitro drug release characteristics were 
determined again after irradiation. 
9.2.2.4. In vivo investicration 
A. Dosage form assembl 
Two types of dosage form were assembled for a two part 
-in 
vivo investigation. 
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i) Into a 000-sized hard gelatin capsule was placed 500 mg 
of SP powder and 100 mg of finely-ground Amberlite IRA410 
ion-exchange resin labelled with 99mTc as described in 
chapter 6. The capsule was coated by dipping three times 
into a solution of 15% w/v "Polymer A" in acetone (see 
chapter 6). 
ii) 130 mg of irradiated and 320 mg of non-irradiated 
Eudragit RS-SP microspheres were placed into a 000-sized 
capsule. The capsule was coated as described above. Only 
part of the microsphere dose was radiolabelled to ensure 
that the radioactivity was not too diffuse following 
capsule disintegration. If the same amount of activity had 
been divided between all of the microspheres, the quality 
of scintigraphic images may have been unsatisfactory. 
B. Studv desiqn 
Six healthy male volunteers (age 23-29 years) were 
recruited f or the biopharmaceutical study to evaluate SP 
administered as a powder and as sustained-release 
microspheres. The study received the prior approval of the 
Nottingham University Medical School ethical committee and 
was conducted in accordance with the Declaration of 
Helsinki Guidelines for Ethics in Research. 
The investigation was carried out in two parts, separated 
by a period of two weeks. 
On each occasion, subjects arrived at the study room at 
7.30 am having fasted from 10 pm the previous evening. A 
forearm cannula was inserted to enable blood samples to be 
withdrawn during the study day and markers containing a 
small quantity of irradiated Sm203 powder were attached to 
the f ront and back over the right lobe of the liver to 
allow alignment during scintigraphic imaging. At 
approximately 8 am subjects were asked to swallow, with a 
glass of water, either one capsule containing SP powder or 
248 
three capsules containing SP microspheres. The former 
capsule contained 4 MBq of 99MTc whereas the latter three 
capsules contained a total of approximately 1.5 MBq of 
153Sm. The quantity of SP administered in each case was 500 
Mg. 
Anterior and posterior scintigraphic images of 30 seconds 
duration were recorded at 30-60 minute intervals throughout 
the day as described previously (chapter 7). Once the 
capsules had left the stomach, subjects received breakfast 
and thereafter a set lunch, coffee/tea and biscuits, and 
dinner (chapter 7). Blood samples were withdrawn at 0h and 
approximately 2,4,6,81,11, and 13 h post-dose and 
immediately placed into heparinised tubes to prevent 
clotting. Tubes were centrifuged for 15 minutes at 2000 rpm 
(MSE Centaur) and the plasma fraction removed and frozen at 
-20 *C for later analysis. Subjects returned for imaging 
(120 secs duration, microspheres only) and blood samples 
(by venipuncture) at 24 and 32 hours post-dose. Images were 
not recorded at 24 and 32 h for the drug-powder leg of the 
study due to the short half-life of the 99mTc-label. 
C. Scintiaraphic analvsis 
stored scintigraphic images were analysed to determine the 
distribution of activity in the ICJ, ascending colon, 
transverse colon and descending colon/rectum using the 
methods outlined in chapter 7. This analysis enabled the 
residence time of 50% of the administered radioactivity in 
the ascending colon to be determined (MRT) and, for the 
microspheres only, the residual amount of activity 
remaining after 24 and 32 h. 
Statistical comparisons between paired data (t-test) were 
undertaken using "Statworks" run on an Apple Macintosh 
computer. 
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D. Analvsis of plasma samples 
A number of HPLC methods f or the analysis of SP and its 
metabolites have been reported (Astbury and Dixon, 1987; 
Fischer and Klotz, 1978; Shaw et al., 1983). For this 
study, a method was developed for the plasma assay of SP 
and its principal metabolite, AcSP. For assay development 
and generation of calibration graphs, AcSP was synthesized. 
i) Svnthesis of AcSP 
1g of SP was placed into a small glass beaker and 
approximately 1g of acetic anhydride added. The top of the 
beaker was covered with foil, placed in a fume cupboard, 
and the contents stirred with a magnetic f lea. After 1 
hour, 50 ml of boiling water was added to the beaker to 
convert unreacted acetic anhydride into acetic acid and 
water. The beaker contents were cooled, the liquid removed 
by decantation and the sediment resuspended by adding 
distilled water. The beaker contents were then divided 
between two centrifuge tubes, spun down (2000 rpm/5 mins) 
and the liquid decanted off. Resuspension, centrifugation 
and decantation were repeated until the smell of acetic 
acid could no longer be detected. The sediment was then 
dried in an oven at 50 *C and stored in a desiccator. 
ii) HPLC equipment 
The following HPLC equipment was used for analysis of the 
plasma samples: 
Knauer HPLC 64 pump (Knauer, Berlin, Germany), flow rate 
1.2 ml/min. 
Gilson 401/231 dilutor/autosampler (Gilson, Middleton,, WI). 
Hichrom. Spherisorb ODS column (15 cm. x 4.6 mm ID) fitted 
with a guard column (Upchurch). 
Uvikon 720 LC detector (Kontron Instruments, Switzerland), 
254 nm. 
Spectra-Physics 4400 integrator. 
Mobile phase: A solution of 6.8 g/L of potassium dihydrogen 
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phosphate in double distilled water was adjusted to pH 6.0 
with 1N aqueous sodium hydroxide solution. The buffer 
solution was then vacuum f iltered through a 0.1 pm membrane 
filter (Whatman). Filtered buffer was added to methanol to 
produce a final methanol content of 20% v/v. Prior to use, 
the mobile phase was degassed by bubbling helium through 
for 10 minutes. 
iii) Sample lDreparation 
To 0.5 ml of plasma in an Eppendorf tube was added an equal 
volume of methanol containing 1.7 mg/100 ml sulphadimidine 
sodium as the internal standard. Addition of methanol 
resulted in protein precipitation. The tube was vortex 
mixed (Rotamixer), centrifuged at 13,000 rpm for 10 minutes 
(MSE Microcentaur), and the clear supernatant removed for 
HPLC analysis. 
An injection volume of 20 pL was used, and each plasma 
sample was analysed twice. 
iv) Calibration samples 
To 0.5 ml of a solution of 3.4 mg/loo mi sulphadimidine 
sodium in methanol was added 0.5 ml of methanol containing 
appropriate concentrations of SP and AcSP. 0.5 ml of this 
mixture was added to 0.5 ml of blank plasma and the clear 
supernatant prepared as above. 
Calibration results were pooled and used to produce 
calibration graphs of peak area ratio (drug: internal 
standard) vs. concentration for SP and AcSP which in turn 
were used to calculate drug concentrations. 
v) Data analvsis 
The areas under the concentration vs. time curve (AUC) and 
the f irst moment of concentration vs. time curve (AUMC) 
were calculated using a pharmacokinetic program (MK Model, 
Dr. N. Holford, Auckland University Medical School). 
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The SP elimination half-life was determined from the slope 
of the elimination phase on a graph of log[plasma 
concentration] vs time. 
9.3. RESULTS 
9.3.1. Microsphere characterisation 
Physical properties of the microspheres are recorded in 
table 9.1. 
The assayed SP content was considerably higher than 
expected at 37.2% w/w and represents an incorporation 
efficiency of 112%. It was also observed in chapter 8 that 
Sm203 appeared to increase the drug content of SP-Eudragit 
RS microspheres. 
The in vitro rate of SP release f rom the microspheres 
before and after irradiation is shown in figure 9.2. The 
release rates were identical, and after 12 hours and 24 
hours 75% and 93% of the encapsulated drug had been 
released respectively. The time for 50% of the drug to be 
released was approximately 5 hours. 
SEM micrographs of non-irradiated and irradiated 
microspheres are shown in figures 9.3 and 9.4 respectively. 
The microspheres had a generally misshapen appearance 
(figures 9.3a and 9.4a). High magnification views of the 
surface appeared to show little difference between the two 
samples (figures 9.3b and 9.4b). 
The radioactivity generated by the 15 minute irradiation 
was equivalent to 4.4 MBq/g of microspheres at the time of 
subject dosing (22 hours after irradiation). 
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Table 9.1. Details of microsphere formulation used 
-fDr 
clin cal investigation. 
Samarium oxide content: 1.12%w/w (=74.7% incoiporated). 
Sulphapyridine content: 37.2%w/w (=l 12% incorporated). 
Tap density: 0.35 g/ml. 
Weight of microspheres, 120-500pm: 17.2g (57% by weight). 
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Figure 9.3. Electron micrographs of Eudragit 
RS: sulphapyridine microspheres used for 
clinical investigation: non-irradiated. 
a) Microsphere population (magnification x55). 
b) Microsphere surfdce (xIOOO). 
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Figure 9.4. Electron micrographs of Eudragit 
RS: sulphapyridine microspheres used for 
clinical investigation: irradiated. 
a) Microsphere population (maqnification x55). 
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9.3.2. Transit rate 
As seen for the scintigraphic studies described in chapter 
7,, the coated gelatin capsules in general performed as 
required, releasing their contents into the ICJ or base of 
ascending colon. However in two subjects (2 and 3), the 
capsules containing sulphapyridine powder disintegrated 
prematurely and the contents were released into the lower 
small intestine. 
Table 9.2 presents the mean residence time (MRT) data for 
the two parts of the study. Data is presented for just five 
subjects since in the sixth subject, on both occasions, one 
capsule was resident in the stomach for the entire study 
day. The MRTs of the 0.2 mm resin and the Eudragit 
microspheres in the ascending colon were 7.2il. 9 h and 
8.4±2.0 h respectively. There was statistically no 
significant difference between these values and they were 
comparable to the studies described in chapter 7, where the 
mean MRT of 0.2 mm particles was 11.014.0 h (n=21). 
Figure 9.5 shows scintigraphic images of the 153SM-labelled 
microspheres for subject 4 at three different time 
intervals. In figure 9.5a, 2 hours after dosing, the three 
capsules were all intact in the small intestine and indeed 
one moved during imaging. In the top left hand corner, the 
radioactive marker used for alignment is seen. 5 hours 
after dosing, the microspheres had begun to disperse 
through the ascending colon (figure 9.5b). After 13 hours, 
a large area of activity still resided in the base of the 
ascending colon, whereas the remainder of the microspheres 
had moved ahead to outline the transverse and descending 
colon (figure 9.5c). The scintigraphic data indicated that 
almost 40% of the administered activity resided in the 
ascending colon at this stage. 
The wide spread of the microspheres emphasizes their 
suitability for delivering agents for topical treatment of 
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Table 9.2. Ascending colon MRT of radiolabelled ion-exchange 
resin and Eudragit microspheres. 
MRT (hours) 
Subject 
Ion-exchange resin Microspheres 
1 5.2 7.3 
2 5.4 8.3 
3 7.3 11.7 
4 8.0 8.3 
5 9.9 6.6 
Mean 7.2±1.9 8.4±2.0 
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Figure 9.5. Scintigraphic images of 
153SM_ labelled 
microspheres for subject 4. 
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a) 2 hours. 
5 hours. 
c) 13 hours. 
an extensively diseased colon. This spreading might also 
serve to enhance the absorption of drugs for systemic 
action, by optimising contact between the carrier and the 
colon mucosa. 
Table 9.3 lists the radioactivity from the microspheres 
present 24 and 32 hours after administration in the 
ascending, transverse, descending and whole colon for four 
subjects (Subject 5 was unable to attend the 24 h and 32 h 
imaging/blood sampling sessions). In subjects 1 and 3, in 
excess of 80% of the administered dose of microspheres was 
still resident in the colon after 24 hours. In subjects 2 
and 4, considerably less activity remained. 
As noted for the IBS patients in section 7.3.3, there was 
no apparent correlation between MRT and whole colon 
transit. In this study, the MRTs for subjects 2 and 4 were 
no shorter than for subjects 1 and 3 despite the 
considerable difference in residual activity at 24 and 32 
h. Presumably in subjects 2 and 4, loss of the 
radioactivity, by def aecation, had occurred between the end 
of imaging on the main study day and the 24 hour image, and 
as a result the MRT was unaffected. If defaecation had 
occurred during the main study day, the distal acceleration 
of the microspheres would have significantly reduced their 
residence in the ascending colon. 
The time of dosing in relation to the time of defaecation 
could be an important factor in determining colon 
residence. Indeed, a mass movement associated with 
approximately 80% of a dose of radiolabelled pellets moving 
from the ascending into the transverse and descending colon 
over a 15 minute period has been reported elsewhere (Proano 
et al., 1991). Therefore, ascending colon residence is not 
necessarily uniformly long, and in certain situations the 
opportunity for local drug action or absorption could be 
limited. 
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Table 9.3. Radioactivity from microspheres remaining after 24 and 32 hours in 
the ascending (AC), transverse (TC) and descending (DQ colon. 
% of administered microspheres remaining 
Subject 
At 24 h At 32 h 
AC M 11C AC IC 11C 
1 22.6 36.4 29.4 16.2 28.2 28.3 
2 1.7 5.7 7.6 3.4 0.0 1.1 
3 19.5 25.7 35.3 16.1 15.3 0.0 
4 8.1 1.6 16.8 7.4 1.6 0.3 
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9.3.3. Pharmacokinetics 
The chosen HPLC conditions allowed SP, AcSP and the 
internal standard, sulphadimidine sodium, to be resolved 
and identified in plasma. The total run time for each 
sample was 15 minutes. Figure 9.6a shows a chromatograph of 
blank plasma spiked with the three compounds, whereas 
figure 9.6b shows a chromatograph of a drug-containing 
sample taken from one of the subjects and containing the 
internal standard. The elution times were extremely 
sensitive to buffer methanol content and so slight 
variations were seen between different batches of buffer. 
The minimum measurable concentrations were approximately 
0.5 mg/L for SP and 2 mg/L for AcSP. The correlation 
coefficients for the SP and AcSP calibration graphs were 
both 0.991. 
The mean group profiles of SP and AcSP following 
administration of the drug powder are presented in figure 
9.7a. Absorption of SP appeared to be fairly rapid. In all 
cases, concentrations of SP were higher than AcSP, 
suggesting that all of the subjects were slow acetylators. 
In f igure 9.7b is a comparison of plasma sulphapyridine 
levels following administration of the drug powder and the 
sustained-release microspheres. In most cases, levels of 
AcSP following microsphere administration were too low to 
be measured and so are not shown. 
Figures 9.8a)-e) present the individual SP plasma data. 
Subject 5 was unable to attend at 24 and 32 h in the 
microsphere leg and thus this part of figure 9.8e does not 
extend beyond 14 hours. 
The elimination half-lives of SP were estimated, from the 
powder leg of the study,, to be 8.0,8.0,10.4 and 12.4 
hours for subjects 2,3,4 and 5 respectively. 
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Figure 9.6. HPLC traces of sulphapyridine (SP), acetyl-sulphapyridine 
(AcSP), and internal standard, sulphadimidine sodium (SDNa). 
QI = elution time in minutes). 
a) Blank plasma spiked with the dm compounds. 
b) Plasma sample from one of subjects spiked with internal standard. 
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Figure 9.7. Mean plasma data from biopharmaceutical study (S subjects). 
a) Mean sulphapyridine/Ac-sulphapyridine plasma profiles (drug powder). 
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The area under the SP plasma concentration vs. time curve 
(AUC) was calculated for each of the two formulations. By 
dividing the microsphere AUC by the drug powder AUC, the 
relative bioavailability of the microsphere formulation was 
estimated. The mean relative bioavailability of the 
microspheres was 41.3±12.7 % (table 9.4). 
The relative bioavailability was lowest in subject 4. 
Although this may have been related to the low percentage 
of the administered microspheres resident in the colon at 
24 h (table 9.3), the dose remaining in subject 2 at 24 h 
was even lower, yet bioavailability was not af f ected to the 
same extent. 
The relatively long half-life of SP made the in vivo 
demonstration of microsphere sustained-release properties 
difficult, although the shape of the microsphere plasma 
profiles did suggest an extension of release. Looking at 
figures 9.8a-e, between 13 and 25 hours plasma 
sulphapyridine either decreased very little or actually 
increased, implying that drug absorption may have occurred 
well beyond 13 hours. Since the in vitro release of drug 
from the microspheres was relatively rapid (50 % released 
after 5h and 75 % after 12 h) this suggested that the in 
vivo release behaviour may be very different. 
To assess in a more quantitative manner the degree to which 
the microspheres demonstrated sustained-release properties, 
the drug mean residence time was calculated (dMRT). The 
dMRT is def ined as the average time that the number of 
molecules introduced reside in the body (Rowland and Tozer, 
1989). It is calculated by dividing the AUC of the plasma 
concentration vs. time curve by the area under the f irst 
moment of concentration vs. time curve (AUMC) and 
subtracting the mean absorption time (Rowland and Tozer, 
1989). (The first moment of concentration is equal to the 
product of concentration x time). For the purpose of 
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Table 9.4. Bioavailability of sulphapyridine:. Eudragit microspheres (m) 
vs. unencapsulated drug powder (u). 
Subject Relative bioavailability = [AUC(m)/AUC(u)] x 100 
1 50.0% 
2 50.5% 
3 41.3% 
4 23.4% 
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Table 9.5. Mean residence time of sulphapyridine (dMRT) 
absorbed from powder and microspheres. 
Subject dMRT (h) Difference (M 
- 
P) (h) 
Powder Alicrospheres 
1 8.0 14.3 +6.3 
2 12.8 17.9 +5.1 
3 10.7 18.0 +7.3 
4 1 9.8 
10.4 +0.6 
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demonstrating differences in dosage form performance, the 
dMRT has been calculated by subtracting from [AUC/AUMCi the 
time at which drug absorption commenced, represented by the 
point of capsule disintegration on the scintigraphic 
images. 
The results of this analysis are presented in table 9.5. In 
three out of four cases,, the dMRT was longer for the 
microsphere formulation. However, this difference was not 
statistically significant (p=0.058), which may reflect the 
small sample number. 
There are a number of possible explanations for the marked 
reduction in SP bioavailability observed for the 
microsphere formulation: 
1. In vitro/in vivo differences in drug release rate. 
one obvious difference in microsphere in vitro/in vivo 
performance might result from the degree of agitation the 
microspheres receive. Whereas the in vitro release rate was 
established using paddle stirrers at 100 rpm, the degree of 
agitation in the colon is likely to be considerably less. 
The ef f ects of the degree of agitation on the rate of SP 
release were assessed using the USP dissolution apparatus 
(as described elsewhere) with paddle stirrers set to 50 rpm 
or 0 rpm (figure 9.9). For comparison, the release rate 
with agitation at 100 rpm is presented in figure 9.2. The 
drug release rate appeared to be little af f ected by the 
degree of agitation. 
other in vitro/in vivo differences in release conditions 
which might be of importance are less easy to assess , in 
particular the viscosity of the colon contents. 
2. Regional differences in drug absorption within the colon 
In section 1.2.4-3. it was remarked that relatively little 
is known about the rate of drug absorption in the different 
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regions of the colon. In theory, the absorptive capacity 
should decrease the further one travels around the colon, 
and indeed this has been demonstrated for ciprofloxacin 
(section 1.2.4.3). 
Unfortunately, for the study described here, the long-half 
life of SP makes assessment of declining drug absorption 
beyond the ascending colon difficult. Difficulty in 
assessment is also compounded by the fact that the drug 
carriers are of a highly dispersed nature and so drug may 
be simultaneously released throughout a wide area of the 
colon. 
3. Interaction of druq with colonic bacteria 
As discussed in chapter 1, colonic bacteria have 
considerable potential f or metabolising a variety of drugs. 
However, there are no reports of the biotransformation of 
SP. 
It is probable that some of the SP will be sequestered by 
bacteria. In common with other sulphonamide antibiotics, Sp 
is an analogue of gamma-amino butyric acid (GABA) and 
inhibits bacterial folic acid production. It decreases 
folic acid production by competition with endogenous GABA 
for the bacterial enzyme, dihydropteroate synthetase. In 
addition,, some of the sulphonamide will be incorporated 
into a folic acid analogue which will disrupt various 
bacterial functions (Bowman and Rand, 1980). 
If inactivation of SP by bacterial action does occur it 
would have the greatest effect on the bioavailability from 
the microspheres. With the SP powder, lumenal 
concentrations of drug will initially be very high, and 
thus overwhelm the bacterial removal processes. However,, 
with the sustained-release microspheres, lumenal drug 
concentrations will be very much lower, saturation of 
sequestration processes will not occur,, and the 
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bioavailability will be reduced. 
9.4. CONCLUSIONS 
The work undertaken in this chapter has demonstrated that 
microspheres radiolabelled with 153 Sm203 by neutron 
activation techniques can be successfully visualised 
scintigraphically to provide high quality images, even when 
highly dispersed. 
The MRT of the microspheres in the ascending colon was 
generally comparable to the studies investigating the 
transit of model particulates and tablets, described in 
chapter 7. 
There was good evidence to suggest a prolongation of 
release from the microspheres, both from drug mean 
residence time calculations and also from the extended 
appearance of the microsphere plasma-time profiles. 
The relative bioavailability of SP absorbed f rom sustained- 
release microspheres was reduced by about 50% compared to 
unencapsulated drug. There are potentially a number of 
factors which might explain the poor in vivo performance of 
the microspheres and without a considerable amount of 
further work it is not possible to isolate any single one 
as being the most important. 
In retrospect,, SP was not the ideal candidate drug f or this 
study, f or primarily two reasons. Firstly, its plasma half - 
life is relatively long making assessment of sustained- 
release more difficult. Secondly, there is the possibility 
of interaction with colonic bacteria. By choosing a model 
drug which has less likelihood of interacting with bacteria 
and which is known to be well absorbed from the colon, for 
example oxprenolol (Davis et al., 1988) or ibuprofen 
(wilson et al., 1989), the evaluation of in vitro/in vivo 
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differences in release performance and regional variations 
in drug absorption within the colon would be made easier. 
This study has established methods for the in vivo 
biopharmaceutical evaluation of drug-polymer microspheres 
in the colon. Further work is needed to assess their 
relative merits compared to other types of sustained- 
release dosage form. 
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CHAPTER 10. 
CONCLUDING REMARKS. 
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one of the areas examined in some detail in this thesis has 
been the microencapsulation of poorly water-soluble drugs 
into Eudragit RS using emulsification-solvent evaporation. 
The effects of parameters such as mixing time and speed on 
microsphere properties are easily predicted using this 
process, as demonstrated in Chapter 2. The influence of 
other factors is less easy to assess and unfortunately is 
complicated by the dynamic nature of the solvent 
evaporation process; With a highly volatile solvent such as 
dichloramethane, probing structural changes taking place 
during microsphere formation is difficult. However, some of 
the experiments described in this thesis have provided 
interesting insights into the mechanism of microsphere 
formation using emulsification-solvent evaporation. 
The work undertaken in Chapter 3 revealed that the 
concentration of surfactant used for microsphere 
preparation could influence the subsequent rate of drug 
release. The mechanism may have been different for the two 
surfactants investigated, since for SDS the enhancement in 
drug release was seen at sub-cmc concentrations, whereas at 
higher concentrations, highly porous and brittle 
microspheres were produced. On the other hand, f or Tween 
20, sustained-release microspheres were still produced at 
greater-than-cmc concentrations. It was considered that the 
high rate of drug release from microspheres produced using 
0.25% w1v SDS was due to a very porous surface and internal 
structure. It is noteworthy that the internal structure of 
the SASP microspheres described in Chapter 8 was similar, 
although the number of surface pores appeared to be lower 
and the matrix density higher which may have explained the 
lower rate of drug release. On the other hand, the 
structure of the 5-ASA microspheres produced without 
surfactant was similar to the SP microspheres described in 
Chapter 8. It is perhaps the case that a honeycombed 
internal structure is associated with high concentrations 
of surfactant (e. g. 0.25% SDS for 5-ASA microspheres and 
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0.1% Tween 20 for SASP microspheres) whereas a denser 
structure is associated with lower concentrations of 
surfactant (e. g. no surfactant in the case of 5-ASA and 
0.05% Tween 20 in the case of SP). With SDS as surfactant, 
there was also the possibility of an interaction between 
dodecyl sulphate anions and the cationic trimethyl 
ammonioethyl functions in Eudragit RS. There is clearly 
scope for considerably more work in this area, and in 
particular to investigate the microscopic structure of 
microspheres across a range of surfactant concentrations, 
and whether surf actant 
-enhanced drug release applies to 
other encapsulating polymers. 
Another factor which was shown to influence microsphere 
structure was the presence of samarium oxide, an apparently 
inert,, insoluble,, particulate material. Incorporation of 
very low concentrations (1% w/w) was able to influence the 
physical properties of SP-Eudragit RS microspheres, most 
evident in increased density and a reduced drug release 
rate. It appeared that one of the effects of samarium oxide 
was to reduce the porosity of the microsphere surface, 
perhaps by accumulation at the polymer solution-surfactant 
solution interface during microsphere formation. It might 
be possible to determine whether or not this is the case by 
X-ray microanalysis of microsphere samples to compare 
surface and bulk concentrations of samarium. The mechanism 
by which samarium oxide accumulation at the microsphere 
surface could influence porosity and density is unclear. 
Finally, XPS analysis of sulphasalazine-containing 
microspheres revealed that the surface drug content 
remained remarkably constant across a wide-range of bulk 
drug loadings. Further examination of this phenomenon might 
assist in understanding the microsphere formation process. 
The incorporation of samarium oxide followed by neutron 
irradiation was used successfully to radiolabel 
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microspheres. From work in the literature investigating 
this technique for radiolabelling other types of dosage 
form, it appeared to be desirable to minimise the amount of 
incorporated target nuclide and the irradiation time. The 
microsphere investigations in this thesis supported these 
findings; In the case of sulphasalazine microspheres, high 
neutron exposure enhanced the rate of drug release, whereas 
high levels of samarium oxide were shown to suppress the 
drug release rate. It was not possible to determine the 
mechanism by which the rate of drug release was enhanced by 
irradiation. There were certainly physical changes evident 
from electron micrographs, possibly heat-induced. The 
polymer molecular weight analysis was inconclusive. More 
detailed investigations with drug-free microspheres would 
probably be a more appropriate method of assessing the 
effects of irradiation on polymer properties. 
It was hoped that in vivo investigations of the transit of 
radiolabelled model dosage forms, described in Chapter 7, 
would provide more definitive data on the effects of 
particle size on the rate of transit through the colon. It 
appeared that in the healthy human colon, there was no 
difference in the colonic transit rate of materials in the 
size-range 0.2 mm to 8.4 mm, which conflicted with 
investigations published in the literature. For example, 
Proano et al. (1990) reported that the ascending colon 
transit rate was 9.9±3.8 h for 0.5-1.8 mm pellets, and 
11.9±2.0 h for 6 mm pellets. Although these two values were 
statistically significantly different, the numerical 
difference was clearly only small. In Chapter 7, particle 
transit was also investigated in the hypermotile colon, 
either induced by lactulose or as a consequence of IBS. For 
lactulose-induced hypermotility, 5 mm tablets passed 
significantly more rapidly through the ascending colon than 
0.2 mm particles. However this effect was not universal, 
and was only seen in six out of the group of eleven 
subjects. In the study involving IBS patients,, extreme 
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differences in the transit rate of the particles and 
tablets were seen. However, due to the small number of 
subjects investigated and the fact that the disease 
characteristics differed greatly, it is difficult to draw 
any definite conclusions. Clearly, as more studies of this 
nature are undertaken, it will be possible to define more 
clearly the relationship between particle size and colon 
residence. 
Although it was unclear whether small particles could 
reside in the ascending colon for longer periods than 
larger single units, it was considered that there may be 
benefits in using the former as carriers for sustained- 
release of drugs into the colon, whether for systemic 
absorption or local action. Firstly, the dispersed nature 
of multiparticulates might enhance contact between colonic 
mucosa and drug carrier. Secondly, using a dispersed 
system, the probability of longer total residence in the 
colon is increased, as discussed in Chapter 7. The in vivo 
pharmacokinetic study indicated a marked difference between 
the bioavailability of microencapsulated and unencapsulated 
sulphapyridine. The shortfall in bioavailability with 
microencapsulated drug could have been due to a number of 
factors. The most important of these were considered to be 
the possible sequestration of sulphapyridine by colonic 
bacteria, or in vitro/in vivo differences in microsphere 
drug release. Investigations with a different drug, less 
susceptible to bacterial interaction might allow a better 
evaluation of the in vivo microsphere performance. It would 
also be desirable to compare the colonic performance of a 
sustained-release microparticulate dosage form with a 
sus tained-re lease single unit, both designed to provide the 
same in vitro rate of drug release. 
The ability of "Polymer A"-coated capsules to deliver 
materials into the colon for the in vivo investigations was 
entirely unexpected and deserves further investigation, 
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particularly in fed human subjects. 
To conclude, the work undertaken for this thesis has 
provided an interesting insight into aspects of the 
preparation and in vitro and in vivo performance of 
microparticulate dosage forms intended for colon drug 
delivery,, and has revealed a number of areas worthy of 
further exploration. 
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APPENDIX 1. 
Recipe for phosphate buffer: 
i) 6.8 g/L potassium dihydrogen orthophosphate (BDH, 
Poole, UK) dissolved in 800 ml of distilled water. 
ii) Dissolve sodium hydroxide pellets (BDH) in distilled 
water to produce a1N solution. 
iii) Adjust potassium dihydrogen orthophosphate solution 
to required pH (range 6-8) with 1N aqueous sodium 
hydroxide solution. 
iv) Make to 1L with distilled water. 
v) For microsphere dissolution tests, add 0.02% w/v Tween 
20 to buffer solution. 
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CORRIGENDA 
p. 27, Figure 1.4, "arterial" for "aterial". 
p. 29, Line 1, "7-12 pm" for 113-11 jim". 
P. 34, Line 18, "drug" for "drugs" and "is" for "are". 
p. 35, Line 28, "In common with the rest.. " 
p. 49, Line 10, "since it is now.. " 
p. 89, Line 31, "were" for "was". 
P. 95, Line 32, "was" for "were". 
P. 119, Line 20, "was" for "were". 
p. 145, remove lines 8 and 9. 
p. 151, Figure 5.5, "molecule" for "mole". 
3+ 
p. 161, Line 15, In 
p. 163, Line 10, "slurry" for "paste". 
p. 165, Line 19, ".. coating polymer in acetone". 
p. 210, Line 32, "with concentration up to 0.67% w/w". 
p. 217, Line 14, "bound" for "glued". 
Throughout thesis, "sec" (second) for W. 
